RNA molecules
By designing the loop terminal dsRNA (ledRNA) structure, the problem of inefficient application of existing dsRNA in eukaryotic cells and plant leaf cells is solved, and a more efficient gene silencing effect is achieved.
Patent Information
- Application Number
- CN201880072998.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-08
- Filing Date
- 2018-09-17
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2038-12-16
AI Technical Summary
The existing double-stranded RNA (dsRNA) has problems of synthesis and low efficiency in inducing RNA interference (RNAi), especially in eukaryotic cells, and the existing dsRNA molecules are not efficient in plant leaf cells.
A new RNA molecular structure is designed called loop terminal dsRNA (ledRNA). Through specific nucleotide ligation and sequence arrangement, this structure can easily form dsRNA structure and induce target gene silencing in eukaryotic cells, and locally Effective when applied to plant leaves.
LEDRNA can induce target gene silencing more efficiently in eukaryotic cells, improve the efficiency of RNAi, and show significant gene downregulation effects in plant leaf cells.
Smart Images

Figure HDA0002486187470000011 
Figure HDA0002486187470000021 
Figure HDA0002486187470000031
Abstract
Description
Technical Field
[0001] The present invention relates to novel double-stranded RNA (dsRNA) structures and their use in gene silencing. Background Art
[0002] Conventional dsRNA molecules for inducing RNA interference (RNAi) in animal cells are formed by annealing single-stranded sense and antisense RNA or self-complementary RNA, which has a complementary region that allows the formation of a stem-loop structure, also referred to as hairpin RNA (hpRNA). In plants, it has been shown that transgenics expressing long hairpin RNAs are highly effective in inducing RNAi. Some studies on long hpRNAs show that, relative to the open end of the hpRNA structure, the processed RNA products of short interfering RNAs (siRNAs) formed by sequences near the hpRNA loop ends are more abundant, suggesting that the Dicer processing of the dsRNA stems of hpRNAs seems to be from the loop ends. The entire loop can be precisely excised from the hpRNA structure, which can provide the dsRNA ends for the RNase Dicer to combine and initiate siRNA processing.
[0003] While dsRNA-induced gene silencing has proven to be a valuable tool for altering the phenotype of an organism, there is a need for alternative, preferably improved, dsRNA molecules that can be used for RNAi. Summary of the Invention
[0004] The present inventors have devised a new design of RNAi-inducing molecules, herein termed loop-terminated dsRNA (ledRNA), which possess one or more of the following characteristics: ease of synthesis, greater ease of forming dsRNA structures, and induction of efficient silencing of target genes in eukaryotic cells. LedRNA is also effective when topically applied to plant leaves.
[0005] In a first aspect, the present invention provides a ribonucleic acid (RNA) molecule comprising a first RNA component, a second RNA component covalently linked to the first RNA component, and optionally one or more or all of the following: (i) a linker ribonucleotide sequence covalently linked to the first and second RNA components, (ii) a 5' leader sequence and (iii) a 3' trailer sequence,
[0006] wherein the first RNA component consists of, in 5' to 3' order, a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide, wherein the first 5' and 3' ribonucleotides are base paired with each other in the RNA molecule, wherein the first RNA sequence comprises a first sense ribonucleotide sequence of at least 20 contiguous ribonucleotides, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence of at least 20 contiguous ribonucleotides, wherein the first antisense ribonucleotide sequence hybridizes to the first sense ribonucleotide sequence in the RNA molecule, and wherein the first antisense ribonucleotide sequence is capable of hybridizing to a first region of a target RNA molecule,
[0007] wherein the second RNA component is covalently linked to the first 5' ribonucleotide or the first 3' ribonucleotide via the linking ribonucleotide sequence if present, or directly if no linking ribonucleotide sequence is present,
[0008] wherein the second RNA component consists of, in 5′ to 3′ order, a second 5′ ribonucleotide, a second RNA sequence, and a second 3′ ribonucleotide, wherein the second 5′ and 3′ ribonucleotides are base paired with each other in the RNA molecule, wherein the second RNA sequence comprises a second sense ribonucleotide sequence, a second loop sequence of at least 4 ribonucleotides, and a second antisense ribonucleotide sequence, wherein the second sense ribonucleotide sequence hybridizes to the second antisense ribonucleotide sequence in the RNA molecule;
[0009] wherein the 5' leader sequence, if present, consists of a ribonucleotide sequence that is covalently linked to the first 5' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or covalently linked to the second 5' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide, and
[0010] wherein the 3' trailer sequence, if present, consists of a ribonucleotide sequence that is covalently linked to the second 3' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or that is covalently linked to the first 3' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide.
[0011] In a second aspect, the present invention provides an RNA molecule comprising a first RNA component, a second RNA component covalently linked to the first RNA component, and optionally one or more or all of the following: (i) a linker ribonucleotide sequence covalently linked to the first and second RNA components, (ii) a 5' leader sequence and (iii) a 3' trailer sequence,
[0012] wherein the first RNA component consists of, in 5' to 3' order, a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide, wherein the first 5' and 3' ribonucleotides are base paired, wherein the first RNA sequence comprises a first sense ribonucleotide sequence, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence, wherein the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence each consist of at least 20 contiguous ribonucleotides, wherein the at least 20 contiguous ribonucleotides of the first sense ribonucleotide sequence are perfectly base paired with at least 20 contiguous ribonucleotides of the first antisense ribonucleotide sequence, wherein the at least 20 contiguous ribonucleotides of the first sense ribonucleotide sequence or the at least 20 contiguous ribonucleotides of the first antisense ribonucleotide sequence are identical in sequence to a first region of a target RNA molecule or its complement, or both, respectively,
[0013] wherein, if the linking ribonucleotide sequence is present, the second RNA component is covalently linked to the first 5' ribonucleotide or the first 3' ribonucleotide via the linking ribonucleotide sequence,
[0014] wherein the second RNA component consists of, in 5' to 3' order, a second 5' ribonucleotide, a second RNA sequence, and a second 3' ribonucleotide, wherein the second 5' and 3' ribonucleotides are base paired, wherein the second RNA sequence comprises a second sense ribonucleotide sequence, a second loop sequence of at least 4 ribonucleotides, and a second antisense ribonucleotide sequence, wherein the second sense ribonucleotide sequence is base paired with the second antisense ribonucleotide sequence,
[0015] wherein the 5' leader sequence, if present, consists of a ribonucleotide sequence that is covalently linked to the first 5' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or covalently linked to the second 5' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide, and
[0016] wherein the 3' trailer sequence, if present, consists of a ribonucleotide sequence that is covalently linked to the second 3' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or that is covalently linked to the first 3' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide.
[0017] In a preferred embodiment, the RNA molecule of the invention is a chimeric RNA molecule.
[0018] In a third aspect, the present invention provides a chimeric ribonucleic acid (RNA) molecule comprising a double-stranded RNA (dsRNA) region comprising a sense ribonucleotide sequence and an antisense ribonucleotide sequence capable of hybridizing to each other to form a dsRNA region, wherein
[0019] i) the sense ribonucleotide sequence consists of a first 5' ribonucleotide, a first RNA sequence and a first 3' ribonucleotide covalently linked in 5' to 3' order,
[0020] ii) the antisense ribonucleotide sequence consists of a second 5' ribonucleotide, a second RNA sequence and a second 3' ribonucleotide covalently linked in a 5' to 3' order,
[0021] iii) the first 5' ribonucleotide base pairs with the second 3' ribonucleotide base to form the terminal base pair of the dsRNA region,
[0022] iv) the second 5' ribonucleotide base pairs with the first 3' ribonucleotide base to form the terminal base pair of the dsRNA region,
[0023] v) about 5% to about 40% of the ribonucleotides of the sense ribonucleotide sequence and the antisense ribonucleotide sequence collectively are base paired with non-canonical base pairs or are not base paired,
[0024] vi) the dsRNA region does not comprise 20 contiguous canonical base pairs,
[0025] vii) the RNA molecule is capable of being processed in a eukaryotic cell or in vitro, whereby the antisense ribonucleotide sequence is cleaved to produce a short antisense RNA (asRNA) molecule of 20-24 ribonucleotides in length,
[0026] viii) the RNA molecule or at least some of the asRNA molecules, or both, are capable of reducing the expression or activity of a target RNA molecule in the eukaryotic cell, and
[0027] ix) The RNA molecule can be produced enzymatically by transcription in vitro or in a cell or both.
[0028] In a fourth aspect, the present invention provides a chimeric RNA molecule comprising a first RNA component and a second RNA component covalently linked to the first RNA component,
[0029] wherein the first RNA component comprises a first double-stranded RNA (dsRNA) region and a first intervening ribonucleotide sequence of at least 4 nucleotides, wherein the first double-stranded RNA (dsRNA) region comprises a first sense ribonucleotide sequence and a first antisense ribonucleotide sequence that can hybridize with each other to form the first dsRNA region, and the first intervening ribonucleotide sequence is covalently linked to the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence,
[0030] wherein the second RNA component comprises a second sense ribonucleotide sequence, a second antisense ribonucleotide sequence, and a second intervening ribonucleotide sequence of at least 4 ribonucleotides, wherein the second intervening ribonucleotide sequence is covalently linked to the second sense ribonucleotide sequence and the second antisense ribonucleotide sequence, wherein the second sense ribonucleotide sequence in the RNA molecule hybridizes to the second antisense ribonucleotide sequence,
[0031] Wherein in the first RNA component,
[0032] i) the first sense ribonucleotide sequence consists of at least 20 contiguous ribonucleotides covalently linked in 5' to 3' order, a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide,
[0033] ii) the first antisense ribonucleotide sequence consists of at least 20 contiguous ribonucleotides covalently linked in 5' to 3' order, a second 5' ribonucleotide, a second RNA sequence, and a second 3' ribonucleotide,
[0034] iii) a first 5' ribonucleotide base pair with a second 3' ribonucleotide,
[0035] iv) a second 5' ribonucleotide base pair with a first 3' ribonucleotide,
[0036] v) 5% to 40% of the ribonucleotides of the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence collectively are base paired with non-canonical base pairs or are not base paired, and
[0037] vi) said first dsRNA region does not comprise 20 contiguous canonical base pairs,
[0038] wherein the chimeric RNA molecule is capable of being processed in a eukaryotic cell or in vitro, whereby the first antisense ribonucleotide sequence is cleaved to produce a short antisense RNA (asRNA) molecule of 20-24 ribonucleotides in length, and wherein
[0039] (a) the chimeric RNA molecule or at least some of the asRNA molecules, or both, are capable of reducing the expression or activity of a target RNA molecule in the eukaryotic cell, or
[0040] (b) the first antisense ribonucleotide sequence comprises a sequence of at least 20 contiguous ribonucleotides that are at least 50% identical in sequence to the complementary region of the target RNA molecule, or
[0041] (c) Both (a) and (b).
[0042] In the first, second, and fourth aspects, the first 5' ribonucleotide and the first 3' ribonucleotide of the first RNA component are base paired to form a base pair. This base pair is defined herein as the terminal base pair of the dsRNA region formed by self-hybridization of the first RNA component. In embodiments where the first sense ribonucleotide sequence is covalently linked to the first 5' ribonucleotide without any intervening nucleotides and the first antisense ribonucleotide sequence is covalently linked to the first 3' ribonucleotide without any intervening nucleotides, the first 5' ribonucleotide is directly linked to one of the sense and antisense sequences and the first 3' ribonucleotide is directly linked to the other of the sense and antisense sequences.
[0043] In a preferred embodiment, at least 20 contiguous ribonucleotides of the first antisense ribonucleotide sequence are capable of base pairing with nucleotides of the first region of the target RNA molecule. In one embodiment, the first sense ribonucleotide sequence is covalently linked to the first 5' ribonucleotide without any intervening nucleotides, or the first antisense ribonucleotide sequence is covalently linked to the first 3' ribonucleotide without any intervening nucleotides, or both.
[0044] In one embodiment, the RNA molecule comprises a linker ribonucleotide sequence, wherein the linker ribonucleotide sequence is related in sequence to the target gene, or is at least partially identical to or complementary to a region of the target RNA molecule. In a preferred embodiment, the linker ribonucleotide sequence forms part of a contiguous sense sequence together with the sense sequence in the first and second RNA components, or forms part of a contiguous antisense sequence together with the antisense sequence in the first and second RNA components. In one embodiment, the RNA molecule comprises a linker ribonucleotide sequence, wherein the linker ribonucleotide sequence is less than 20 ribonucleotides. In one embodiment, the linker ribonucleotide sequence hybridizes to the target RNA molecule. In one embodiment, the linker ribonucleotide sequence is identical to a portion of the complement of the target RNA molecule. In one embodiment, the linker ribonucleotide sequence is between 1 and 10 ribonucleotides.
[0045] In the embodiments of the first, second or fourth aspects, the RNA molecule comprises one or more or all of the following: (i) a linking ribonucleotide sequence that covalently links the first and second RNA components, (ii) a 5' extension sequence and (iii) a 3' extension sequence, wherein respectively, if the 5' extension sequence is present, it consists of a ribonucleotide sequence that is covalently linked to the first RNA component or the second RNA component, and wherein if the 3' extension sequence is present, it consists of a ribonucleotide sequence that is covalently linked to the second RNA component or the first RNA component. In one embodiment, the first RNA component and the second RNA component are covalently linked via the linking ribonucleotide sequence. In another embodiment, the first RNA component and the second RNA component are directly linked without any linking ribonucleotide sequence.
[0046] In the embodiments of the first to fourth aspects, the RNA molecule comprises two or more sense ribonucleotide sequences, each sense ribonucleotide sequence is identical in sequence to a region of the target RNA molecule, and the RNA molecule comprises one or more antisense ribonucleotide sequences based on pairing with the sense ribonucleotide sequence, wherein the one or more antisense sequences are complementary to the region of the target molecule, preferably completely complementary. In one embodiment, the two or more sense ribonucleotide sequences are identical in sequence to different regions of the same target RNA molecule, which may or may not be adjacent in the target RNA molecule. In one embodiment, the two or more sense ribonucleotide sequences are identical in sequence to regions of different target RNA molecules. In one embodiment, the two or more sense ribonucleotide sequences do not have an intervening loop sequence, i.e., they are adjacent relative to the target RNA molecule.
[0047] In a preferred embodiment of the first to fourth aspects, the RNA molecule comprises two or more antisense ribonucleotide sequences and a sense ribonucleotide sequence with its base pairing, and the antisense sequence is complementary to the district of the target RNA molecule. The target RNA molecule and its complementary district may be or may not be adjacent in the target RNA molecule. In one embodiment, the two or more antisense ribonucleotide sequences are complementary to the different districts of the same target RNA molecule. In one embodiment, the second of the two or more antisense ribonucleotide sequences is complementary to the district of the target RNA molecule that is different from the first of the two or more antisense ribonucleotide sequences. In a preferred embodiment, two or more antisense ribonucleotide sequences do not have an intervening loop sequence, that is, they are adjacent relative to the complementary sequence of the target RNA molecule. In a preferred embodiment, one or both of the two or more antisense ribonucleotide sequences and the sense ribonucleotide sequence are base paired along their full length by standard base pairs, or by some standard and some non-standard base pairs, preferably G:U base pairs are base paired.
[0048] In preferred embodiments of the first to fourth aspects, the RNA molecule is a single-stranded ribonucleotide. For example, the RNA molecule can comprise a single-stranded ribonucleotide with a 5' end, at least one sense ribonucleotide sequence of at least 21 nucleotides in length, an antisense ribonucleotide sequence that is fully base-paired with each sense ribonucleotide sequence on at least 21 adjacent nucleotides, at least two loop sequences, and a 3' end. The 5' to 3' order can be a sense ribonucleotide sequence followed by an antisense ribonucleotide sequence, or vice versa. In one embodiment, the ribonucleotide at the 5' end and the ribonucleotide at the 3' end are adjacent, with each base being paired and not directly covalently bound, see, e.g. Figure 1 .
[0049] In another embodiment of the first to fourth aspects, the RNA molecule comprises a first antisense ribonucleotide sequence that hybridizes to a first region of the target RNA; a second antisense ribonucleotide sequence that hybridizes to a second region of the target RNA, the second region of the target RNA being different from the first region of the target RNA; and the RNA molecule comprises only one sense ribonucleotide sequence that hybridizes to the target RNA, wherein the two antisense sequences are not adjacent in the RNA molecule. In one embodiment, the first and second regions of the target RNA are adjacent in the target RNA. Alternatively, they are not adjacent.
[0050] In another embodiment of the first to fourth aspects, the RNA molecule comprises a first sense ribonucleotide sequence that is at least 60% identical to a first region of a target RNA; and a second sense ribonucleotide sequence that is at least 60% identical to a second region of the target RNA, the second region of the target RNA being different from the first region of the target RNA; and the RNA molecule comprises only one antisense ribonucleotide sequence that hybridizes to the target RNA, wherein the two sense sequences are not adjacent in the RNA molecule. In one embodiment, the first and second regions of the target RNA are adjacent in the target RNA molecule. Alternatively, they are not adjacent. In preferred embodiments, the first and second sense ribonucleotide sequences are each independently at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% identical to the corresponding regions of the target RNA, i.e., the first sense sequence may be at least 70% identical to its target region, the second sequence may be at least 80% identical to its target sequence, and so on.
[0051] In preferred embodiments of the first to fourth aspects, the RNA molecule is a single-stranded ribonucleotide having a 5' end, at least one sense ribonucleotide sequence of at least 21 nucleotides in length, an antisense ribonucleotide sequence that is fully base paired with each sense ribonucleotide sequence over at least 21 contiguous nucleotides, at least two loop sequences, and a 3' end. In a more preferred embodiment, the base pairing in the RNA molecule is contained within a double-stranded region of at least 21 contiguous base pairs in length, the double-stranded region including some non-canonical base pairs, most preferably some G:U base pairs, the double-stranded region comprising at least one sense ribonucleotide sequence of at least 21 nucleotides in length.
[0052] In preferred embodiments of the first and second aspects, the second RNA component is characterized by:
[0053] i) the second sense ribonucleotide sequence consists of at least 20 contiguous second 5' ribonucleotides, a third RNA sequence, and a third 3' ribonucleotide covalently linked in 5' to 3' order,
[0054] ii) the second antisense ribonucleotide sequence consists of at least 20 contiguous ribonucleotides covalently linked in 5' to 3' order, a third 5' ribonucleotide, a fourth RNA sequence, and a second 3' ribonucleotide,
[0055] iii) a second 5' ribonucleotide base pair with a second 3' ribonucleotide,
[0056] iv) a third 3' ribonucleotide base pair with a third 5' ribonucleotide,
[0057] wherein the chimeric RNA molecule is capable of being processed in a eukaryotic cell or in vitro such that the second antisense ribonucleotide sequence is cleaved to produce a short antisense RNA (asRNA) molecule of 20-24 ribonucleotides in length, and wherein most preferably, the asRNA molecule produced from the second antisense sequence is capable of reducing the expression of the target RNA in the absence of or in combination with the asRNA produced from the first antisense sequence of the first RNA component.
[0058] In a preferred embodiment of the fourth aspect, the second RNA component is characterized in that:
[0059] i) the second sense ribonucleotide sequence consists of at least 20 contiguous 5' ribonucleotides, a third RNA sequence, and a third 3' ribonucleotide covalently linked in 5' to 3' order,
[0060] ii) the second antisense ribonucleotide sequence consists of at least 20 contiguous ribonucleotides covalently linked in 5' to 3' order, a fourth 5' ribonucleotide, a fourth RNA sequence and a fourth 3' ribonucleotide,
[0061] iii) a third 5' ribonucleotide base pair with a fourth 3' ribonucleotide,
[0062] iv) a third 3' ribonucleotide base pair with a third 5' ribonucleotide,
[0063] wherein the chimeric RNA molecule is capable of being processed in a eukaryotic cell or in vitro, whereby the second antisense ribonucleotide sequence is cleaved to produce a short antisense RNA (asRNA) molecule of 20-24 ribonucleotides in length, and wherein
[0064] In these preferred embodiments, more preferably, 5% to 40% of the ribonucleotides of the second sense ribonucleotide sequence and the second antisense ribonucleotide sequence are base paired with non-canonical base pairs or are not base paired, and / or the second dsRNA region does not contain 20 adjacent canonical base pairs. More preferably, about 12%, about 15%, about 18%, about 21%, about 24%, or 15% to 30%, or even more preferably 16% to 25% of the ribonucleotides of the second sense ribonucleotide sequence and the second antisense ribonucleotide sequence are base paired with non-canonical base pairs, or are not base paired. In preferred embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% of the non-canonical base pairs of the second dsRNA region are G:U base pairs. Most preferably, in these embodiments,
[0065] (a) the chimeric RNA molecule or at least some of the asRNA molecules, or both, are capable of reducing the expression or activity of a target RNA molecule in the eukaryotic cell, or
[0066] (b) the second antisense ribonucleotide sequence comprises a sequence of at least 20 contiguous ribonucleotides that are at least 50% identical in sequence to the complementary region of the target RNA molecule, preferably at least 60% identical, more preferably at least 70% identical, even more preferably at least 80% identical, and most preferably at least 90% identical or 100% identical to the complementary region of the target RNA molecule, or (c) both (a) and (b).
[0067] In the embodiments of the first to fourth aspects, the RNA molecule comprises a 5' leader sequence or a 5' extension sequence. In one embodiment, the RNA molecule comprises a 3' trailer sequence or a 3' extension sequence. In a preferred embodiment, the RNA molecule comprises a 5' leader / extension sequence and a 3' trailer / extension sequence.
[0068] In the embodiments of the first to fourth aspects, each ribonucleotide of the RNA molecule is covalently linked to two other nucleotides, i.e. it is a covalent closed ring. Alternatively, the RNA molecule can be represented as a dumbbell ( Figure 1 ), but with a gap or break in a portion of the double-stranded structure.
[0069] In the embodiment of the first to fourth aspects, at least one or all of the loop sequences of the RNA molecule are longer than 20 nucleotides. In a preferred embodiment, the length of at least one loop of the RNA molecule is 4 to 1,000 ribonucleotides. In a more preferred embodiment, the length of all loops is 4 to 1,000 ribonucleotides. In a more preferred embodiment, the length of at least one loop of the RNA molecule is 4 to 200 ribonucleotides. In an even more preferred embodiment, the length of all loops is 4 to 200 ribonucleotides. In an even more preferred embodiment, the length of at least one loop of the RNA molecule is 4 to 50 ribonucleotides. In a most preferred embodiment, the length of all loops is 4-50 ribonucleotides. In one embodiment, the eukaryotic cell is a vertebrate cell, and the length of each loop of the RNA molecule is 20 to 50, or 20 to 30 ribonucleotides.
[0070] In the embodiment of the first to fourth aspects, the RNA molecule does not have, or has one or two or more protuberances in the double-stranded region. In this article, a protuberance is a nucleotide in a sense or antisense ribonucleotide sequence, or two or more adjacent nucleotides, which is not base-paired in the dsRNA district and does not have mismatched nucleotides in the corresponding position in the complementary sequence in the dsRNA district. The dsRNA district of the RNA molecule can be included in a sense or antisense sequence or a sequence that exceeds 2 or 3 nucleotides, and when the dsRNA structure is formed, it is looped from the dsRNA district. The looped sequence itself can form some internal base pairings, for example it itself can form a stem-loop structure.
[0071] In the embodiment of the first to fourth aspects, the RNA molecule does not have, or has one or two or more protuberances in the double-stranded region. In this article, a protuberance is a nucleotide in a sense or antisense ribonucleotide sequence, or two or more adjacent nucleotides, which is not base-paired in the dsRNA district and does not have mismatched nucleotides in the corresponding position in the complementary sequence in the dsRNA district. The dsRNA district of the RNA molecule can be included in a sense or antisense sequence or a sequence that exceeds 2 or 3 nucleotides, and when the dsRNA structure is formed, it is looped from the dsRNA district. The looped sequence itself can form some internal base pairings, for example it itself can form a stem-loop structure.
[0072] In one embodiment, the RNA molecule has three, four or more loops. In a preferred embodiment, the RNA molecule has only two loops. In one embodiment, the first double-stranded region or the first dsRNA region and the second dsRNA region of the RNA molecule contain one or two or more nucleotides that are not base paired in the double-stranded region, or at most 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% of the nucleotides that are not base paired in the double-stranded region.
[0073] In preferred embodiments of the first to fourth aspects, the target RNA molecule of the present invention or the RNA molecule or both are in eukaryotic cells. For example, the eukaryotic cell can be a plant cell, an animal cell, or a fungal cell. In one embodiment, the eukaryotic cell is a fungal cell. In one embodiment, the RNA molecule of the present invention is produced in a cell, such as a bacterial cell or other microbial cell, which is different from the cell containing the target RNA. Similarly, in one embodiment, when producing the RNA molecule of the present invention, the RNA molecule of the present invention is produced in a eukaryotic cell that does not contain the target RNA, but if the target RNA is, for example, a viral RNA or other introduced RNA, the eukaryotic cell containing the RNA molecule of the present invention and / or its processed RNA product can become a host for the target RNA. Such cells can be preventively protected against viral or other introduced RNA.
[0074] In preferred embodiments of the first to fourth aspects, the RNA molecule can be enzymatically prepared by transcription in vitro or in a cell, or both. In one embodiment, the RNA molecule of the present invention is expressed in a cell, i.e., produced in the cell by transcription from one or more nucleic acids encoding the RNA molecule. The one or more nucleic acids encoding the RNA molecule are preferably DNA molecules, which may be present on a vector in the cell or integrated into the cell's genome, the cell's nuclear genome, or the cell's plastid DNA. The one or more nucleic acids encoding the RNA molecule may also be RNA molecules, such as viral vectors.
[0075] Thus, in one embodiment, the present invention provides a cell comprising an RNA molecule as described herein. In a preferred embodiment, the present invention provides an RNA molecule as described herein that is expressed in a cell and has been isolated and / or purified from the cell. Thus, the present invention provides a formulation of an isolated RNA molecule according to one or more of the first to fourth aspects, suitable for administration to a cell comprising or potentially comprising a target RNA.
[0076] In one embodiment, the one or more target RNAs encode a protein. Alternatively, the one or more target RNAs do not encode a protein, such as rRNA, tRNA, snoRNA, or miRNA.
[0077] In the embodiments of the first to fourth aspects, about 12%, about 15%, about 18%, about 21%, about 24%, or about 15% to about 30%, or preferably about 16% to about 25% of the ribonucleotides forming the sense ribonucleotide sequence and antisense ribonucleotide sequence of the dsRNA district as a whole are base paired or not base paired with non-canonical base pairs. In preferred embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or 100% of the non-canonical base pairs in the dsRNA district or all dsRNA districts in the RNA molecule are G:U base pairs. The G nucleotide in each G:U base pair can be independently in the sense ribonucleotide sequence or preferably in the antisense ribonucleotide sequence. With respect to the G nucleotides in the G:U base pairs in the dsRNA region, preferably at least 50% are in the antisense ribonucleotide sequence, more preferably at least 60% or 70%, even more preferably at least 80% or 90%, and most preferably at least 95% are in the antisense ribonucleotide sequence in the dsRNA region. This feature can be applied to all dsRNA regions in the RNA molecule. In one embodiment, less than 25%, less than 20%, less than 15%, less than 10%, preferably less than 5%, more preferably less than 1%, or most preferably no ribonucleotides are base paired in the RNA molecule as a whole. In a preferred embodiment, in the dsRNA region or in the dsRNA region as a whole, every 4 to every 1 of the 6 ribonucleotides form a non-canonical base pair or are not base paired within the RNA molecule. In a preferred embodiment, the dsRNA region or in the dsRNA region as a whole does not contain 8 adjacent canonical base pairs. In another embodiment, the dsRNA region contains at least 8 adjacent canonical base pairs, for example 8-12 or 8-14 adjacent canonical base pairs. In preferred embodiments, all ribonucleotides in the dsRNA region are base paired in canonical base pairs or non-canonical base pairs. In one embodiment, one or more ribonucleotides of the sense ribonucleotide sequence or one or more ribonucleotides of the antisense ribonucleotide sequence, or both, are not base paired. In one embodiment, in an RNA molecule of the invention, one or more ribonucleotides of each sense ribonucleotide sequence and one or more ribonucleotides of each antisense ribonucleotide sequence are not base paired.
[0078] In one embodiment, the antisense RNA sequence of the first RNA component or the second RNA component, or both, is less than 100% identical in sequence, or about 80% to 99.9% identical, or about 90% to 98% identical, or about 95% to 98% identical, preferably 98% to 99.9% identical to the complement of one region of the target RNA molecule or two such regions, which may or may not be contiguous in the target RNA molecule. In a preferred embodiment, the antisense RNA sequence is 100% identical in sequence to the complementary region of the target RNA molecule, such as a region comprising 21, 23, 25, 27, 30, or 32 contiguous nucleotides. In one embodiment, the sense or antisense ribonucleotide sequence, or both, is at least 40, at least 50, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1,000, or about 100 to about 1,000 contiguous nucleotides in length. When the RNA molecule is used in plant cells or fungal cells, or for non-vertebrate cells, a length of at least 100 nucleotides is preferred. When the RNA molecule is used in vertebrate cells, a length of 50 nucleotides or less, for example, 31 to 50 nucleotides, is preferred for the sense and antisense ribonucleotide sequences in the dsRNA. In one embodiment, the number of ribonucleotides in the sense ribonucleotide sequence is about 90% to about 110%, preferably 95% to 105%, more preferably 98% to 102%, and even more preferably 99% to 101% of the number of ribonucleotides in the antisense ribonucleotide sequence. In a most preferred embodiment, the number of ribonucleotides in the sense ribonucleotide sequence is the same as the number of ribonucleotides in the antisense ribonucleotide sequence.These features can be applied to every dsRNA region in an RNA molecule.
[0079] In the embodiments of the first to fourth aspects, the first 3' ribonucleotide and the second 5' ribonucleotide in the RNA molecule are covalently linked by a loop sequence consisting of at least 4 ribonucleotides, or 4 to 1,000 ribonucleotides, or preferably 4 to 200 ribonucleotides, more preferably 4 to 50 ribonucleotides. In one embodiment, the RNA molecule further comprises a 5' extension sequence covalently linked to the first 5' ribonucleotide or a 3' extension sequence covalently linked to the second 3' ribonucleotide, or both. In one embodiment, the chimeric RNA molecule further comprises a 5' extension sequence covalently linked to the second 5' ribonucleotide or a 3' extension sequence covalently linked to the first 3' ribonucleotide, or both. In this embodiment, the RNA molecule comprises two separate RNA chains that hybridize to form the RNA molecule, although it may have been produced by transcribing from a nucleic acid molecule into a single RNA transcript and then being processed to comprise two RNA chains.
[0080] After splicing out from any introns but before any processing of the RNA molecule by Dicer enzyme or other RNase, the total length of the RNA molecule of the present invention produced as single-stranded RNA is typically 50 to 2000 ribonucleotides, preferably 60 or 70 to 2000 ribonucleotides, more preferably 80 or 90 to 2000 ribonucleotides, even more preferably 100 or 110 to 2000 ribonucleotides. In preferred embodiments, the minimum length of the RNA molecule is 120, 130, 140, 150, 160, 180 or 200 nucleotides, and the maximum length is 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1500 or 2000 ribonucleotides. Each combination of the above minimum and maximum lengths is contemplated. The production of RNA molecules of such lengths can be readily accomplished by in vitro transcription or transcription in cells such as bacteria or other microbial cells or in eukaryotic cells in which the target gene is downregulated.
[0081] In an embodiment of the first to fourth aspects, the chimeric RNA molecule comprises two or more identical or preferably different dsRNA regions.
[0082] In preferred embodiments of the first to fourth aspects, the RNA molecule is expressed in a eukaryotic cell, i.e., produced by transcription in the cell. In these embodiments, a greater proportion of dsRNA molecules are formed by processing RNA molecules of 22 and / or 20 ribonucleotides in length, compared to processing of similar RNA molecules having corresponding dsRNA regions that are completely base-paired with canonical base pairs. That is, the RNA molecules of these embodiments are more easily processed than similar RNA molecules whose dsRNA regions are completely base-paired with canonical base pairs to provide 22- and / or 20-ribonucleotide short antisense RNAs as part of the total 20-24 nucleotide asRNA produced by the RNA molecule.
[0083] In one embodiment, an RNA molecule of the invention comprises a combination of two or more features of the RNA molecules described herein.
[0084] On the other hand, the present invention provides polynucleotides encoding RNA molecules described herein, preferably chimeric RNA molecules described herein. In one embodiment, the polynucleotide is a DNA construct that can be integrated into a larger DNA molecule such as a chromosome. In one embodiment, the polynucleotide is operably linked to a promoter capable of directing expression of the RNA molecule in a host cell. The host cell can be: a bacterial cell, such as Escherichia coli; a fungal cell, such as a yeast cell; or a eukaryotic cell, such as a plant cell or an animal cell. In one embodiment, the promoter is heterologous to the polynucleotide. The polynucleotide encoding the RNA molecule can be a chimeric or recombinant polynucleotide, or an isolated and / or exogenous polynucleotide. In one embodiment, the promoter can function in vitro, such as a bacteriophage promoter, such as a T7 RNA polymerase promoter or an SP6 RNA polymerase promoter. In one embodiment, the promoter is an RNA polymerase III promoter, such as a U6 promoter or an H1 promoter. In one embodiment, the promoter is an RNA polymerase II promoter, which can be a constitutive promoter, a tissue-specific promoter, a developmentally regulated promoter, or an inducible promoter. In one embodiment, the polynucleotide encodes an RNA precursor molecule comprising an intron in at least one loop sequence that can be spliced out during or after transcription of the polynucleotide in a host cell. In one embodiment, the invention provides a vector comprising the polynucleotide as described herein. In one embodiment, the vector is a viral vector. In one embodiment, the vector is a plasmid vector, such as a binary vector suitable for use with Agrobacterium tumefaciens.
[0085] In one embodiment, wherein the polynucleotide or vector of the present invention is operably linked to a region encoding an RNA molecule of the present invention in a eukaryotic host cell, preferably a plant, the promoter region of the polynucleotide or vector has a lower level of methylation compared to the promoter of the corresponding polynucleotide or vector encoding an RNA molecule having a corresponding dsRNA region that is perfectly base-paired with canonical base pairs. In one embodiment, the lower level of methylation is less than 50%, less than 40%, less than 30%, or less than 20% when compared to the promoter of the corresponding polynucleotide or vector. In one embodiment, the host cell comprises at least two copies of a polynucleotide or vector encoding an RNA molecule of the present invention. In this example:
[0086] i) the expression and / or activity of the target RNA molecule in the eukaryotic cell is reduced to at least the same level relative to a corresponding eukaryotic cell having a single copy of the polynucleotide or vector, and / or
[0087] ii) expression and / or activity of the target RNA molecule is reduced to a lower level in the eukaryotic cell when compared to a corresponding cell comprising an RNA molecule having a corresponding dsRNA region that is perfectly base paired to canonical base pairs.
[0088] On the other hand, the present invention provides host cells comprising RNA molecules described herein, polynucleotides described herein, or vectors comprising the same. In one embodiment, the host cell is a non-human cell, such as a bacterial cell, a fungal cell, a plant cell, or a non-human animal cell. In one embodiment, the cell is a non-human cell or a human cell in cell culture. In one embodiment, the cell is a eukaryotic cell, such as a cell other than an animal cell. In one embodiment, the cell is a microbial cell such as a prokaryotic cell. In one embodiment, the host cell is alive. In another embodiment, the host cell is dead.
[0089] In another aspect, the present invention provides a non-human organism comprising an RNA molecule of the present invention, preferably a chimeric RNA molecule as described herein, a polynucleotide or vector of the present invention comprising the same, or a host cell comprising the same. In one embodiment, the non-human organism is transgenic, as long as it comprises a polynucleotide of the present invention. In one embodiment, the polynucleotide is stably integrated into the genome of the non-human organism.
[0090] In another aspect, the invention provides a method for producing an RNA molecule of the invention, the method comprising expressing a polynucleotide of the invention in a host cell or a cell-free expression system. In this embodiment, the method may further comprise at least partially purifying or not purifying the RNA molecule.
[0091] On the other hand, the present invention provides a method for producing a cell or a non-human organism, preferably a plant or a fungus, comprising introducing a polynucleotide or a vector of the present invention into a cell, preferably a plant cell or a fungus, preferably such that the polynucleotide or vector encoding the RNA molecule or a portion thereof is stably integrated into the genome of the cell. In one embodiment, the non-human organism is produced, for example, by regenerating a plant from a cell or a daughter cell. In one embodiment, the non-human organism is produced by introducing a cell or one or more daughter cells into a non-human organism. As an alternative to stably integrating a polynucleotide or a vector into the genome of a cell, the polynucleotide or vector can be introduced into the cell without integrating the polynucleotide or vector into the genome, for example, to transiently express an RNA molecule in a cell or an organism.
[0092] On the other hand, the invention provides an extract of a host cell or organism of the invention or a part thereof, wherein the extract comprises an RNA molecule of the invention, a small RNA molecule (20-24 nt in length) produced by processing the RNA molecule, or both, and / or a polynucleotide or vector of the invention. In one embodiment, the invention provides a composition comprising one or more RNA molecules of the invention, small RNA molecules (20-24 nt in length) produced by processing the RNA molecule, or both; a polynucleotide of the invention; a vector of the invention; a host cell of the invention; or an extract produced by the method of the invention; and one or more suitable carriers. In one embodiment, the composition is a pharmaceutical composition, such as a composition suitable for application to humans or other animals. The pharmaceutical composition may be suitable for use in preventing or treating disease, or for topical application, such as cosmetic application. In one embodiment, the composition is suitable for application to plants, preferably plants or plant groups in a field, or to insects or insect groups. In one embodiment, the composition is suitable for application to crops, such as by spraying onto crop plants in a field.
[0093] In one embodiment, the extract or composition comprising the RNA molecules of the invention or the small RNA molecules (20-24 nt in length) produced by processing the RNA molecules, or both, further comprises at least one compound that enhances the stability of the RNA molecules or polynucleotides and / or vectors, wherein the at least one compound facilitates the uptake of the RNA molecules, polynucleotides or vectors by cells, such as cells of an organism. In one embodiment, the compound is a transfection facilitator, such as a lipid-containing compound.
[0094] In another aspect, the invention provides methods for reducing or downregulating the level and / or activity of a target RNA molecule in a cell or organism, the method comprising delivering to the cell or organism one or more RNA molecules of the invention or small RNA molecules (20-24 nt in length) produced by processing the RNA molecules, or both; a polynucleotide of the invention; a vector of the invention; or a composition of the invention. In one embodiment, the target RNA molecule encodes a protein. In one embodiment, the method reduces the level and / or activity of more than one target RNA molecule, for example, reduces the level and / or activity of two or more target RNAs, the target RNA molecules being different, the level and / or activity of the target RNAs being related, for example, in sequences from a gene family.
[0095] In another aspect, the present invention provides a method for controlling a non-human organism, the method comprising delivering to the non-human organism one or more RNA molecules of the present invention or small RNA molecules (20-24 nt in length) produced by processing the RNA molecules, or both; polynucleotides or vectors of the present invention; host cells of the present invention; extracts produced by the methods of the present invention; or compositions of the present invention, wherein the RNA molecules or small RNA molecules have a deleterious effect on the non-human organism. In one embodiment, the non-human organism is an arthropod, such as an insect; or a plant, such as a weed. In one embodiment, the non-human organism is a plant, and the arthropod ingests the plant or a part thereof, thereby controlling the arthropod.
[0096] In one embodiment, the present invention provides a method for preventing or treating a disease in a subject, the method comprising administering to the subject one or more RNA molecules of the present invention or small RNA molecules (20-24 nt in length) produced by processing of RNA molecules, or both; polynucleotides or vectors of the present invention; host cells of the present invention; extracts produced by the methods of the present invention; or compositions of the present invention, wherein the RNA molecules or small RNA molecules have a beneficial effect on at least one symptom of the disease. In one embodiment, the RNA molecules or small RNA molecules, polynucleotides, vectors or compositions are administered topically, orally or by injection. In one embodiment, the subject is a vertebrate. In one embodiment, the vertebrate is a mammal, such as a human, livestock such as a cow or sheep; or a bird, such as a chicken and other poultry.
[0097] In another aspect, the present invention provides the use of an RNA molecule of the present invention, a polynucleotide or vector of the present invention, a host cell of the present invention, an extract produced by the method of the present invention, or a composition of the present invention for treating a disease in a subject, wherein the RNA molecule or small RNA molecule has a beneficial effect on at least one symptom of the disease. In one embodiment, the present invention provides the use of an RNA molecule of the present invention or a small RNA molecule produced therefrom, a polynucleotide or vector of the present invention, a host cell of the present invention, an extract produced by the method of the present invention, or a composition of the present invention for the manufacture of a medicament for preventing or treating a disease in a subject, wherein the RNA molecule or small RNA molecule produced therefrom has a beneficial effect on at least one symptom of the disease.
[0098] In another aspect, the invention provides a kit comprising one or more of the following: an RNA molecule of the invention or a small RNA molecule produced therefrom, a polynucleotide or vector of the invention, a host cell of the invention, an extract produced by a method of the invention, or a composition of the invention.
[0099] Unless specifically stated otherwise, any embodiment herein should be understood to be mutatis mutandis applicable to any other embodiment.
[0100] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for illustrative purposes only. Functionally equivalent products, compositions, and methods are clearly within the scope of the present invention, as described herein.
[0101] Throughout this specification, unless specifically stated otherwise or the context requires otherwise, references to individual steps, compositions of matter, groups of steps or groups of compositions of matter are to be taken as including both one and multiple (i.e., one or more) those steps, compositions of matter, groups of steps or groups of compositions of matter.
[0102] The invention is now described by way of the following non-limiting examples and with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0103] Figure 1 Schematic diagrams of two ledRNA molecules. (A) The ledRNA molecule comprises a sense sequence, which can be considered as two adjacent sense sequences covalently linked without an intervening spacer sequence and identical to the target RNA; an antisense sequence that is complementary to the sense sequence and divided into two regions, a 5' region and a 3' region; and two loops separating the sense sequence from the antisense sequence. (B) The ledRNA molecule comprises an antisense sequence, which can be considered as two adjacent antisense sequences covalently linked without an intervening spacer sequence and identical to the complement of the target RNA; a sense sequence that is complementary to the antisense sequence and divided into two regions; and two loops separating the sense sequence from the antisense sequence. RNA molecules are produced by transcription, for example, by in vitro transcription from a promoter such as a T7 or Sp6 promoter, with self-annealing by base pairing between complementary sense and antisense sequences to form a double-stranded region with a loop at each end and a "gap" in the antisense or sense sequence. Additional sequences may be attached to the 5' and / or 3' ends as 5' or 3' extension sequences.
[0104] Figure 2 Compared to sense / antisense annealing or hairpin RNA, ledRNA is more efficient at forming dsRNA. Schematic diagrams of three forms of double-stranded RNA molecules are shown: A, conventional dsRNA formed by annealing two separate strands; B, hairpin RNA with 5' or 3' extensions; and C, ledRNA. The lower panel shows photographs of RNA transcripts from the three types of RNA molecules targeting the GUS or GFP genes after gel electrophoresis.
[0105] Figure 3Northern blot hybridization of treated (A and B) and untreated distal (C and D) tissues shows that ledRNA is more stable than dsRNA and spreads through tobacco leaf tissue. In contrast to the strong ledRNA signal, no dsRNA signal was detected in distal tissues (C and D, upper panels).
[0106] Figure 4 .ledRNA treatment induced GUS downregulation in both the treated area (1) and the untreated area (3).
[0107] Figure 5 .ledRNA induces FAD2.1 gene silencing in Nicotiana benthamiana leaves.
[0108] Figure 6 Northern blot hybridization confirmed that FAD2.1 mRNA was strongly down-regulated by treatment with ledFAD2.1 at 6 and 24 hours.
[0109] Figure 7 The nucleotide sequence of the GUS target gene region (SEQ ID NO: 14) was aligned with the sense sequence of the hpGUS[G:U] construct (nucleotides 9 to 208 of SEQ ID NO: 11). Fifty-two cytosine (C) nucleotides were substituted with thymine (T) nucleotides. The retained nucleotides are marked with an asterisk; the substituted C nucleotides are not marked with an asterisk.
[0110] Figure 8 The nucleotide sequence of the GUS target gene region (SEQ ID NO: 14) was aligned with the sense sequence of the hpGUS[1:4] construct (nucleotides 9 to 208 of SEQ ID NO: 12). Relative to the corresponding wild-type sense sequence, every fourth nucleotide in hpGUS[1:4] was substituted, such that for every fourth nucleotide, C was changed to G, G was changed to C, A was changed to T, and T was changed to A. Retained nucleotides are marked with an asterisk, substituted G and C are not marked with an asterisk, and substituted A and T are marked with a semicolon.
[0111] Figure 9The nucleotide sequence of the GUS target gene region (SEQ ID NO: 14) was aligned with the sense sequence of the hpGUS [2:10] construct (nucleotides 9 to 208 of SEQ ID NO: 13). Relative to the corresponding wild-type sense sequence, every 9th and 10th nucleotide in each 10-nucleotide segment of hpGUS [2:10] was substituted, such that for every 9th and 10th nucleotide, C was changed to G, G was changed to C, A was changed to T, and T was changed to A. Retained nucleotides are marked with an asterisk, substituted G and C are not marked with an asterisk, and substituted A and T are marked with a semicolon.
[0112] Figure 10 Schematic diagram showing the structure of the genetic construct encoding the modified hairpin RNA targeting GUS mRNA.
[0113] Figure 11 Schematic diagram of the pWBPPGH vector, used to transform tobacco plants and deliver the GUS target gene. The T-DNA extends from the right border (RB) to the left border (LB) of the vector. The selectable marker gene on the T-DNA is the 35S-HPT-tm1' gene, which encodes hygromycin resistance.
[0114] Figure 12 GUS activity in plants transformed with a construct encoding a modified hairpin RNA for reducing GUS target gene expression. No hp: Control PPGH11 and PPGH24 plants without the hpGUS construct. The number of plants showing less than 10% GUS activity compared to the corresponding control PPGH11 or PPGH24 plants and the percentage of such plants relative to the number of plants tested are given in parentheses.
[0115] Figure 13 (A) Average GUS activity of all transgenic plants: 59 for hpGUS[wt], 74 for hpGUS[G:U], 33 for hpGUS[1:4], and 41 for hpGUS[2:10]. (B) Average GUS activity of all silenced plants (32 for hpGUS[wt], 71 for hpGUS[G:U], 33 for hpGUS[1:4], and 28 for hpGUS[2:10]).
[0116] Figure 14 . GUS activity in transgenic progeny plants containing hpGUS[wt], hpGUS[G:U] or hpGUS[1:4].
[0117] Figure 15Autoradiograph of a Southern blot of DNA from 16 plants transformed with the hpGUS[G:U] construct. DNA was digested with HindIII and probed with an OCS-T probe before gel electrophoresis. Lane 1: size marker (HindIII-digested lambda DNA); lanes 2 and 3: DNA from parental plants PPGHII and PPGH24; lanes 4-19: DNA from 16 different transgenic plants.
[0118] Figure 16 Autoradiographs of Northern blot hybridization experiments detecting sense (upper panel) and antisense (lower panel) sRNA from hairpin RNA expressed in transgenic tobacco plants. Lanes 1 and 2 contain RNA obtained from parental plants PPGHII and PPGH24 lacking the hpGUS construct. Lanes 3-11 contain RNA from hpGUS[wt] plants, and lanes 12-20 contain RNA from hpGUS[G:U] plants.
[0119] Figure 17 Autoradiograph of a Northern blot hybridization detecting antisense sRNA from transgenic plants. Lanes 1-10 are from hpGUS[wt] plants, and lanes 11-19 are from hpGUS[G:U] plants. The antisense sRNA has a mobility corresponding to a length of 20-24 nt. The blot was reprobed using antisense RNA to U6 RNA as a lane loading control.
[0120] Figure 18 Autoradiograph of repeated Northern blot hybridizations detecting antisense sRNA from transgenic plants.
[0121] Figure 19 DNA methylation analysis of the junction region between the 35S promoter and the sense GUS region in the hpGUS construct in transgenic plants. Before treating plant DNA with McrBC enzyme, the junction fragment was PCR amplified with (+) or without (-).
[0122] Figure 20 DNA methylation analysis of the 35S promoter region in the hpGUS construct in transgenic plants. Before treating plant DNA with McrBC enzyme, PCR amplification of the 35S fragment was performed with (+) or without (-).
[0123] Figure 21 Size distribution and abundance of processed RNA. (A) EIN2 construct. (B) GUS construct.
[0124] Figure 22Alignment of the sense sequence of the .hpEIN2[G:U] construct (upper sequence, nucleotides 17 to 216 of SEQ ID NO: 22) and the nucleotide sequence corresponding to the cDNA region of the Arabidopsis thaliana EIN2 target gene (lower sequence, SEQ ID NO: 27). The sense sequence was generated by replacing 43 cytosine (C) nucleotides in the wild-type sequence with thymine (T) nucleotides. The retained nucleotides are marked with an asterisk; the substituted C nucleotides are not marked with an asterisk.
[0125] Figure 23 Alignment of the sense sequence of the .hpCHS[G:U] construct (top sequence, nucleotides 13 to 212 of SEQ ID NO:24) with the nucleotide sequence corresponding to the cDNA region of the Arabidopsis thaliana CHS target gene (SEQ ID NO:28, in reverse order). The sense sequence was generated by replacing 65 cytosine (C) nucleotides in the wild-type sequence with thymine (T) nucleotides. The retained nucleotides are marked with an asterisk; the substituted C is not marked with an asterisk.
[0126] Figure 24 Alignment of the antisense sequence of the .hpEIN2[G:U / U:G] construct (upper sequence, nucleotides 8 to 207 of SEQ ID NO:25) and the nucleotide sequence corresponding to the complement region of the Arabidopsis thaliana EIN2 target gene (lower sequence, SEQ ID NO:29). The antisense sequence was generated by replacing 49 cytosine (C) nucleotides in the wild-type sequence with thymine (T) nucleotides. The retained nucleotides are marked with an asterisk; the substituted C nucleotides are not marked with an asterisk.
[0127] Figure 25 Alignment of the antisense sequence of the .hpCHS[G:U / U:G] construct (upper sequence, nucleotides 13 to 212 of SEQ ID NO:26) and the nucleotide sequence corresponding to the complement region of the Arabidopsis thaliana CHS target gene (lower sequence, SEQ ID NO:30). The antisense sequence was generated by replacing 49 cytosine (C) nucleotides in the wild-type sequence with thymine (T) nucleotides. The retained nucleotides are marked with an asterisk; the substituted Cs are not marked with an asterisk.
[0128] Figure 26 Schematic diagram of ethylene-insensitive 2 (EIN2) and chalcone synthase (CHS) hpRNA constructs. 35S: CaMV 35S promoter; EIN2 and CHS regions are shown as wild-type (wt) or G:U-modified (G:U) sequences. Arrows indicate the orientation of the DNA fragments; arrows from right to left indicate antisense sequences. Restriction enzyme sites are also shown.
[0129] Figure 27 Hypocotyl length of transgenic Arabidopsis thaliana seedlings containing hpEIN2[wt] or hpEIN2[G:U] in the EIN2 assay.
[0130] Figure 28 For CHS mRNA in transgenic A. thaliana, qRT-PCR normalized the transgene expression of hpCHS[wt] or hpCHS[G:U] constructs to the level of Actin 2 RNA. Col-0 is wild-type (non-transgenic) A. thaliana.
[0131] Figure 29 Autoradiographs of Northern blot hybridizations of RNA from plants transformed with hpEIN2[wt] or hpEIN2[G:U]. The upper panel shows the hypocotyl length of the lines. The autoradiograph shows a Northern blot probed with the EIN2 sense probe to detect antisense sRNA. The same blot was reprobed with the U6 RNA probe as a loading control (U6 RNA).
[0132] Figure 30 DNA methylation analysis of the 35S promoter and 35S-sense EIN2 sequences in genomic DNA from transgenic Arabidopsis (A. thaliana) plants.
[0133] Figure 31 .DNA methylation levels in the promoter and 5' regions of hairpin RNA constructs.
[0134] Figure 32 The 35S promoter in the least methylated line of the .hpEIN2[wt] population still showed significant methylation.
[0135] Figure 33 .G: The 35S promoter in the U hpEIN2 line showed only weak methylation (P<10%).
[0136] Figure 34 .ledRNA and hpRNA with G:U gene silencing in CHO and Vero cells at 72 hours.
[0137] Figure 35 .The dumbbell-shaped plasmid was tested in HeLa cells at 48 hours.
[0138] Figure 36 Examples of possible modifications of dsRNA molecules.
[0139] Figure 37Aphid performance decreased after feeding an artificial diet supplemented with ledRNA to downregulate the expression of the MpC002 or MpRack-1 genes in green peach aphids. Upper panel (A): Average number of nymphs per adult aphid after a ten-day period with 100 μl of 50 ng / μl ledRNA. Lower panel (B): Percentage of aphids surviving over a five-day period after feeding 100 μl of 200 ng / μl ledRNA containing MpC002, MpRack-1, or the control ledGFP.
[0140] Keywords for sequence listings
[0141] SEQ ID NO: 1—Ribonucleotide sequence of GFP ledRNA.
[0142] SEQ ID NO: 2—Ribonucleotide sequence of GUS ledRNA.
[0143] SEQ ID NO: 3—Ribonucleotide sequence of N. benthamiana FAD2.1 ledRNA.
[0144] SEQ ID NO:4—Nucleotide sequence encoding GFP ledRNA.
[0145] SEQ ID NO:5—Nucleotide sequence encoding GUS ledRNA.
[0146] SEQ ID NO:6—Nucleotide sequence encoding N. benthamiana FAD2.1 ledRNA.
[0147] SEQ ID NO:7—Nucleotide sequence encoding GFP.
[0148] SEQ ID NO:8—Nucleotide sequence encoding GUS.
[0149] SEQ ID NO:9—Nucleotide sequence encoding N. benthamiana FAD2.1.
[0150] SEQ ID NO: 10—Nucleotide sequence used to provide the GUS sense region for a construct encoding a hairpin RNA molecule that targets GUS mRNA.
[0151] SEQ ID NO: 11—Nucleotide sequence used to provide the GUS sense region for a construct encoding the hairpin RNA molecule hpGUS[G:U].
[0152] SEQ ID NO: 12—Nucleotide sequence used to provide the GUS sense region for the construct encoding the hairpin RNA molecule hpGUS[1:4].
[0153] SEQ ID NO: 13—Nucleotide sequence used to provide the GUS sense region for the construct encoding the hairpin RNA molecule hpGUS[2:10].
[0154] SEQ ID NO: 14 - Nucleotide sequence of nucleotides 781-1020 of the protein coding region of the GUS gene.
[0155] SEQ ID NO: 15 - Ribonucleotide sequence of the hairpin structure (including its loop) of hpGUS [wt] RNA.
[0156] SEQ ID NO: 16 - Ribonucleotides of the hairpin structure (including the loop) of hpGUS[G:U] RNA.
[0157] SEQ ID NO: 17 - Ribonucleotides of the hairpin structure (including its loop) of hpGUS[1:4] RNA.
[0158] SEQ ID NO: 18 - Ribonucleotides of the hairpin structure (including the loop) of hpGUS[2:10] RNA.
[0159] SEQ ID NO: 19—Nucleotide sequence corresponding to the cDNA of the A. thaliana EIN2 gene, Accession No. NM_120406.
[0160] SEQ ID NO:20—Nucleotide sequence corresponding to the cDNA of the Arabidopsis thaliana CHS gene, Accession No. NM_121396, 1703 nt.
[0161] SEQ ID NO:21—Nucleotide sequence of a DNA fragment comprising a 200 nt sense sequence from the cDNA corresponding to the A. thaliana EIN2 gene flanked by restriction enzyme sites.
[0162] SEQ ID NO:22 - Nucleotide sequence of a DNA fragment comprising the 200 nt sense sequence of EIN2, identical to SEQ ID NO:21, except that 43 C's are replaced by T's, used to construct hpEIN2[G:U].
[0163] SEQ ID NO:23—Nucleotide sequence of a DNA fragment comprising a 200 nt sense sequence from the cDNA corresponding to A. thaliana CHS flanked by restriction enzyme sites.
[0164] SEQ ID NO:24 - Nucleotide sequence of a DNA fragment containing the 200 nt sense sequence of CHS, identical to SEQ ID NO:23, except that 65 C's are replaced by T's, used to construct hpCHS[G:U].
[0165] SEQ ID NO:25—Nucleotide sequence of a DNA fragment comprising the 200 nt antisense sequence of EIN2, except that 50 C's were substituted for T's, used to construct hpEIN2[G:U / U:G].
[0166] SEQ ID NO:26—Nucleotide sequence of a DNA fragment comprising the 200 nt antisense sequence of CHS, except that 49 C's were substituted for T's, used to construct hpCHS[G:U / U:G].
[0167] SEQ ID NO:27—Nucleotide sequence corresponding to nucleotides 601-900 of the cDNA of the A. thaliana EIN2 gene (Accession No. NM_120406).
[0168] SEQ ID NO:28—Nucleotide sequence corresponding to nucleotides 813-1112 of the cDNA of the A. thaliana CHS gene (Accession No. NM_121396).
[0169] SEQ ID NO:29—Nucleotide sequence corresponding to the complement of nucleotides 652-891 of the cDNA of the A. thaliana EIN2 gene (Accession No. NM_120406).
[0170] SEQ ID NO:30—Nucleotide sequence corresponding to the complement of nucleotides 804-1103 of the cDNA of the Arabidopsis thaliana CHS gene.
[0171] SEQ ID NO: 31 - FANCM I protein coding region of cDNA from Arabidopsis thaliana, accession number NM_001333162. Target region nucleotides 675-1174 (500 nucleotides)
[0172] SEQ ID NO: 32 - FANCM I protein coding region of Brassica napus cDNA. Target region nucleotides 896-1395 (500 bp)
[0173] SEQ ID NO: 33 - Nucleotide sequence encoding hpFANCM-At[wt], which targets the FANCM I protein coding region of Arabidopsis thaliana. FANCM sense sequence, nucleotides 38-537; loop sequence, nucleotides 538-1306; FANCM antisense sequence, nucleotides 1307-1806.
[0174] SEQ ID NO: 34 - Nucleotide sequence encoding hpFANCM-At[G:U], which targets the FANCM I protein coding region of Arabidopsis thaliana. FANCM sense sequence, nucleotides 38-537; loop sequence, nucleotides 538-1306; FANCM antisense sequence, nucleotides 1307-1806.
[0175] SEQ ID NO: 35 - Nucleotide sequence encoding hpFANCM-Bn [wt], which targets the FANCM I protein coding region of B. napus. FANCM sense sequence, nucleotides 34-533; loop sequence, nucleotides 534-1300; FANCM antisense sequence, nucleotides 1301-1800.
[0176] SEQ ID NO: 36 - Nucleotide sequence encoding hpFANCM-Bn[G:U], which targets the FANCM I protein coding region of B. napus. FANCM sense sequence, nucleotides 34-533; loop sequence, nucleotides 534-1300; FANCM antisense sequence, nucleotides 1301-1800.
[0177] SEQ ID NO:37—Nucleotide sequence corresponding to the protein coding region of the cDNA of B. napus DDM1 gene; Accession No. XR_001278527.
[0178] SEQ ID NO:38—Nucleotide sequence of DNA encoding hpDDM1-Bn[wt], which targets the DDM1 protein coding region of B. napus.
[0179] SEQ ID NO: 39 - Nucleotide sequence encoding hpDDM1-Bn[G:U], which targets the DDM1 protein coding region of B. napus. DDM1 sense sequence, nucleotides 35-536; loop sequence, nucleotides 537-1304; DDM1 antisense sequence, nucleotides 1305-1805.
[0180] SEQ ID NO:40—EGFP cDNA.
[0181] SEQ ID NO: 41 - Nucleotide sequence of the coding region of hpEGFP [wt], in antisense / loop / sense order relative to the promoter.
[0182] SEQ ID NO:42 - Nucleotide sequence of the coding region of hpEGFP[G:U] having 157 C to T substitutions in the EGFP sense sequence.
[0183] SEQ ID NO:43 - Nucleotide sequence of the coding region of ledEGFP[wt] without the C to T substitution in the EGFP sense sequence.
[0184] SEQ ID NO:44 - Nucleotide sequence of the coding region of ledEGFP[G:U] having 162 C to T substitutions in the EGFP sense sequence.
[0185] SEQ ID NO:45—Nucleotide sequence used to provide the GUS sense region for a construct encoding the hairpin RNA molecule hpGUS[G:U] not flanked by restriction enzyme sites.
[0186] SEQ ID NO:46—Nucleotide sequence used to provide the GUS sense region for a construct encoding the hairpin RNA molecule hpGUS[1:4] not flanked by restriction enzyme sites.
[0187] SEQ ID NO:47—Nucleotide sequence used to provide the GUS sense region for a construct encoding the hairpin RNA molecule hpGUS[2:10] not flanked by restriction enzyme sites.
[0188] SEQ ID NO:48 - Nucleotide sequence of a DNA fragment comprising the 200 nt sense sequence of EIN2, identical to SEQ ID NO:21, except that 43 C's are replaced with T's, used to construct hpEIN2[G:U] without flanking sequences.
[0189] SEQ ID NO:49 - Nucleotide sequence of a DNA fragment containing the 200 nt sense sequence of CHS, identical to SEQ ID NO:23, except that 65 C's are replaced with T's, used to construct hpCHS[G:U] without flanking sequences.
[0190] SEQ ID NO:50—Nucleotide sequence of a DNA fragment comprising the 200 nt antisense sequence of EIN2, except that 50 C's replace T's, used to construct hpEIN2[G:U / U:G] without flanking sequences.
[0191] SEQ ID NO:51 —Nucleotide sequence of a DNA fragment comprising a 200 nt antisense sequence of CHS, except that 49 C's replace T's, used to construct the hpCHS[G:U / U:G] sequence without flanking sequences.
[0192] SEQ ID No: 52 - Oligonucleotide primer for amplifying 200 bp GUS sense sequence (GUS-WT-F)
[0193] SEQ ID No: 53 - Oligonucleotide primer for amplifying 200 bp GUS sense sequence (GUS-WT-R)
[0194] SEQ ID NO:54 - Oligonucleotide primer (forward) for production of hpGUS[G:U] fragment in which each C is replaced by a T (GUS-GU-F)
[0195] SEQ ID NO:55 - Oligonucleotide primer (reverse) for production of hpGUS[G:U] fragments in which each C is replaced by a T (GUS-GU-R)
[0196] SEQ ID NO:56 - Oligonucleotide primer (forward) for production of hpGUS[1:4] fragments in which every fourth nucleotide is substituted (GUS-4M-F)
[0197] SEQ ID NO:57 - Oligonucleotide primer (reverse) for production of hpGUS[1:4] fragments in which every fourth nucleotide is substituted (GUS-4M-R)
[0198] SEQ ID NO:58 - Oligonucleotide primer (forward) for production of hpGUS[2:10] fragment in which every 9th and 10th nucleotides are substituted (GUS-10M-F)
[0199] SEQ ID NO:59 - Oligonucleotide primer (reverse) for production of hpGUS[2:10] fragment in which every 9th and 10th nucleotides are substituted (GUS-10M-R)
[0200] SEQ ID No: 60 - Nucleotide sequence encoding forward primer (35S-F3)
[0201] SEQ ID NO:61 - Nucleotide sequence encoding reverse primer (GUSwt-R2)
[0202] SEQ ID NO:62 - Nucleotide sequence encoding forward primer (GUSgu-R2)
[0203] SEQ ID NO:63 - Nucleotide sequence encoding reverse primer (GUS4m-R2)
[0204] SEQ ID No: 64 - Nucleotide sequence encoding forward primer (35S-F2)
[0205] SEQ ID NO: 65 - Nucleotide sequence encoding reverse primer (35S-R1)
[0206] SEQ ID NO: 66 - Oligonucleotide primer for amplifying the wild-type 200 bp EIN2 sense sequence (EIN2wt-F)
[0207] SEQ ID NO:67 - Oligonucleotide primer for amplifying the wild-type 200 bp EIN2 sense sequence (EIN2wt-R)
[0208] SEQ ID No: 68 - Oligonucleotide primer for amplification of wild-type 200 bp CHS sense sequence (CHSwt-F)
[0209] SEQ ID No: 69 - Oligonucleotide primer for amplification of wild-type 200 bp CHS sense sequence (CHSwt-R)
[0210] SEQ ID NO:70 - Oligonucleotide primer (forward) for producing a hpEIN2[G:U] fragment in which each C is replaced by a T (EIN2gu-F)
[0211] SEQ ID NO:71 - Oligonucleotide primer (reverse) for production of hpEIN2[G:U] fragment in which each C is replaced by a T (EIN2gu-R)
[0212] SEQ ID NO:72 - Oligonucleotide primer (forward) for production of hpCHS[G:U] fragments in which each C is replaced by a T (CHSgu-F)
[0213] SEQ ID NO:73 - Oligonucleotide primer (reverse) for production of hpCHS[G:U] fragments in which each C is replaced by a T (CHSgu-R)
[0214] SEQ ID NO:74 - Oligonucleotide primer (forward) for generating a hpEIN2[G:U / U:G] fragment in which each C is replaced by a T (asEIN2gu-F)
[0215] SEQ ID NO:75 - Oligonucleotide primer (reverse) for producing a hpEIN2[G:U / U:G] fragment in which each C is replaced by a T (asEIN2gu-R)
[0216] SEQ ID NO:76 - Oligonucleotide primer (forward) for production of hpCHS[G:U / U:G] fragment in which each C is replaced by a T (asCHSgu-F)
[0217] SEQ ID NO:77 - Oligonucleotide primer (reverse) for production of hpCHS[G:U / U:G] fragments in which each C is replaced by a T (asCHSgu-R)
[0218] SEQ ID No: 78 - Nucleotide sequence encoding forward primer (CHS-200-F2)
[0219] SEQ ID NO:79 - Nucleotide sequence encoding reverse primer (CHS-200-R2)
[0220] SEQ ID No: 80 - Nucleotide sequence encoding forward primer (Actin2-For)
[0221] SEQ ID NO:81 - Nucleotide sequence encoding reverse primer (Actin2-Rev)
[0222] SEQ ID NO:82 - Nucleotide sequence encoding forward primer (Top-35S-F2)
[0223] SEQ ID NO:83 - Nucleotide sequence encoding reverse primer (Top-35S-R2)
[0224] SEQ ID NO:84 - Nucleotide sequence encoding forward primer (Link-35S-F2)
[0225] SEQ ID NO:85 - Nucleotide sequence encoding reverse primer (Link-EIN2-R2)
[0226] SEQ ID NO: 86 - sense si22 - ribonucleotide sequence
[0227] SEQ ID NO: 87 - Antisense si22-ribonucleotide sequence
[0228] SEQ ID NO:88 - Ribonucleotide sequence of forward primer
[0229] SEQ ID NO:89 - Ribonucleotide sequence of reverse primer
[0230] SEQ ID NO:90 - Ribonucleotide sequence of forward primer
[0231] SEQ ID NO:91 - Ribonucleotide sequence of reverse primer
[0232] SEQ ID NO:92 - Possible modifications of dsRNA molecules
[0233] SEQ ID NO:93—Nucleotide sequence corresponding to the cDNA of the B. napus DDM1 gene (Accession No. XR_001278527).
[0234] SEQ ID NO:94—Nucleotide sequence of chimeric DNA encoding a hairpin RNAi (hpRNA) construct targeting the B. napus DDM1 gene.
[0235] SEQ ID NO:95—Nucleotide sequence encoding a chimeric DNA hairpin RNAi (hpRNA) construct targeting the B. napus DDM1 gene with G:U base pairs.
[0236] SEQ ID NO:96—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the B. napus DDM1 gene.
[0237] SEQ ID NO:97—Nucleotide sequence corresponding to the cDNA of the A. thaliana FANCM gene (Accession No. NM_001333162).
[0238] SEQ ID NO:98—Nucleotide sequence of chimeric DNA encoding a hairpin RNAi (hpRNA) construct targeting the Arabidopsis (A. thaliana) FANCM gene.
[0239] SEQ ID NO:99—Nucleotide sequence encoding a chimeric DNA hairpin RNAi (hpRNA) construct targeting the Arabidopsis thaliana (A. thaliana) FANCM gene with G:U base pairs.
[0240] SEQ ID NO: 100—Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the Arabidopsis (A. thaliana) FANCM gene.
[0241] SEQ ID NO: 101—Nucleotide sequence corresponding to the cDNA of the B. napus FANCM gene (Accession No. XM_022719486.1).
[0242] SEQ ID NO: 102—Nucleotide sequence of chimeric DNA encoding a hairpin RNAi (hpRNA) construct targeting the B. napus FANCM gene.
[0243] SEQ ID NO: 103—Nucleotide sequence encoding a chimeric DNA hairpin RNAi (hpRNA) construct targeting the B. napus FANCM gene with G:U base pairs.
[0244] SEQ ID NO: 104—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the B. napus FANCM gene.
[0245] SEQ ID NO: 105—Nucleotide sequence corresponding to the protein coding region of the cDNA of the Nicotiana benthamiana TOR gene.
[0246] SEQ ID NO: 106—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the Nicotiana benthamiana TOR gene.
[0247] SEQ ID NO: 107: Nucleotide sequence corresponding to the protein coding region of the cDNA of the acetolactate synthase (ALS) gene from barley ( Hordeum vulgare ) (Accession No. LT601589).
[0248] SEQ ID NO: 108—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the barley (H. vulgare) ALS gene.
[0249] SEQ ID NO: 109: Nucleotide sequence corresponding to the protein coding region of the cDNA of the barley (Hordeum vulgare) HvNCED1 gene (Accession No. AK361999).
[0250] SEQ ID NO: 110—Nucleotide sequence corresponding to the protein coding region of the cDNA corresponding to the Hordeum vulgare HvNCEDD2 gene (Accession No. DQ145931).
[0251] SEQ ID NO: 111—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the NCED1 gene of barley (Hordeum vulgare) and wheat (Triticum aestivum).
[0252] SEQ ID NO: 112—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the NCED2 gene of barley (Hordeum vulgare) and wheat (Triticum aestivum).
[0253] SEQ ID NO: 113: Nucleotide sequence corresponding to the protein coding region of the cDNA of the barley gene encoding ABA-OH-2 (Accession No. DQ145933).
[0254] SEQ ID NO: 114—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the ABA-OH-2 gene of barley (Hordeum vulgare) and wheat (Triticum aestivum).
[0255] SEQ ID NO: 115—Nucleotide sequence corresponding to the cDNA protein coding region of the A. thaliana gene (At5g03280) encoding EIN2.
[0256] SEQ ID NO: 116—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the Arabidopsis (A. thaliana) EIN2 gene.
[0257] SEQ ID NO: 117: Nucleotide sequence corresponding to the protein coding region of the cDNA of the Arabidopsis thaliana gene encoding CHS (Accession No. NM_121396).
[0258] SEQ ID NO: 118—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the Arabidopsis thaliana CHS gene.
[0259] SEQ ID NO: 119: Nucleotide sequence corresponding to the protein coding region of the cDNA encoding the Lupinus angustifolius N-like gene (Accession No. XM_019604347).
[0260] SEQ ID NO: 120—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting a L. angustifolius N-like gene.
[0261] SEQ ID NO: 121 - Nucleotide sequence corresponding to the protein coding region of the cDNA of the Vitis pseudoreticulata MLO gene (Accession No. KR362912).
[0262] SEQ ID NO: 122—Nucleotide sequence of chimeric DNA encoding a first ledRNA construct targeting the Vitis huadong MLO gene.
[0263] SEQ ID NO: 123—Nucleotide sequence corresponding to the protein coding region of the cDNA of the Myzus persicae MpC002 gene.
[0264] SEQ ID NO: 124—Nucleotide sequence corresponding to the protein coding region of the cDNA of the MpRack-1 gene of Myzus persicae.
[0265] SEQ ID NO: 125—Nucleotide sequence of a chimeric construct encoding a ledRNA targeting the M. persicae C002 gene.
[0266] SEQ ID NO: 126—Nucleotide sequence of a chimeric construct encoding a ledRNA targeting the M. persicae Rack-1 gene.
[0267] SEQ ID NO: 127—Nucleotide sequence corresponding to the cDNA of the Helicoverpa armigera ABCwhite gene.
[0268] SEQ ID NO: 128—Nucleotide sequence of chimeric DNA encoding a ledRNA construct targeting the ABC transporter gene of Helicoverpa armigera.
[0269] SEQ ID NO: 129—Nucleotide sequence corresponding to the cDNA of the Argentine ant (Linepithema humile) PBAN-type neuropeptide-like (Accession No. XM_012368710).
[0270] SEQ ID NO: 130: Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the PBAN gene in Argentine ants (Accession No. XM_012368710).
[0271] SEQ ID NO: 131: Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the gene encoding the catalytic subunit A of the V-type proton ATPase of L. cuprina (Accession No. XM_023443547).
[0272] SEQ ID NO: 132—Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the gene encoding RNAse 1 / 2 of L. cuprina.
[0273] SEQ ID NO: 133—Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the gene encoding chitin synthase of L. cuprina.
[0274] SEQ ID NO: 134—Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the gene encoding the ecdysone receptor (EcR) of L. cuprina.
[0275] SEQ ID NO: 135—Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the gene encoding gamma-tubulin 1 / 1 of L. cuprina.
[0276] SEQ ID NO: 136—TaMlo target gene (AF384144).
[0277] SEQ ID NO: 137—Nucleotide sequence of a chimeric DNA encoding a ledRNA construct targeting the gene encoding TaMlo.
[0278] SEQ ID NO: 138 - Nucleotide sequence corresponding to the protein coding region of the cDNA of the Vitis pseudoreticulata MLO gene (Accession No. KR362912).
[0279] SEQ ID NO: 139—Nucleotide sequence of chimeric DNA encoding a first ledRNA construct targeting the Vitis huadong MLO gene. DETAILED DESCRIPTION
[0280] General techniques and definitions
[0281] Unless specifically defined otherwise, all technical and scientific terms used herein should be understood to have the same meanings as commonly understood by one of ordinary skill in the art (eg, cell culture, molecular genetics, gene silencing, protein chemistry, and biochemistry).
[0282] Unless otherwise indicated, the recombinant protein, cell culture, and immunological techniques utilized in the present invention are standard methods well known to those skilled in the art. This technique is described throughout the literature in sources such as: J. Perbal, APractical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), TA Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press(1991),DMGlover and BDHames(editors),DNACloning:A Practical Approach,Volumes 1-4,IRL Press(1995and 1996),andF.M.Ausubel et al.(editors),Current Protocols in Molecular Biology,GreenePub.Associates and Wiley-Interscience(1988,including all updates untilpresent),Ed Harlow and David Lane(editors)Antibodies:A Laboratory Manual,ColdSpring Harbor Laboratory, (1988), and JEColigan et al. (editors) CurrentProtocols in Immunology, John Wiley&Sons (including all updates until present).
[0283] As used herein, the term "antisense regulatory element" or "antisense ribonucleic acid sequence" or "antisense RNA sequence" refers to an RNA sequence that is at least partially complementary to at least a portion of a target RNA molecule to which it hybridizes. In certain embodiments, the antisense RNA sequence modulates (increases or decreases) the expression or amount of the target RNA molecule or its activity, for example by reducing the translation of the target RNA molecule. In certain embodiments, the antisense RNA sequence alters the splicing of the target precursor mRNA, resulting in different splice variants. Exemplary components of antisense sequences include, but are not limited to, oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics, and chimeric combinations of these.
[0284] The term "antisense activity" is used in the context of the present invention to refer to any detectable and / or measurable activity attributed to the hybridization of an antisense RNA sequence with its target RNA molecule. This detection and / or measurement can be direct or indirect. In one embodiment, antisense activity is assessed by detecting and / or measuring the amount of the target RNA molecule transcript. Antisense activity can also be detected as a phenotypic change associated with the target RNA molecule. As used herein, the term "target RNA molecule" refers to a gene transcript regulated by an antisense RNA sequence according to the present invention. Therefore, a "target RNA molecule" can be any RNA molecule whose expression or activity can be regulated by an antisense RNA sequence. Exemplary target RNA molecules include, but are not limited to, RNA (including but not limited to pre-mRNA and mRNA or portions thereof), rRNA, tRNA, small nuclear RNA, and miRNA transcribed from DNA encoding the target protein, including their precursor forms. The target RNA can be the genomic RNA of a pathogen or pest such as a virus, or an RNA molecule derived therefrom, such as a replication form of a viral pathogen, or its transcript. In one embodiment, the target RNA molecule is a protein encoding a target protein. For example, the target RNA molecule can be an RNA from an endogenous gene (or from an mRNA transcribed from the gene), or is introduced into or can be introduced into a gene of a eukaryotic cell whose expression is relevant to a particular phenotype, proterties, disease or morbid state, or a nucleic acid molecule from an infectious agent. In one embodiment, the target RNA molecule is in a eukaryotic cell. In another embodiment, the target RNA molecule encodes a protein. In this article, antisense activity can be assessed by detecting and / or measuring the amount of the target protein, for example, by its activity such as enzymatic activity, or by being different from the function of an enzyme, or by the phenotype related to its function. As used herein, the term "target protein" refers to a protein regulated by an antisense RNA sequence according to the present invention.
[0285] In certain embodiments, antisense activity is assessed by detecting and / or measuring the amount of a target RNA molecule and / or a cleaved target RNA molecule and / or an alternatively spliced target RNA molecule.
[0286] Antisense activity can be detected or measured using various methods. For example, antisense activity can be detected or assessed by comparing the activity in a particular sample and comparing that activity to the activity of a control sample.
[0287] The term "targeting" is used in the context of the present invention to refer to the association of an antisense RNA sequence with a specific target RNA molecule or a specific nucleotide region within a target RNA molecule. In one embodiment, the antisense RNA sequence according to the present invention shares complementarity with at least one region of a target RNA molecule. In this article, the term "complementarity" refers to a ribonucleotide sequence that can base-pair with a ribonucleotide sequence on a target RNA molecule through hydrogen bonds between bases on the ribonucleotide. For example, in RNA, adenine (A) is complementary to uracil (U), and guanine (G) is complementary to cytosine (C).
[0288] In certain embodiments, "complementary bases" refer to ribonucleotides of an antisense RNA sequence that can base pair with ribonucleotides of a sense RNA sequence in an RNA molecule of the present invention or its target RNA molecule. For example, if a ribonucleotide at a certain position of the antisense RNA sequence is capable of hydrogen bonding with a ribonucleotide at a certain position of the target RNA molecule, the position of hydrogen bonding between the antisense RNA sequence and the target RNA molecule is considered to be complementary on that ribonucleotide. In contrast, the term "non-complementary" refers to a pair of ribonucleotides that do not form hydrogen bonds with each other or otherwise support hybridization. The term "complementary" can also be used to refer to the ability of an antisense RNA sequence to hybridize with another nucleic acid through complementarity. In certain embodiments, when a sufficient number of corresponding positions in each molecule are occupied by ribonucleotides, the RNA sequence and its target are complementary to each other, and the ribonucleotides can bind to each other to allow stable association between the antisense RNA sequence and the sense RNA sequence in the RNA molecule of the present invention and / or the target RNA molecule. Those skilled in the art recognize that mismatches can be included without eliminating the ability of the antisense RNA sequence and the target to remain associated. Thus, antisense RNA sequences are described herein that may contain up to about 20% mismatched nucleotides (i.e., not complementary to the corresponding nucleotides of the target sequence). Preferably, the antisense compound contains no more than about 15%, more preferably no more than about 10%, most preferably no more than 5% or no mismatches. The remaining ribonucleotides are complementary or do not disrupt the hybridization between the antisense RNA sequence and the sense RNA sequence or the target RNA molecule (e.g., G:U or A:G pairs). One of ordinary skill in the art will recognize that the antisense RNA sequences described herein are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% (completely) complementary to at least one region of the target RNA molecule.
[0289] As used herein, a "chimeric RNA molecule" refers to any RNA molecule that does not exist in nature. In one embodiment, the chimeric RNA molecules disclosed herein have been modified to create mismatches in a region of the dsRNA. For example, the chimeric RNA molecule can be modified to convert cytosine to uracil. In one embodiment, the chimeric RNA molecule has been modified by treatment with bisulfite for a time and under conditions sufficient to convert unmethylated cytosine to uracil.
[0290] Those skilled in the art will appreciate that various ribonucleotide combinations can base pair. The present invention contemplates both canonical and non-canonical base pairs. In one embodiment, the base pairing can comprise A:T or G:C in a DNA molecule or U:A or G:C in an RNA molecule. In another embodiment, the base pairing can comprise A:G or G:T or U:G.
[0291] The term "canonical base pairing" as used in the present invention means base pairing between two nucleotides, which is A:T or G:C for deoxyribonucleotides, or A:U or G:C for ribonucleotides.
[0292] As used in the present invention, the term "non-canonical base pairing" means the interaction between the bases of two nucleotides other than canonical base pairing in the context of two DNA or two RNA sequences. For example, non-canonical base pairing includes pairing between G and U (G:U) or between A and G (A:G). Examples of non-canonical base pairing include purine-purine or pyrimidine-pyrimidine. In the context of the present invention, the most common non-canonical base pairing is G:U. Other examples of non-canonical base pairs are less preferably A:C, G:T, G:G and A:A.
[0293] The present invention relates to RNA components that "hybridize" across a series of ribonucleotides. Those skilled in the art will understand that terms such as "hybridization" and "hybridization" are used to describe molecules based on the annealing of complementary nucleic acid sequences. Such molecules do not need to be 100% complementary in order to hybridize (i.e., they do not need to be "perfectly base-paired." For example, there may be one or more mismatches in sequence complementarity. In one embodiment, the RNA components defined herein hybridize under stringent hybridization conditions. The term "stringent hybridization conditions" refers to parameters familiar in the art, including the variation of hybridization temperature with the length of the RNA molecule. Ribonucleotide hybridization parameters can be found in the references compiling these methods, Sambrook et al. (see above), and Ausubel et al. (see above). For example, stringent hybridization conditions as used herein can refer to hybridization at 65°C in hybridization buffer (3.5×SSC, 0.02% polysucrose, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin (BSA), 2.5mM NaH2PO4 (pH 7), 0.5% SDS, 2mM The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below. The hybridization conditions are described in detail below.
[0294] The present invention also encompasses RNA components that span "perfect base pairs" of adjacent ribonucleotides. The term "perfect base pairs" is used in the context of the present invention to refer to a series of adjacent ribonucleotide base pairs. A perfectly base-paired series of adjacent ribonucleotides does not contain gaps or non-base-paired nucleotides within the series. The term "adjacent" is used to refer to a series of ribonucleotides. A ribonucleotide comprising an adjacent series will be connected by a continuous series of phosphodiester bonds, with each ribonucleotide directly bonded to the next.
[0295] The RNA molecules of the present invention comprise a sense sequence and a corresponding antisense sequence. The relationship between these sequences is defined herein. The sequence relationship and activity of the antisense sequence and the target RNA molecule are also defined herein.
[0296] The term "covalently linked" is used in the context of the present invention to refer to the connection between the first and second RNA components or any RNA sequence or ribonucleotides. As will be understood by those skilled in the art, a covalent link or bond is a chemical bond involving the sharing of electron pairs between atoms. In one embodiment, the first and second RNA components or the sense RNA sequence and the antisense RNA sequence are covalently linked as part of a single RNA strand that can fold back on itself through self-complementarity. In this embodiment, the components are covalently linked across one or more ribonucleotides via phosphodiester bonds.
[0297] In the context of the present invention, the term "hybridization" means pairing of complementary polynucleotides by base pairing of complementary bases. Although not limited to a particular mechanism, the most common pairing mechanism involves hydrogen bonding between complementary ribonucleotides, which can be Watson-Crick hydrogen bonding.
[0298] As used herein, the phrase "an RNA molecule has a deleterious effect on a non-human organism" or similar phrases means that a target RNA molecule of the molecule is present in the non-human organism and that exposing a cell expressing the target RNA molecule to the target RNA molecule results in a decrease in the level and / or activity of the target RNA molecule when compared to the same cell lacking the RNA molecule. In one embodiment, the target RNA molecule encodes a protein that is important for growth, reproduction, or survival. As an example, if the non-human organism is a crop pest or pathogen, or an animal pest or pathogen, the RNA molecule can have a deleterious effect on the pest's or pathogen's feeding, apoptosis, cell differentiation and development, ability or desire for sexual reproduction, muscle formation, muscle twitching, muscle contraction, juvenile hormone formation, juvenile hormone regulation, ion regulation and transport, maintenance of cell membrane potential, amino acid biosynthesis, amino acid degradation, sperm formation, pheromone synthesis, pheromone sensing, antennae formation, wing formation, leg formation, egg formation, larval maturation, digestive enzyme formation, hemolymph synthesis, hemolymph maintenance, neurotransmission, larval stage transition, pupation, emergence from pupation, cell division, energy metabolism, respiration, chitin metabolism, or formation of cytoskeletal structure. In another example, the non-human organism is a weed, and the RNA molecule has a deleterious effect on amino acid biosynthesis, photosynthesis, fatty acid synthesis, cell membrane integrity, pigment synthesis, or growth.
[0299] As used herein, the phrase "the RNA molecule has a beneficial effect on at least one symptom of a disease" or similar phrases means that the target RNA of the molecule is present in a subject and that exposure of cells expressing the target RNA to the RNA molecule results in a decrease in the level and / or activity of the target RNA when compared to the same cells lacking the RNA molecule. In one embodiment, the target RNA encodes a protein that exerts an effect in the presence of a disease. In one embodiment, the disease is cancer or a cancerous disease, an infectious disease, a cardiovascular disease, a neurological disease, a prion disease, an inflammatory disease, an autoimmune disease, a lung disease, a kidney disease, a liver disease, a mitochondrial disease, an endocrine disease, a reproductive-related disease and disorder, and any other indication that can respond to the level of a gene product expressed in a cell or organism.
[0300] The RNA molecules according to the present invention and compositions comprising the RNA molecules can be administered to a subject. Terms such as "subject," "patient," or "individual" are terms that can be used interchangeably in the present invention in context. In one embodiment, the subject is a mammal. The mammal can be a pet, such as a dog or cat, or a domestic animal, such as a horse or a cow. In one embodiment, the subject is a human. For example, the subject can be an adult. In another embodiment, the subject can be a child. In another embodiment, the subject can be a teenager. In another embodiment, the RNA molecules according to the present invention and compositions comprising the same can be administered to insects. In another embodiment, the RNA molecules according to the present invention and compositions comprising the same can be administered to plants. In another embodiment, the RNA molecules according to the present invention and compositions comprising the same can be administered to fungal cells or colonies.
[0301] The term "and / or," such as "X and / or Y," should be understood to mean "X and Y" or "X or Y," and should be understood to provide explicit support for both meanings.
[0302] As used herein, unless otherwise indicated to the contrary, the term "about" means + / - 20%, more preferably + / - 10%, of the specified value.
[0303] Throughout the specification, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0304] RNA molecules
[0305] In certain embodiments, the RNA molecules of the invention comprise a first RNA component covalently linked to a second RNA component. In preferred embodiments, the RNA molecule self-hybridizes or folds to form a "dumbbell" or ledRNA structure, e.g., see Figure 1 In one embodiment, the molecule further comprises one or more of the following:
[0306] - a linker ribonucleotide sequence which covalently links the first and second RNA components;
[0307] -5' leader sequence; and,
[0308] -3' trailer sequence.
[0309] In one embodiment, the first RNA component consists of, in 5' to 3' order, a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide, wherein the first 5' and 3' ribonucleotides are base paired with each other in the RNA molecule, wherein the first RNA sequence comprises a first sense ribonucleotide sequence of at least 20 contiguous ribonucleotides, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence of at least 20 contiguous ribonucleotides, wherein the first antisense ribonucleotide sequence hybridizes to the first sense ribonucleotide sequence in the RNA molecule, and wherein the first antisense ribonucleotide sequence is capable of hybridizing to a first region of a target RNA molecule.
[0310] In another embodiment, the first RNA component consists of a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide in 5' to 3' order, wherein the first 5' and 3' ribonucleotides are base paired with each other in the RNA molecule, wherein the first RNA sequence comprises a first sense ribonucleotide sequence of at least 20 contiguous ribonucleotides, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence of at least 20 contiguous ribonucleotides, wherein the first antisense ribonucleotide sequence is completely base paired with the first sense ribonucleotide sequence in the RNA molecule, and wherein the first antisense ribonucleotide sequence is identical to the sequence of the complement of the first region of the target RNA molecule. Examples of the first RNA component of these two embodiments are schematically shown in Figure 1 The left half of A or Figure 1 In the right half of B.
[0311] In another embodiment, the first RNA component consists of a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide, wherein the first 5' and 3' ribonucleotides in the first RNA component are base paired with each other, wherein the first RNA sequence comprises a first sense ribonucleotide sequence, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence, wherein the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence each have at least 20 consecutive ribonucleotides, wherein the at least 20 consecutive ribonucleotides of the first sense ribonucleotide sequence are completely base paired with the at least 20 consecutive ribonucleotides of the first antisense ribonucleotide sequence, and wherein the at least 20 consecutive ribonucleotides of the first sense ribonucleotide sequence are substantially identical in sequence to the first region of the target RNA molecule.
[0312] In these embodiments, the base pair formed between the first 5' ribonucleotide and the first 3' ribonucleotide is considered to be the terminal base pair of the dsRNA region formed by self-hybridization of the first RNA component, ie, it defines the end of the dsRNA region.
[0313] In one embodiment, the first sense sequence has substantial sequence identity to a region of the target RNA, which identity can be to a sequence of less than 20 nucleotides in length. In one embodiment, at least 15, at least 16, at least 17, at least 18, or at least 19 contiguous ribonucleotides, preferably at least 20 contiguous ribonucleotides, of the first sense ribonucleotide sequence are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identical in sequence to the first region of the target RNA molecule. In another embodiment, at least 15, at least 16, at least 17, at least 18, or at least 19 contiguous ribonucleotides of the first sense ribonucleotide sequence are 100% identical to the first region of the target RNA molecule. In one embodiment, the first 3, first 4, first 5, first 6 or first 7 ribonucleotides from the 5' end of the first sense ribonucleotide sequence are 100% identical to a region of the target RNA molecule, and the remaining ribonucleotides are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the target RNA molecule.
[0314] In one embodiment, at least 20 contiguous ribonucleotides of the first sense ribonucleotide sequence are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the first region of the target RNA molecule. Similarly, in this embodiment, the first 3, first 4, first 5, first 6, or first 7 ribonucleotides may be 100% identical to the region of the target RNA molecule, with the remaining ribonucleotides being at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the target RNA molecule. In another embodiment, at least 20 contiguous ribonucleotides of the first sense ribonucleotide sequence are 100% identical to the first region of the target RNA molecule.
[0315] In one embodiment, the first antisense sequence has substantial sequence identity to the complement of the region of the target RNA, which identity can be identity to a sequence of less than 20 nucleotides in length of the complement. In one embodiment, at least 15, at least 16, at least 17, at least 18, or at least 19 contiguous ribonucleotides, preferably at least 20 contiguous ribonucleotides, of the first antisense ribonucleotide sequence are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or 99% identical in sequence to the complement of the first region of the target RNA molecule. In another embodiment, at least 15, at least 16, at least 17, at least 18, or at least 19 contiguous ribonucleotides of the first antisense ribonucleotide sequence are 100% identical to the complement of the first region of the target RNA molecule. In one embodiment, the first 3, first 4, first 5, first 6 or first 7 ribonucleotides from the 5' end of the first antisense ribonucleotide sequence are 100% identical to the complementary sequence of the target RNA molecule region, and the remaining ribonucleotides are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the complement of the target RNA molecule.
[0316] In one embodiment, at least 20 contiguous ribonucleotides of the first antisense ribonucleotide sequence are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the complement of the first region of the target RNA molecule. Similarly, in this embodiment, the first 3, first 4, first 5, first 6, or first 7 ribonucleotides are 100% identical to the complement of the region of the target RNA molecule, and the remaining ribonucleotides are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the complement of the target RNA molecule. In another embodiment, at least 20 contiguous ribonucleotides of the first antisense ribonucleotide sequence are 100% identical to the first region of the target RNA molecule.
[0317] In another embodiment, the second RNA component consists of, in 5' to 3' order, a second 5' ribonucleotide, a second RNA sequence, and a second 3' ribonucleotide, wherein the second 5' and 3' ribonucleotides are base paired, wherein the second RNA sequence comprises a second sense ribonucleotide sequence, a second loop sequence of at least 4 ribonucleotides, and a second antisense ribonucleotide sequence, wherein the second sense ribonucleotide sequence is base paired with the second antisense ribonucleotide sequence. In this embodiment, the base pair formed between the second 5' ribonucleotide and the second 3' ribonucleotide is considered to be the terminal base pair of the dsRNA region formed by self-hybridization of the second RNA component.
[0318] In one embodiment, the RNA molecule comprises a 5' leader sequence or a 5' extension sequence, which can be used as a promoter in a genetic construct, and is transcribed from the starting point of the polynucleotide encoding the remainder of the RNA molecule. Preferably, the 5' leader sequence or the 5' extension sequence is relatively short compared to the remainder of the molecule, and can be removed from the RNA molecule after transcription, for example, by RNA enzyme treatment. The 5' leader sequence or the 5' extension sequence can be mostly non-base paired, or can contain one or more stem-loop structures. In this embodiment, the 5' leader sequence can be made up of a ribonucleotide sequence, and if the second RNA component is connected to the first 3' ribonucleotide, the ribonucleotide sequence is covalently linked to the first 5' ribonucleotide, or if the second RNA component is connected to the first 5' ribonucleotide, the ribonucleotide sequence is covalently linked to the second 5' ribonucleotide. In one embodiment, the 5' leader sequence is at least 10, at least 20, at least 30, at least 100, at least 200 ribonucleotides long, preferably to a maximum length of 250 ribonucleotides. In another embodiment, the 5' leader sequence is at least 50 ribonucleotides long. In one embodiment, the 5' leader sequence can serve as an extension sequence for amplifying the RNA molecule by a suitable amplification reaction. For embodiments, the extension sequence can promote amplification by a polymerase.
[0319] In another embodiment, the RNA molecule comprises a 3' tail sequence or a 3' extension sequence, which may be produced due to continuous transcription until the transcription termination or polyadenylation signal in the construct encoding the RNA molecule. The 3' tail sequence or the 3' extension sequence may comprise a poly A (polyA) tail. Preferably, the 3' tail sequence or the 3' extension sequence is relatively short compared to the remainder of the molecule and can be removed from the RNA molecule after transcription, for example, by RNA enzyme treatment. The 3' tail sequence or the 3' extension sequence can be mostly non-base paired, or can contain one or more stem-loop structures. In this embodiment, the 3' tail sequence can be composed of a ribonucleotide sequence, and if the second RNA component is connected to the first 3' ribonucleotide, the ribonucleotide sequence is covalently linked to the second 3' ribonucleotide, or if the second RNA component is connected to the first 5' ribonucleotide, the ribonucleotide sequence is covalently linked to the first 3' ribonucleotide. In one embodiment, the 3' leader sequence is at least 10, at least 20, at least 30, at least 100, at least 200 ribonucleotides long, preferably up to a maximum length of 250 ribonucleotides. In another embodiment, the 3' leader sequence is at least 50 ribonucleotides long. In one embodiment, the 3' trailer sequence can serve as an extension sequence for amplifying RNA molecules by a suitable amplification reaction. For embodiments, the extension sequence can promote amplification by a polymerase.
[0320] In one embodiment, all nucleotides except two ribonucleotides are covalently linked to two other nucleotides, i.e., the RNA molecule consists of only one RNA strand with a self-complementary region and, therefore, has only one 5'-terminal nucleotide and one 3'-terminal nucleotide. In another embodiment, all nucleotides except four ribonucleotides are covalently linked to two other nucleotides, i.e., the RNA molecule consists of two RNA strands with hybridized complementary regions and, therefore, has only two 5'-terminal nucleotides and two 3'-terminal nucleotides. In another embodiment, each ribonucleotide is covalently linked to two other nucleotides, i.e., the RNA molecule is circular and has a self-complementary region and, therefore, has no 5'-terminal nucleotide and no 3'-terminal nucleotide.
[0321] In one embodiment, the double-stranded region of RNA molecule can comprise one or more protuberances produced by the unpaired nucleotides in sense RNA sequence or antisense RNA sequence or both. In one embodiment, RNA molecule comprises a series of protuberances. For embodiment, the double-stranded region of RNA molecule can have 2,3,4,5,6,7,8,9,10 or more protuberances. Each protuberance can be one, two or more unpaired nucleotides independently, up to 10 nucleotides. Longer sequence can loop out the sense or antisense sequence in the dsRNA district, and it can be in internal base pairing or keep unpairing. In another embodiment, the double-stranded region of RNA molecule does not comprise protuberance, i.e., along the full length complete base pairing in the dsRNA district.
[0322] In another embodiment, the first sense ribonucleotide sequence is covalently linked to the first 5' ribonucleotide without any intervening nucleotides, or the first antisense ribonucleotide sequence is covalently linked to the first 3' ribonucleotide without any intervening nucleotides, or both. In another embodiment, there are at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 intervening nucleotides. It is understood that such intervening nucleotides are not related in sequence to the target RNA molecule, but may help stabilize base pairing of adjacent sense and antisense sequences.
[0323] In another embodiment, 20 contiguous nucleotides of the first sense ribonucleotide sequence are covalently linked to the first 5' ribonucleotide without any intervening nucleotides, and 20 contiguous nucleotides of the first antisense ribonucleotide sequence are covalently linked to the first 3' ribonucleotide without any intervening nucleotides. In another embodiment, there are at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 intervening nucleotides. Intervening nucleotides can base pair as part of the double-stranded region of the RNA molecule but are not related to the target RNA in sequence. They can help provide increased stability to the double-stranded region or bind the two ends of the RNA molecule together without leaving an unpaired 5' or 3' end, or both.
[0324] In one embodiment, the first and second RNA components comprise a connecting ribonucleotide sequence. In one embodiment, the connecting ribonucleotide sequence serves as a spacer between the first sense ribonucleotide sequence and the other components of the molecule, and the first sense ribonucleotide sequence is substantially identical in sequence to the first district of the target RNA molecule. For example, the connecting ribonucleotide sequence can serve as a spacer between the district and the loop. In another embodiment, the RNA molecule comprises a plurality of sense ribonucleotide sequences and a connecting ribonucleotide sequence, and the sense ribonucleotide sequence is substantially identical in sequence to the first district of the target RNA molecule, and the connecting ribonucleotide sequence serves as a spacer between these sequences. In one embodiment, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 ribonucleotide sequences are provided in the RNA molecule that are substantially identical in sequence to the first district of the target RNA molecule, and each ribonucleotide sequence is separated from each other by a connecting ribonucleotide sequence.
[0325] In one embodiment, the RNA molecule comprises a 5' leader sequence. In one embodiment, the 5' leader sequence consists of a ribonucleotide sequence that is covalently linked to the first 5' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or to the second 5' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide. In one embodiment, the RNA molecule has a modified 5' or 3' end, for example, by a linked lipid group such as cholesterol, or a vitamin such as biotin, or a polypeptide. Such modifications can help the RNA molecule be taken up into the eukaryotic cell where the RNA will function.
[0326] In one embodiment, the length of the connecting ribonucleotide sequence is less than 100 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is less than 50 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is less than 20 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is less than 10 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is less than 5 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is 1 to 100 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is 1 to 50 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is 1 to 20 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is 1 to 10 ribonucleotides. In one embodiment, the length of the connecting ribonucleotide sequence is 1 to 5 ribonucleotides. In one embodiment, the ribonucleotides connecting the ribonucleotide sequence are not base paired. In a preferred embodiment, the ribonucleotides connecting the ribonucleotide sequence are all base paired, or all except 1, 2 or 3 ribonucleotides are base paired.
[0327] In one embodiment, the first or second RNA component comprises a hairpin structure. In a preferred embodiment, the first and second RNA components each comprise a hairpin structure. In these embodiments, the hairpin structure can be a stem-loop. Thus, in one embodiment, an RNA molecule can comprise a first and a second RNA component each comprising a hairpin structure, wherein the hairpins are covalently attached via a linker sequence. For example, see Figure 1 In one embodiment, the linker sequence is one or more unpaired ribonucleic acids (RNA). In one embodiment, the linker sequence is 1 to 10 unpaired ribonucleotides.
[0328] In one embodiment, the RNA molecule has a double hairpin structure, i.e., a "ledRNA structure" or a "dumbbell structure." In this embodiment, the first hairpin is the first RNA component and the second hairpin is the second RNA component. In these embodiments, the first 3' ribonucleotide and the second 5' ribonucleotide, or the second 3' ribonucleotide and the first 5' ribonucleotide, but not both, are covalently linked. In this embodiment, the other 5' / 3' ribonucleotides can be separated by a cleft (i.e., a discontinuity in the dsRNA molecule where there is no phosphodiester bond between the 5' / 3' ribonucleotides). Figure 1B shows an example of this type of arrangement. In another embodiment, the corresponding 5' / 3' ribonucleotides can be separated by a loop. The length of the 5' leader sequence and the 3' trailer sequence can be the same or different. For embodiments, the 5' leader can be about 5, 10, 15, 20, 25, 50, 100, 200, 500 ribonucleotides longer than the 3' trailer sequence, or vice versa.
[0329] In embodiments where the RNA molecule has a double hairpin structure, the second hairpin (in addition to the first hairpin structure) comprises a sense RNA sequence and an antisense RNA sequence, each of which is substantially identical in sequence to a region of the target RNA molecule or its complement. In one embodiment, each hairpin has a series of ribonucleotides that are substantially identical in sequence to a region of the same target RNA molecule. In one embodiment, each hairpin has a series of ribonucleotides that are substantially identical in sequence to different regions of the same target RNA molecule. In one embodiment, each hairpin has a series of ribonucleotides that are substantially identical in sequence to regions of different target RNA molecules, i.e., the RNA molecule can be used to reduce the expression and / or activity of two target RNA molecules that are unrelated in sequence.
[0330] In each hairpin structure of the double hairpin structure of the RNA molecule, the order of the sense and antisense RNA sequences in each hairpin structure can independently be sense then antisense, or antisense then sense in the 5' to 3' order. In a preferred embodiment, the order of the sense and antisense sequences in the double hairpin structure of the RNA molecule is antisense-sense-sense-antisense ( Figure 1 A), or sense-antisense-antisense-sense ( Figure 1 B).
[0331] In one embodiment, in a 5' to 3' order, the RNA molecule can comprise a 5' leader sequence, a first loop, a sense RNA sequence, a second loop, and a 3' trailer sequence, wherein the 5' and 3' leader sequences are covalently bound to the sense strand to form a dsRNA sequence. In one embodiment, the 5' leader sequence and the 3' trailer sequence are not covalently bound to each other. In one embodiment, the 5' leader sequence and the 3' trailer sequence are separated by a cleft. In one embodiment, the 5' leader sequence and the 3' trailer sequence are linked together to provide an RNA molecule with a closed structure. In another embodiment, the 5' leader sequence and the 3' trailer sequence are separated by a loop.
[0332] The term "ring" used in the context of the present invention refers to a ring structure formed by a series of non-complementary ribonucleotides in the RNA molecule disclosed herein. The ring usually follows a series of base pairs between the first and second RNA components or connects the sense RNA sequence and the antisense RNA sequence in one or both of the first and second RNA components. In one embodiment, usually for a shorter ring of 4-10 ribonucleotides, all ring ribonucleotides are non-complementary. In other embodiments, some ribonucleotides in one or more rings are complementary and can base pair within the ring sequence, as long as these base pairings can form a ring structure. For example, at least 5%, at least 10% or at least 15% of the ring ribonucleotides are complementary. The embodiment of the ring includes stem loop or hairpin, pseudoknot and tetraloop.
[0333] In one embodiment, the RNA molecule comprises only two loops. In another embodiment, the RNA molecule comprises at least two, at least three, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 loops, preferably at most 10 loops. For example, the RNA molecule may comprise 4 loops.
[0334] The present invention contemplates loops of various sizes. For example, the loop may comprise 4, 5, 6, 7, 8, 9, 10, 11, or 12 ribonucleotides. In other embodiments, the loop comprises 15, 20, 25, or 30 nucleotides. In one embodiment, one or all of the loop sequences are longer than 20 nucleotides. In other embodiments, the loop is larger, for example, comprising 50, 100, 150, 200, or 300 ribonucleotides. In one embodiment, the loop comprises 160 ribonucleotides. In another less preferred embodiment, the loop comprises 200, 500, 700, or 1,000 ribonucleotides, provided that the loop does not interfere with hybridization of sense and antisense RNA sequences. In one embodiment, each loop has the same number of ribonucleotides. For example, the loop may have a length of 100 to 1,000 ribonucleotides. For example, the loop may have a length of 600 to 1,000 ribonucleotides. For example, the loop may have a length of 4 to 1,000 ribonucleotides. For example, the loop preferably has 4-50 ribonucleotides.In another embodiment, the loop comprises a different number of ribonucleotides.
[0335] In another embodiment, one or more loops comprise introns that can be spliced out of the RNA molecule. In one embodiment, the introns are from plant genes. Exemplary introns include intron 3 of the corn alcohol dehydrogenase 1 (Adhl) (GenBank: AF044293), intron 4 of the soybean β-conglycinin α subunit (GenBank: AB051865), and one of the introns of the pea rbcS-3A gene (GenBank: X04333), the ribulose-1,5-bisphosphate carboxylase (RBC) small subunit. Other embodiments of suitable introns are discussed in (McCullough and Schuler, 1997; Smith et al., 2000).
[0336] In various embodiments, the loop may end at at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 contiguous base pairs, which may be canonical base pairs or may include one or more non-canonical base pairs. In other embodiments, particularly for vertebrate cells, less preferred, the loop may end at at least 20, 30, 50, 100, 200, 500, or more contiguous base pairs.
[0337] In another embodiment, the RNA molecule comprises two or more sense ribonucleotide sequences and antisense ribonucleotide sequences based entirely on their base pairing, each of which is identical in sequence to a region of the target RNA molecule. For example, the RNA molecule can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more sense ribonucleotide sequences and antisense ribonucleotide sequences that are completely paired therewith, each of which is independently identical in sequence to a region of the target RNA molecule. In this embodiment, any one or more or all of the sequences can be separated by a connecting ribonucleotide sequence. In this embodiment, any one or more or all of the sequences can be separated by a loop.
[0338] In one embodiment, two or more sense ribonucleotide sequences are identical in sequence to different regions of the same target RNA molecule. For example, the sequence can be identical to at least 2, at least 3, at least 4, at least 5, or at least 6 regions of the same target molecule. In another embodiment, two or more sense ribonucleotide sequences are identical in sequence. In one embodiment, two or more sense ribonucleotide sequences are identical in sequence to the same region of the same target RNA molecule. In another embodiment, two or more sense ribonucleotide sequences are identical in sequence to different target RNA molecules. For embodiments, the sequence can be identical to at least 2, at least 3, at least 4, at least 5, or at least 6 regions of different target molecules.
[0339] In another embodiment, the two or more sense ribonucleotide sequences have no intervening loop (spacer) sequence.
[0340] In one embodiment, the RNA molecule can comprise a single-stranded ribonucleotide having a 5' end, at least one sense ribonucleotide sequence of at least 21 nucleotides in length, an antisense ribonucleotide sequence that is fully base-paired to each sense ribonucleotide sequence over at least 21 contiguous nucleotides, at least two loop sequences, and a 3' end. In this embodiment, the ribonucleotide at the 5' end and the ribonucleotide at the 3' end are not directly covalently bound, but are adjacent to each base-paired position.
[0341] In another embodiment, the adjacent base pairs of the RNA component are spaced at least one gap. In one embodiment, the "gap" is provided by unpaired ribonucleotides. In another embodiment, the "gap" is provided by unconnected 5' leader sequences and / or 3' trailer sequences. In this embodiment, the gap can be referred to as an "unconnected gap". Mismatches and unconnected gaps can be located at different positions of the RNA molecule. For embodiments, the unconnected gap can be immediately after the antisense sequence. In another embodiment, the unconnected gap can be close to the loop of the RNA molecule. In another embodiment, the unconnected gap is positioned to be approximately equidistant between at least two loops.
[0342] In one embodiment, the RNA molecule is produced by single-stranded RNA. In one embodiment, the single strand is not circularly closed, for example, comprises an unconnected gap. In another embodiment, the RNA molecule is a circular closed molecule. Closed molecules can be produced by, for example, connecting the above-mentioned RNA molecules comprising an unconnected gap with RNA ligase.
[0343] In another embodiment, the RNA molecule comprises a 5' or 3' extension sequence, or both. For example, the RNA molecule may comprise a 5' extension sequence covalently linked to a first 5' ribonucleotide. In another embodiment, the RNA molecule comprises a 3' extension sequence covalently linked to a second 3' ribonucleotide. In another embodiment, the RNA molecule comprises a 5' extension sequence covalently linked to a first 5' ribonucleotide and a 3' extension sequence covalently linked to a second 3' ribonucleotide.
[0344] In another embodiment, the RNA molecule comprises a 5' extension sequence covalently linked to a second 5' ribonucleotide. In another embodiment, the RNA molecule comprises a 3' extension sequence covalently linked to a first 3' ribonucleotide. In another embodiment, the RNA molecule comprises a 5' extension sequence covalently linked to a second 5' ribonucleotide and a 3' extension sequence covalently linked to a first 3' ribonucleotide.
[0345] In another embodiment, the RNA molecule may comprise one or more of the following:
[0346] - a 5' extension sequence covalently linked to the first 5' ribonucleotide;
[0347] - a 3' extension sequence covalently linked to a second 3' ribonucleotide;
[0348] - a 5' extension sequence covalently linked to the first 5' ribonucleotide and a 3' extension sequence covalently linked to the second 3' ribonucleotide;
[0349] - a 5' extension sequence covalently linked to a second 5' ribonucleotide;
[0350] - a 3' extension sequence covalently linked to the first 3' ribonucleotide;
[0351] - a 5' extension sequence covalently linked to the second 5' ribonucleotide and a 3' extension sequence covalently linked to the first 3' ribonucleotide.
[0352] Non-canonical base pairing
[0353] In one embodiment, the RNA molecule of the present invention comprises a sense ribonucleotide sequence and an antisense ribonucleotide sequence that are capable of hybridizing to each other to form a double-stranded (ds) RNA region with some non-canonical base pairing, i.e., a combination of canonical and non-canonical base pairing. In one embodiment, the RNA molecule of the present invention comprises two or more sense ribonucleotide sequences, each of which is capable of hybridizing to a region of a (contiguous) antisense ribonucleotide sequence to form a dsRNA region with some non-canonical base pairing. See, e.g. Figure 1 B. In one embodiment, the RNA molecule of the invention comprises two or more antisense sense ribonucleotide sequences, each of which is capable of hybridizing to a region of a (contiguous) sense ribonucleotide sequence to form a dsRNA region with some non-canonical base pairing. See, e.g. Figure 1 A. In one embodiment, an RNA molecule of the invention comprises two or more antisense sense ribonucleotide sequences and two or more sense ribonucleotide sequences, wherein each antisense ribonucleotide sequence is capable of hybridizing with an antisense ribonucleotide sequence to form two or more dsRNA regions, one or both of the dsRNA regions comprising some non-canonical base pairing.
[0354] In the following embodiments, if there is only one (adjacent) dsRNA district, it is considered that the full length (i.e., the entire dsRNA district) of the dsRNA district of the RNA molecule of the present invention is the context of the feature, or if there are two or more dsRNA districts in the RNA molecule, it is considered to be the context of each dsRNA district of the RNA molecule. In one embodiment, at least 5% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 6% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 7% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 8% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 9% or 10% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 11% or 12% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 15% or about 15% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 20% or approximately 20% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 25% or approximately 25% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, at least 30% or approximately 30% of the base pairs in the dsRNA district are non-canonical base pairs. In each of these embodiments, preferably at most 40% of the base pairs in the dsRNA district are non-canonical base pairs, more preferably at most 35% of the base pairs in the dsRNA district are non-canonical base pairs, and even more preferably at most 30% of the base pairs in the dsRNA district are non-canonical base pairs. In a less preferred embodiment, approximately 35% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, even more less preferably, approximately 40% of the base pairs in the dsRNA district are non-canonical base pairs. In each of the above embodiments, the dsRNA district may or may not include one or more non-base-paired ribonucleotides in the sense sequence or antisense sequence or both.
[0355] In one embodiment, 10%-40% of the base pairs in the dsRNA region of the RNA molecule of the present invention are non-canonical base pairs. In one embodiment, 10%-35% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 10%-30% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 10%-25% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 10%-20% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 10%-15% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 15%-30% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 15%-25% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 15%-20% of the base pairs in the dsRNA region are non-canonical base pairs. In one embodiment, 5%-30% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, 5%-25% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, 5%-20% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, 5%-15% of the base pairs in the dsRNA district are non-canonical base pairs. In one embodiment, 5%-10% of the base pairs in the dsRNA district are non-canonical base pairs. In each of the above embodiments, the dsRNA district may or may not include one or more non-base paired ribonucleotides in the sense sequence or antisense sequence or both.
[0356] In one embodiment, the dsRNA district of the RNA molecule of the present invention comprises 20 adjacent base pairs, at least one base pair in the wherein said 20 adjacent base pairs is a non-canonical base pair. In one embodiment, the dsRNA district comprises 20 adjacent base pairs, wherein at least 2 base pairs in the 20 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 20 adjacent base pairs, wherein at least 3 base pairs in the 20 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 20 adjacent base pairs, wherein at least 4 base pairs in the 20 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 20 adjacent base pairs, wherein at least 5 base pairs in the 20 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 20 adjacent base pairs, wherein at least 6 base pairs in the 20 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 20 adjacent base pairs, and wherein at least 7 base pairs in the 20 adjacent base pairs are non-conventional base pairs.In one embodiment, the dsRNA district comprises 20 adjacent base pairs, and wherein at least 8 base pairs in the 20 adjacent base pairs are non-conventional base pairs.In one embodiment, the dsRNA district comprises 20 adjacent base pairs, and wherein at least 9 base pairs in the 20 adjacent base pairs are non-conventional base pairs. In each of these embodiments, preferably in the dsRNA district, 10 of the 20 adjacent base pairs are non-conventional base pairs, more preferably in the dsRNA district, 9 of the non-conventional base pairs are at most, also more preferably in the dsRNA district, 8 of the non-conventional base pairs are at most, even more preferably in the dsRNA district, 7 of the non-conventional base pairs are at most, and most preferably in the dsRNA district, 6 of the non-conventional base pairs are at most. Preferably, in the above embodiments, the non-canonical base pairs comprise at least one G:U base pair, and more preferably all non-canonical base pairs are G:U base pairs. Preferably, the features of the above embodiments apply to each of the 20 contiguous base pairs present in the RNA molecule of the invention.
[0357] In one embodiment, the dsRNA district of the RNA molecule of the present invention comprises 21 adjacent base pairs, at least one base pair in the wherein said 21 adjacent base pairs is a non-canonical base pair. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, at least two base pairs in the wherein 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, at least three base pairs in the wherein 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, at least four base pairs in the wherein 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, at least five base pairs in the wherein 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, at least six base pairs in the wherein 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, and wherein at least 7 base pairs in the 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, and wherein at least 8 base pairs in the 21 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 21 adjacent base pairs, and wherein at least 9 base pairs in the 21 adjacent base pairs are non-canonical base pairs. In each of these embodiments, preferably in the dsRNA district, 10 of the 21 adjacent base pairs are non-canonical base pairs at most, more preferably in the dsRNA district, 9 of the non-canonical base pairs at most, also more preferably in the dsRNA district, 8 of the non-canonical base pairs at most, even more preferably in the dsRNA district, 7 of the non-canonical base pairs at most, and most preferably in the dsRNA district, 6 of the non-canonical base pairs at most. Preferably, in the above embodiments, the non-canonical base pairs comprise at least one G:U base pair, and more preferably all non-canonical base pairs are G:U base pairs. Preferably, the features of the above embodiments apply to each of the 21 contiguous base pairs present in the RNA molecule of the present invention.
[0358] In one embodiment, the dsRNA district of the RNA molecule of the present invention comprises 22 adjacent base pairs, at least one base pair in the wherein said 22 adjacent base pairs is a non-canonical base pair. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, wherein at least 2 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, wherein at least 3 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, wherein at least 4 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, wherein at least 5 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, wherein at least 6 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, and wherein at least 7 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, and wherein at least 8 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 22 adjacent base pairs, and wherein at least 9 base pairs in the 22 adjacent base pairs are non-canonical base pairs. In each of these embodiments, preferably in the dsRNA district, 10 of the 22 adjacent base pairs are non-canonical base pairs at most, more preferably in the dsRNA district, 9 of the non-canonical base pairs at most, also more preferably in the dsRNA district, 8 of the non-canonical base pairs at most, even more preferably in the dsRNA district, 7 of the non-canonical base pairs at most, and most preferably in the dsRNA district, 6 of the non-canonical base pairs at most. Preferably, in the above embodiments, the non-canonical base pairs comprise at least one G:U base pair, and more preferably all non-canonical base pairs are G:U base pairs. Preferably, the features of the above embodiments apply to each of the 22 contiguous base pairs present in the RNA molecule of the invention.
[0359] In one embodiment, the dsRNA district of the RNA molecule of the present invention comprises 23 adjacent base pairs, wherein at least one base pair in the 23 adjacent base pairs is a non-canonical base pair. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, wherein at least 2 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, wherein at least 3 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, wherein at least 4 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, wherein at least 5 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, wherein at least 6 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, and wherein at least 7 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, and wherein at least 8 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 23 adjacent base pairs, and wherein at least 9 base pairs in the 23 adjacent base pairs are non-canonical base pairs. In each of these embodiments, preferably in the dsRNA district, 10 of the 23 adjacent base pairs are non-canonical base pairs at most, more preferably in the dsRNA district, 9 of the non-canonical base pairs at most, also more preferably in the dsRNA district, 8 of the non-canonical base pairs at most, even more preferably in the dsRNA district, 7 of the non-canonical base pairs at most, and most preferably in the dsRNA district, 6 of the non-canonical base pairs at most. Preferably, in the above embodiments, the non-canonical base pairs comprise at least one G:U base pair, and more preferably all non-canonical base pairs are G:U base pairs. Preferably, the features of the above embodiments apply to each of the 23 contiguous base pairs present in the RNA molecule of the invention.
[0360] In one embodiment, the dsRNA district of the RNA molecule of the present invention comprises 24 adjacent base pairs, at least one base pair in the wherein said 24 adjacent base pairs is a non-canonical base pair. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, wherein at least 2 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, wherein at least 3 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, wherein at least 4 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, wherein at least 5 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, wherein at least 6 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, and wherein at least 7 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, and wherein at least 8 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 24 adjacent base pairs, and wherein at least 9 base pairs in the 24 adjacent base pairs are non-canonical base pairs. In each of these embodiments, preferably in the dsRNA district, 10 of the 24 adjacent base pairs are non-canonical base pairs, more preferably in the dsRNA district, 9 of the non-canonical base pairs are non-canonical base pairs, also more preferably in the dsRNA district, 8 of the non-canonical base pairs are non-canonical base pairs, even more preferably in the dsRNA district, 7 of the non-canonical base pairs are non-canonical base pairs, and most preferably in the dsRNA district, 6 of the non-canonical base pairs are non-canonical base pairs. Preferably, in the above embodiments, the non-canonical base pairs comprise at least one G:U base pair, and more preferably all non-canonical base pairs are G:U base pairs. Preferably, the features of the above embodiments apply to each of the 24 contiguous base pairs present in the RNA molecule of the present invention.
[0361] In the following embodiments, if there is only one (adjacent) dsRNA district, it is considered that the full length (i.e., the entire dsRNA district) of the dsRNA district of the RNA molecule of the present invention is the context of the feature, or if there are two or more dsRNA districts in the RNA molecule, it is considered to be the context of each dsRNA district of the RNA molecule. In one embodiment, the dsRNA district does not include 20 adjacency standard base pairs, i.e., each sub-district of 20 adjacency base pairs includes at least one non-standard base pair, preferably at least one G:U base pair. In one embodiment, the dsRNA district does not include 19 adjacency standard base pairs. In one embodiment, the dsRNA district does not include 18 adjacency standard base pairs. In one embodiment, the dsRNA district does not include 17 adjacency standard base pairs. In one embodiment, the dsRNA district does not include 16 adjacency standard base pairs. In one embodiment, the dsRNA district does not include 15 adjacency standard base pairs. In one embodiment, the dsRNA district does not include 14 adjacency standard base pairs. In one embodiment, the dsRNA district does not include 13 adjoining canonical base pairs. In one embodiment, the dsRNA district does not include 12 adjoining canonical base pairs. In one embodiment, the dsRNA district does not include 11 adjoining canonical base pairs. In one embodiment, the dsRNA district does not include 10 adjoining canonical base pairs. In one embodiment, the dsRNA district does not include 9 adjoining canonical base pairs. In one embodiment, the dsRNA district does not include 8 adjoining canonical base pairs. In one embodiment, the dsRNA district does not include 7 adjoining canonical base pairs. In the above-mentioned embodiments, the longest sub-region of the adjoining canonical base pairing of each dsRNA district in the dsRNA district of the preferred RNA molecule or the RNA molecule is 5, 6 or 7 adjoining canonical base pairings, i.e., towards the shorter length. Each feature of the above-mentioned embodiment is preferably combined with the following features in the RNA molecule. In one embodiment, the dsRNA district includes 10-19 or 20 adjoining base pairs. In a preferred embodiment, the dsRNA district comprises 12-19 or 20 adjacent base pairs. In one embodiment, the dsRNA district comprises 14-19 or 20 adjacent base pairs. In these embodiments, the dsRNA district comprises 15 adjacent base pairs. In one embodiment, the dsRNA district comprises 16, 17, 18 or 19 adjacent base pairs. In one embodiment, the dsRNA district comprises 20 adjacent base pairs. Preferably, in the above-mentioned embodiment, the adjacent base pairs comprise at least one non-canonical base pair including at least one G:U base pair, more preferably, all non-canonical base pairs in the adjacent base pair district are G:U base pairs.
[0362] In one embodiment, the dsRNA district comprises a subregion of 4 standard base pairs of flank non-canonical base pairs, i.e., at least 1, preferably 1 or 2 (no more than 2) non-canonical base pairs adjacent to each end of the 4 canonical base pairs. In one embodiment, the dsRNA district comprises 2 subregions, each of which is 4 standard base pairs of flank non-canonical base pairs. In one embodiment, the dsRNA district comprises 3 subregions, each of which is 4 standard base pairs of flank non-canonical base pairs. In one embodiment, the dsRNA district comprises 4 or 5 subregions, each of which is 4 standard base pairs of flank non-canonical base pairs. In one embodiment, the dsRNA district comprises 6 or 7 subregions, each of which is 4 standard base pairs of flank non-canonical base pairs. In one embodiment, the dsRNA district comprises 8 to 10 subregions, each of which is 4 standard base pairs of flank non-canonical base pairs. In one embodiment, the dsRNA district comprises 11 to 15 sub-districts, each of which is 4 standard base pairs of a side joint non-canonical base pair. In one embodiment, the dsRNA district comprises 2 to 50 sub-districts, each of which is 4 standard base pairs of a side joint non-canonical base pair. In one embodiment, the dsRNA district comprises 2 to 40 sub-districts, each of which is 4 standard base pairs of a side joint non-canonical base pair. In one embodiment, the dsRNA district comprises 2 to 30 sub-districts, each of which is 4 standard base pairs of a side joint non-canonical base pair. In one embodiment, the dsRNA district comprises 2 to 20 sub-districts, each of which is 4 standard base pairs of a side joint non-canonical base pair. Preferably, in the above-mentioned embodiment, the non-canonical base pair comprises at least one G:U base pair, and more preferably, all non-canonical base pairs of the canonical base pair side joints adjacent in the sub-district are G:U base pairs. In variations of the above embodiments, for some or all of the subregions, one or both of the flanking non-canonical base pairs are replaced by non-base-pairing ribonucleotides in the sense sequence, the antisense sequence, or in both sequences. It will be readily appreciated that in the above embodiments, the maximum number of subregions is determined by the length of the dsRNA region in the RNA molecule.
[0363] In one embodiment, the dsRNA district comprises a subregion of 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 2 subregions, each of which is 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 3 subregions, each of which is 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 4 or 5 subregions, each of which is 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 6 or 7 subregions, each of which is 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 8 to 10 subregions, each of which is 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 11 to 15 subregions, each of which is 5 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 2 to 50 sub-districts, and each sub-district is 5 standard base pairs of the non-canonical base pairs of the side joints. In one embodiment, the dsRNA district comprises 2 to 50 sub-districts, and each sub-district is 5 standard base pairs of the non-canonical base pairs of the side joints. In one embodiment, the dsRNA district comprises 2 to 30 sub-districts, and each sub-district is 5 standard base pairs of the non-canonical base pairs of the side joints. In one embodiment, the dsRNA district comprises 2 to 20 sub-districts, and each sub-district is 5 standard base pairs of the non-canonical base pairs of the side joints. Preferably, in the above-mentioned embodiment, the non-canonical base pair comprises at least one G:U base pair, and more preferably, all non-canonical base pairs of the canonical base pair side joints adjacent in the sub-district are G:U base pairs. In the variant of the above-mentioned embodiment, for some or all of the sub-districts, one or two of the non-canonical base pairs of the side joints are replaced by non-base-paired ribonucleotides in the sense sequence, the antisense sequence or in the two sequences. It will be readily understood that, in the above embodiments, the maximum number of subregions is determined by the length of the dsRNA region in the RNA molecule.
[0364] In one embodiment, the dsRNA district comprises a subregion of 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 2 subregions, each of which is 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 3 subregions, each of which is 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 4 or 5 subregions, each of which is 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 6 or 7 subregions, each of which is 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 8 to 10 subregions, each of which is 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 11 to 16 subregions, each of which is 6 standard base pairs flanking non-canonical base pairs. In one embodiment, the dsRNA district comprises 2 to 60 sub-districts, and each sub-district is 6 standard base pairs of the non-canonical base pairs of the side joints. In one embodiment, the dsRNA district comprises 2 to 60 sub-districts, and each sub-district is 6 standard base pairs of the non-canonical base pairs of the side joints. In one embodiment, the dsRNA district comprises 2 to 30 sub-districts, and each sub-district is 6 standard base pairs of the non-canonical base pairs of the side joints. In one embodiment, the dsRNA district comprises 2 to 20 sub-districts, and each sub-district is 6 standard base pairs of the non-canonical base pairs of the side joints. Preferably, in the above-mentioned embodiment, the non-canonical base pair comprises at least one G:U base pair, and more preferably, all non-canonical base pairs of the canonical base pair side joints adjacent in the sub-district are G:U base pairs. In the variant of the above-mentioned embodiment, for some or all of the sub-districts, one or two of the non-canonical base pairs of the side joints are replaced by non-base-paired ribonucleotides in the sense sequence, the antisense sequence or in the two sequences. It will be readily understood that, in the above embodiments, the maximum number of subregions is determined by the length of the dsRNA region in the RNA molecule.
[0365] In one embodiment, the dsRNA district comprises the subdistrict of 10 adjacent base pairs, wherein 2-4 base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 2 subdistricts, each subdistrict is 10 adjacent base pairs, wherein 2-4 in 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 3 subdistricts, each is 10 adjacent base pairs, wherein 2-4 in 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 4 subdistricts, each is 10 adjacent base pairs, wherein 2-4 in 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 5 subdistricts, each is 10 adjacent base pairs, wherein 2-4 in 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 10 subdistricts, each of which is 10 adjacent base pairs, and 2-4 of the 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 4 subdistricts, each of which is 15 adjacent base pairs, and 2-6 of the 15 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 2-50 subdistricts, each of which is 10 adjacent base pairs, and 2-4 of the 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 2-40 subdistricts, each of which is 10 adjacent base pairs, and 2-4 of the 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 2-30 subdistricts, each of which is 10 adjacent base pairs, and 2-4 of the 10 adjacent base pairs are non-canonical base pairs. In one embodiment, the dsRNA district comprises 2-20 sub-districts, and each sub-district comprises 10 adjacent base pairs, wherein 2-4 of the 10 adjacent base pairs are non-canonical base pairs. Preferably, in the above-mentioned embodiment, the non-canonical base pair comprises at least one G:U base pair, and more preferably all non-canonical base pairs in the sub-district are G:U base pairs. In the variant of the above-mentioned embodiment, for some or all of the sub-districts, one or more of the 2-4 or 2-6 non-canonical base pairs are replaced by non-base paired ribonucleotides in the sense sequence, the antisense sequence or in the two sequences. It is easy to understand that in the above-mentioned embodiment, the maximum number of sub-districts is determined by the length of the dsRNA district in the RNA molecule.
[0366] In one embodiment, the ratio of canonical to non-canonical base pairs in a dsRNA region is between 2.5:1 and 3.5:1, for example, about 3:1. In one embodiment, the ratio of canonical to non-canonical base pairs in a dsRNA region is between 3.5:1 and 4.5:1, for example, about 4:1. In one embodiment, the ratio of canonical to non-canonical base pairs in a dsRNA region is between 4.5:1 and 5.5:1, for example, about 5:1. In one embodiment, the ratio of canonical to non-canonical base pairs in a dsRNA region is between 5.5:1 and 6.5:1, for example, about 6:1. Different dsRNA regions in an RNA molecule can have different ratios.
[0367] In the above embodiments, the non-canonical base pairs in the dsRNA region of the RNA molecule are preferably all G:U base pairs. In one embodiment, at least 99% of the non-canonical base pairs are G:U base pairs. In one embodiment, at least 98% of the non-canonical base pairs are G:U base pairs. In one embodiment, at least 97% of the non-canonical base pairs are G:U base pairs. In one embodiment, at least 95% of the non-canonical base pairs are G:U base pairs. In one embodiment, at least 90% of the non-canonical base pairs are G:U base pairs. In one embodiment, 90-95% of the non-canonical base pairs are G:U base pairs. For example, if there are 10 non-canonical base pairs, at least 9 (90%) are G:U base pairs.
[0368] The dsRNA region comprising non-canonical base pairing comprises an antisense sequence of 20 adjacent nucleotides, which serves as an antisense regulatory element. In one embodiment, the antisense regulatory element is at least 80%, preferably at least 90%, more preferably at least 95% or most preferably 100% complementary to the target RNA molecule in the eukaryotic cell. In one embodiment, the dsRNA region comprises 2, 3, 4 or 5 antisense regulatory elements that are complementary to the same target RNA molecule (i.e., complementary to different regions of the same target RNA molecule) or to different target RNA molecules.
[0369] In one embodiment, when the sense and antisense sequences hybridize, one or more ribonucleotides of the sense ribonucleotide sequence or one or more ribonucleotides of the antisense ribonucleotide sequence, or both, are not base paired in the dsRNA region. In this embodiment, the dsRNA region does not include any loop sequence that covalently links the sense and antisense sequences. One or more ribonucleotides in a dsRNA region or subregion may not be base paired. Thus, in this embodiment, the sense strand of a dsRNA region is not completely base paired with its corresponding antisense strand.
[0370] In addition, in one embodiment and optionally in combination with any of the features of the above embodiments, the total number of ribonucleotides in the sense sequence and the total number of ribonucleotides in the antisense sequence may be different, although preferably they are the same. In one embodiment, the total number of ribonucleotides in the sense ribonucleotide sequence of the dsRNA region is 90%-110% of the total number of ribonucleotides in the antisense ribonucleotide sequence. In one embodiment, the total number of ribonucleotides in the sense ribonucleotide sequence is 95%-105% of the total number of ribonucleotides in the antisense ribonucleotide sequence. In one embodiment, the chimeric RNA molecule of the present invention may comprise one or more structural elements, such as internal or terminal ridges or loops. Various examples of ridges and loops are discussed above. In one embodiment, the dsRNA regions are separated by structural elements such as ridges or loops. In one embodiment, the dsRNA regions are separated by intervening (spacer) sequences. Some ribonucleotides in the spacer sequence may base pair with other ribonucleotides in the RNA molecule, such as with other ribonucleotides in the spacer sequence, or they may not base pair in the RNA molecule, or some of each may not base pair. In one embodiment, the dsRNA region is linked to the terminal loop.In one embodiment, the dsRNA region is flanked by the terminal loop.
[0371] In one embodiment, when a dsRNA region of an RNA molecule of the invention has at least three non-canonical base pairs in any subregion of five adjacent base pairs, the non-canonical base pairs are not adjacent, but are separated by one or more canonical base pairs, i.e., the dsRNA region does not have three or more adjacent non-canonical base pairs. In one embodiment, the dsRNA region does not have four or more adjacent non-canonical base pairs. For example, in one embodiment, the dsRNA region comprises at least three non-canonical base pairs in a subregion of ten base pairs, wherein each non-canonical base pair is separated by four canonical base pairs.
[0372] In one embodiment, the RNA molecule of the present invention comprises more than one dsRNA region. For example, the RNA molecule comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more dsRNA regions. In this embodiment, one or more or all of the dsRNA regions may comprise the properties exemplified above, such as non-canonical base pairing and / or several antisense regulatory elements.
[0373] Silencing activity
[0374] The RNA molecules of the present invention have antisense activity because they contain a sense ribonucleotide sequence that is substantially complementary to a region of a target RNA molecule. For example, the ribonucleotide sequence is substantially complementary to a region of a target RNA molecule in a eukaryotic cell. In one embodiment, the target RNA molecule can be in a bacterial cell, a fungal cell, a plant cell, an insect cell, or an animal cell. Such components of RNA molecules as defined herein may be referred to as "antisense regulatory elements." "Substantially complementary" means that the sense ribonucleotide sequence may have insertions, deletions, and single point mutations compared to the complementary sequence of the target RNA molecule in a eukaryotic cell. Preferably, the sense ribonucleotide sequence having antisense activity has an identity of at least 80%, preferably at least 90%, preferably at least 95%, and most preferably 100% to the target RNA molecule. For example, the sense ribonucleotide sequence may contain about 15, about 16, about 17, about 18, about 19, or more contiguous nucleotides that are identical in sequence to the first region of the target RNA molecule in a eukaryotic cell. In another embodiment, the sense ribonucleotide sequence may contain about 20 contiguous nucleotides that are identical in sequence to the first region of the target RNA molecule in a eukaryotic cell.
[0375] "Antisense activity" is used in the context of the present invention to refer to an antisense regulatory element from an RNA molecule as defined herein, which modulates (increases or decreases) the expression of a target RNA molecule.
[0376] In various embodiments, the antisense regulatory elements according to the present invention may comprise a plurality of monomeric subunits linked together by a linking group. Embodiments include primers, probes, antisense compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, gapmers, siRNA and microRNA. Thus, the RNA molecules according to the present invention may comprise antisense regulatory elements having single-stranded, double-stranded, circular, branched or hairpin structures. In one embodiment, the antisense sequence may contain structural elements, such as internal or terminal protuberances or loops.
[0377] In one embodiment, the RNA molecules of the present invention comprise chimeric oligomeric components, such as chimeric oligonucleotides. For example, the RNA molecules can comprise differently modified nucleotides, mixed backbone antisense oligonucleotides, or combinations thereof. In one embodiment, the chimeric oligomeric compound can comprise at least one modified region to confer increased resistance to nuclease degradation, increased cellular uptake, and / or increased binding affinity for the target RNA molecule.
[0378] Antisense regulatory elements can have a variety of lengths. In various embodiments, the present invention provides antisense regulatory elements composed of bases connected by X-Y, where X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 (provided that X < Y). For example, in certain embodiments, the present invention provides antisense regulatory elements comprising 8-9, 8-10, 8-11, 8-12, 8-13, 8-14, 8-15, 8-16, 8-17, 8-18, 8-19, 8-20, 8-21, 8-22, 8-23, 8-24, 8-25, 8-26, 8-27, 8-28, 8-29, 8-30, 9-10, 9-11, 9-12, 9-13, 9-14, 9-15, 9-16, 9-17, 9-18, 9-19, 9-20, 9-21, 9-22, 9-23, 9-24, 9-25, 9-26, 9-27, 9-28, 9-29, 9-30, 10-11, 10-12, 10-13, 10-14, 10-15, 10-16, 10-17, 10-18, 10-19, 10-20, 10-21, 10-22, 10-23, 10-24, 10-25, 10-26, 10-27, 10-28, 10-29, 10-30, 11-12, 11-13, 11-14, 11-15, 11-16, 11-17, 11-18, 11-19, 11-20, 11-21, 11-22, 11-23, 11-24, 11-25, 11-26, 11-27, 11-28, 11-29, 11-30, 12-13, 12-14, 12-15, 12-16, 12-17, 12-18, 12-19, 12-20, 12-21, 12-22, 12-23, 12-24, 12-25, 12-26, 12-27, 12-28, 12-29, 12-30, 13-14, 13-15, 13-16, 13-17, 13-18, 13-19, 13-20, 13-21, 13-22, 1-23, 13-24, 13-25, 13-26, 13-?27, 13-28, 13-29, 13-30, 14-15, 14-16, 14-17, 14-18, 14-19, 14-20, 14-21, 14-22, 14-23, 14-24, 14-25, 14-26, 14-27, 14-28, 14-29, 14-30, 15-16, 15-17, 15-18, 15-19, It seems there is a typo in the original text where "13-?27" is present. I've translated it as is while keeping the error. If this is a mistake, you may want to correct the original text for a more accurate translation.15-20, 15-21, 15-22, 15-23, 15-24, 15-25, 15-26, 15-27, 15-28, 15-29, 15-30, 16-17, 16-18, 16-19, 16-20, 16-21, 16-22, 16-23, 16-24, 16-25, 16-26, 16-27, 16-28, 16-29, 16-30, 17-18, 17-19, 17-20, 17-21, 1 7-22, 17-23, 17-24, 17-25, 17-26, 17-27, 17-28, 17-29, 17-30, 18-19, 18-20, 18-21, 18-22, 18-23, 18-24, 18-25, 18-26, 18-27, 18-28, 18-29, 18-30, 19-20, 19-21, 19-22, 19-23, 19-24, 19-25, 19-26, 19-29, 19- 28, 19-29, 19-30, 20-21, 20-22, 20-23, 20-24, 20-25, 20-26, 20-27, 20-28, 20-29, 20-30, 21-22, 21-23, 21-24, 21-25, 21-26, 21-27, 21-28, 21-29, 21-30, 22-23, 22-24, 22-25, 22-26, 22-27, 22-28, 22-29, 22-30 , 23-24, 23-25, 23-26, 23-27, 23-28, 23-29, 23-30, 24-25, 24-26, 24-27, 24-28, 24-29, 24-30, 25-26, 25-27, 25-28, 25-29, 25-30, 26-27, 26-28, 26-29, 26-30, 27-28, 27-29, 27-30, 28-29, 28-30, or 29-30 linked bases.
[0379] The RNA molecule according to the present invention can comprise multiple antisense regulatory elements. For example, the RNA molecule can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 antisense regulatory elements. In one embodiment, the antisense regulatory elements are identical. In this embodiment, the RNA molecule can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 copies of the antisense regulatory elements. In another embodiment, the RNA molecule according to the present invention can comprise different antisense regulatory elements. For example, antisense regulatory elements can be provided to target multiple genes in pathways such as lipid biosynthesis. In this embodiment, the RNA molecule can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10 different antisense regulatory elements.
[0380] Antisense regulatory elements according to the present invention can regulate (increase or decrease) the expression or amount of various target RNA molecules. In one embodiment, the target RNA molecule is a fatty acid biosynthesis gene. Examples of such genes include genes encoding: acetyltransferase; acyl transporter (e.g., "acyl carrier protein"); desaturase, such as stearoyl desaturase or microsomal D12-desaturase, particularly the Fad2-1 gene; malonyltransferase; -ketoacyl-ACP synthase; 3-keto-ACP reductase; enoyl-ACP hydratase; thioesterase, such as acyl-ACP thioesterase; enoyl-ACP reductase. In one embodiment, the target RNA molecule is the FAD2 gene (e.g., those described by Genbank accession number: ). Unpublished: AF124360 (Brassica carinata), AF042841 (Brassica rapa), L26296 (Arabidopsis thaliana), A65102 (Brassica napus). For example, the target RNA molecule can be the FAD2.1 gene. In another embodiment, the target RNA molecule can be the FAD2.2 gene. In another embodiment, the target RNA molecule can be both the FAD2.1 and FAD2.2 genes. Examples of other genes involved in modifying lipid complexes that can be target RNA molecules are known in the art (Shure et al. (1983) Cell 35:225-233; Preiss et al. (1987) Tailoring Genes for Crop Improvement (Bruening et al., eds.), Plenum Press, S. 133-152; Gupta et al. (1988) Plant Mol. Biol. 10:215-224; Olive et al. (1989) Plant Mol Biol 12:525-538; Bhattacharyya et al. (1990) Cell 60:155-122; Dunwell JM (2000) J Exp Botany 51 Spec No:487-96; Brar DS et al. (1996) Biotech Genet. Eng Rev 13:167-79; Kishore G M and Somerville CR (1993) Curr Opin Biotech 4(2):152-8; US 5,530,192 and WO 94 / 18337).
[0381] In another embodiment, the target RNA molecule is an arthropod gene, such as an insect gene transcript. Examples of such genes include chitin synthase genes, such as CHS1 and / or CHS2, or other genes that control insect activity, behavior, reproduction, growth, and / or development. Various essential genes for various pathogens are known to those skilled in the art (e.g., nematode resistance genes are summarized in WO 93 / 10251, WO 94 / 17194).
[0382] In another embodiment, the target RNA molecule is associated with a disease. For example, the target RNA molecule can be an oncogene or tumor suppressor gene transcript. Exemplary oncogenes include ABL1, BCL1, BCL2, BCL6, CBFA2, CBL, CSF1R, ERBA, ERBB, EBRB2, FGR, FOS, FYN, HRAS, JUN, LCK, LYN, MYB, MYC, NRAS, RET, or SRC. Exemplary tumor suppressor genes include BRCA1 or BRCA2; adhesion molecules; cell cycle protein kinases and their inhibitors.
[0383] In another embodiment, the target RNA molecule is associated with the delay of fruit ripening. Delaying fruit ripening can be achieved, for example, by reducing the expression of a gene selected from the group consisting of: polygalacturonase, pectinesterase, β-(1-4)-glucanase (cellulase), β-galactosidase (β-galactosidase); ethylene biosynthesis genes, such as 1-aminocyclopropane-1-carboxylic acid synthase; carotenoid biosynthesis genes, such as, for example, genes for the biosynthesis of pre-phytoene or phytoene.
[0384] In another embodiment, the target RNA molecule is associated with the delay of aging symptoms. Suitable target RNA molecules include cinnamoyl-CoA:NADPH reductase or cinnamoyl alcohol dehydrogenase. Target RNA molecules are further described in WO1995 / 07993.
[0385] In another embodiment, the target RNA molecule is associated with modification of the fiber content in food, preferably seeds. For example, the RNA molecule can reduce the expression of caffeic acid O-methyltransferase or cinnamoyl alcohol dehydrogenase.
[0386] Nucleic acid encoding RNA molecules
[0387] Those skilled in the art will appreciate from the foregoing description that the present invention also provides isolated nucleic acids encoding the RNA molecules disclosed herein, and their components. For example, nucleic acids comprising any one or more of the sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9. The nucleic acids can be partially purified after expression in a host cell. The term "partially purified" is used to refer to RNA molecules that have been generally separated from lipids, nucleic acids, other peptides, and other contaminating molecules with which the RNA molecules associate in the host cell. Preferably, a partially purified polynucleotide is at least 60% free, more preferably at least 75% free, and even more preferably at least 90% free of other components with which it is associated.
[0388] In another embodiment, the polynucleotide according to the present invention is a heterologous polynucleotide. The term "heterologous polynucleotide" is well known in the art and refers to a polynucleotide that is not endogenous to the cell, or a native polynucleotide whose native sequence has been altered, or a native polypeptide whose expression has been quantitatively altered due to manipulation of the cell by recombinant DNA technology.
[0389] In another embodiment, the polynucleotides according to the present invention are synthetic polynucleotides. For example, techniques that do not require pre-existing nucleotide sequences, such as DNA printing and oligonucleotide synthesis, can be used to produce the polynucleotides. In another embodiment, the polynucleotides are produced by heterologous nucleic acids.
[0390] In one embodiment, the polynucleotide encoding RNA precursor molecule disclosed herein comprises an intron in at least one loop sequence, and the intron can be spliced out during the transcription of the polynucleotide in a host cell. In another embodiment, the loop sequence comprises two, three, four, five or more introns. The present invention also provides expression constructs, such as DNA constructs comprising the isolated nucleic acid of the present invention operably connected to a promoter. In one embodiment, such isolated nucleic acid and / or expression constructs are provided in cells or non-human organisms. In one embodiment, the isolated nucleic acid is stably integrated into the genome of a cell or non-human organism. Various embodiments of suitable expression constructs, promoters and cells comprising them are discussed below.
[0391] Synthesis of RNA molecules according to the present invention can be achieved using various methods known in the art. The Examples section provides an example of in vitro synthesis. In this example, constructs containing RNA molecules disclosed herein were subjected to 3' end restriction, precipitation, purification, and quantification. RNA synthesis can be achieved in bacterial culture after transformation of HT115 electrocompetent cells and induction of RNA synthesis using the T7 and IPTG systems.
[0392] recombinant vector
[0393] One embodiment of the present invention includes a recombinant vector comprising at least one RNA molecule as defined herein and capable of delivering the RNA molecule into a host cell. Recombinant vectors include expression vectors. Recombinant vectors contain heterologous polynucleotide sequences, i.e., polynucleotide sequences that are not naturally adjacent to the RNA molecule as defined herein, which are preferably derived from different species. The vector can be RNA or DNA, and is typically a viral vector or plasmid derived from a virus.
[0394] Various viral vectors can be used for delivering and mediating the expression of RNA molecules according to the present invention. The selection of viral vectors generally depends on various parameters, for example, the cells or tissues for delivery, the transduction efficiency and pathogenicity of the vector. In one embodiment, the viral vector is integrated into the host cell chromatin (such as slow virus). In another embodiment, the viral vector is mainly retained in the nucleus as an extrachromosomal episome (such as adenovirus). The embodiment of these types of viral vectors includes oncoretrovirus, slow virus, adeno-associated virus, adenovirus, herpes virus and retrovirus.
[0395] Plasmid vectors typically include additional nucleic acid sequences that provide for easy selection, amplification, and transformation of expression cassettes in prokaryotes, such as pUC-derived vectors, pGEM-derived vectors, or binary vectors containing one or more T-DNA regions. Additional nucleic acid sequences include an origin of replication that provides for autonomous replication of the vector, preferably a selectable marker gene encoding antibiotic or herbicide resistance, a unique multiple cloning site that provides multiple sites for insertion of nucleic acid sequences or genes encoded in the nucleic acid construct, and sequences that enhance transformation of prokaryotic and eukaryotic (particularly plant) cells.
[0396] As used herein, "operably linked" refers to the functional relationship between two or more nucleic acid (e.g., DNA) fragments. Typically, it refers to the functional relationship between a transcriptional regulatory element (promoter) and a transcribed sequence. For example, if a promoter stimulates or regulates the transcription of a coding sequence in a suitable cell, the promoter is operably linked to the coding sequence of an RNA molecule defined herein. Typically, the promoter transcriptional regulatory element operably linked to a transcribed sequence is physically adjacent to the transcribed sequence, i.e., they are cis-acting. However, some transcriptional regulatory elements such as enhancers do not need to be physically adjacent or located near the coding sequence whose transcription is enhanced.
[0397] When multiple promoters are present, each promoter can independently be the same or different.
[0398] For the ease of identifying transformant, recombinant vector desirably comprises selectable or screenable marker gene." marker gene " refers to the gene that gives the cell different phenotypes of expressing this marker gene, therefore allows the cell of this conversion to be distinguished from the cell without this mark. Selectable marker gene gives a kind of proterties, and people can " select " this proterties based on the resistance to selection agent (for example, weed killer herbicide, antibiotic etc.). Screenable marker gene (or reporter gene) gives the proterties that can be identified by observation or test, that is, by " screening " (for example, other enzymatic activities that do not exist in beta-glucuronidase, luciferase, GFP or untransformed cell). Exemplary selectable markers for selecting plant transformants include, but are not limited to, the hyg gene encoding hygromycin B resistance; the neomycin phosphotransferase (nptII) gene that confers resistance to kanamycin and paromomycin; the glutathione-S-transferase gene from rat liver that confers resistance to glutathione-derived herbicides, as described, for example, in EP 256 223; the glutamine synthase gene that, when overexpressed, confers resistance to glutamine synthase inhibitors such as phosphinothricin, as described in WO 20080105. 87 / 05327; an acetyltransferase gene from Streptomyces viridopromogenes, which confers resistance to the selective agent phosphinothricin, as described, for example, in EP 275 957; a gene encoding 5-enolisothiocyanate-3-phosphate synthase (EPSPS), which confers tolerance to N-phosphonomethylglycine, as described, for example, by Hinchee et al. (1988); a bar gene, which confers resistance to bialaphos, as described, for example, in WO 91 / 02071; a nitrilase gene, for example, from Klebsiella ozaenae), which confers resistance to bromoxynil (Stalker et al., 1988); a dihydrofolate reductase (DHFR) gene, which confers resistance to methotrexate (Thillet et al., 1988); a mutant acetolactate synthase gene (ALS), which confers resistance to imidazolinones, sulfonylureas or other ALS-inhibiting chemicals (see EP 154,204); a mutant anthranilate synthase gene, which confers resistance to 5-methyltryptophan; or a dalapon dehalogenase gene, which confers herbicide resistance.
[0399] Preferably, the recombinant vector is stably integrated into the genome of a cell, such as a plant cell. Thus, the recombinant vector may comprise appropriate elements that allow the vector to be incorporated into the genome or chromosome of the cell.
[0400] expression vector
[0401] As used herein, "expression vector" is a DNA vector capable of transforming a host cell and affecting the expression of an RNA molecule defined herein. The expression vector of the present invention comprises regulatory sequences, such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the host cell and control the expression of the RNA molecule according to the present invention. In particular, the expression vector of the present invention includes a transcription control sequence. A transcription control sequence is a sequence that controls the initiation, extension, and termination of transcription. Particularly important transcription control sequences are those that control the initiation of transcription, such as promoter, enhancer, operator, and repressor sequences. The selection of the regulatory sequence used depends on the target organism, such as the plant and / or target organ or tissue of interest. Such regulatory sequences can be obtained from any eukaryotic organism, such as a plant or plant virus, or can be chemically synthesized.
[0402] Exemplary vectors suitable for stable transfection of plant cells or establishment of transgenic plants are described, for example, in Pouwels et al., Cloning Vectors: A Laboratory Manual, 1985, supp. 1987, Weissbach and Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989, and Gelvin et al., Plant Molecular Biology Manual, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include one or more cloned plant genes under the transcriptional control of, for example, 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors may also contain a promoter regulatory region (e.g., a regulatory region that regulates inducible or constitutive, environmentally or developmentally regulated, or cell or tissue-specific expression), a transcription initiation start site, a ribosome binding site, a transcription termination site, and / or a polyadenylation signal.
[0403] The vectors of the invention may also be used to produce RNA molecules as defined herein in cell-free expression systems, such systems being well known in the art.
[0404] In one embodiment, the polynucleotide encoding the RNA molecule according to the present invention is operably linked to a promoter capable of directly expressing the RNA molecule in a host cell. In one embodiment, the promoter functions in vitro. In one embodiment, the promoter is an RNA polymerase promoter. For example, the promoter can be an RNA polymerase III promoter. In another embodiment, the promoter can be an RNA polymerase II promoter. However, the selection of the promoter can depend on the target organism, such as the plant, insect, and / or tissue of interest. Exemplary mammalian promoters include CMV, EF1α, SV40, PGK1, Ubc, human beta actin, CAG, TRE, UAS, CaMKIIa, CAL1, 10, TEF1, GDS, ADH1, CaMV35S, Ubi, H1, and U6. Exemplary insect promoters include Ac5 and polyhedrin. Many constitutive promoters active in plant cells have been described. Suitable promoters for constitutive expression in plants include, but are not limited to, cauliflower mosaic virus (CaMV) 35S promoter, figwort mosaic virus (FMV) 35S, light-inducible promoter from the small subunit (SSU) of ribulose-1,5-bisphosphate carboxylase, rice cytoplasmic triose phosphate isomerase promoter, Arabidopsis thaliana (Arabidopsis) adenine phosphoribosyltransferase promoter, rice actin 1 gene promoter, mannopine synthase and octopine synthase promoters, Adh promoter, sucrose synthase promoter, R gene complex promoter, chlorophyll α / α binding protein gene promoter. These promoters have been used to produce DNA vectors expressed in plants, see, for example, WO 84 / 02913. All of these promoters have been used to produce various types of plant-expressible recombinant DNA vectors.
[0405] In order to express in the source tissue of plant such as leaf, seed, root or stem, the promoter of the present invention is preferably used to have relatively high expression in these specific tissues. For this reason, the gene with tissue or cell specificity or enhanced expression can be selected from many promoters. The embodiment of this type of promoter reported in the document comprises the chloroplast glutamine synthase GS2 promoter from pea, the chloroplast fructose-1 from wheat, the 6-bisphosphatase promoter from the nuclear photosynthesis ST-LSI promoter from potato, the serine / threonine kinase promoter and the glucoamylase (CHS) promoter from Arabidopsis thaliana. The promoters of ribulose-1,5-bisphosphate carboxylase from oriental larch (Larix laricina), Cab gene and Cab6 from pine, Cab-1 gene from wheat, Cab-1 gene from spinach, Cab 1R gene from rice, pyruvate phosphate dikinase (PPDK) from maize (Zea mays), Lhcb1*2 gene from tobacco, Suc2 sucrose-H from Arabidopsis thaliana were also reported. 30 Symporter promoters, promoters of spinach thylakoid membrane protein genes (PsaD, PsaF, PsaE, PC, FNR, AtpC, AtpD, Cab, RbcS). Other promoters of chlorophyll α / β-binding protein can also be used in the present invention, such as the promoters of the LhcB gene and the PsbP gene from white mustard (Sinapis alba).
[0406] A variety of plant gene promoters that are regulated in response to environmental, hormonal, chemical, and / or developmental signals can also be used to express RNA binding protein genes in plant cells, including by (1) heat; (2) light (e.g., pea RbcS-3A promoter, maize RbcS promoter); (3) hormones, such as abscisic acid; (4) wounding (e.g., WunI); or (5) chemicals, such as methyl jasmonate, salicylic acid, steroid hormones, alcohols,
[0407] (Safeners) (WO 97 / 06269); or (6) organ-specific promoters may also be advantageously used.
[0408] As used herein, the term "plant storage organ-specific promoter" refers to a promoter that preferentially directs transcription of genes in plant storage organs when compared to other plant tissues. For expression in plant sink tissues, such as tubers of potato plants, fruits of tomatoes, or seeds of soybeans, rapeseed, cotton, maize, wheat, rice, and barley, the promoters used in the present invention preferably have relatively high expression in these specific tissues. The β-conglycinin promoter, or other seed-specific promoters such as the napin, zein, linin, and phaseolin promoters, can be used. Root-specific promoters can also be used. An example of such a promoter is the promoter of the acid chitinase gene. Expression in root tissue can also be achieved by utilizing the identified root-specific subdomain of the CaMV 35S promoter.
[0409] In a particularly preferred embodiment, the promoter directs expression in tissues and organs where lipid biosynthesis occurs. Such promoters can act at the appropriate time in seed development to modify the lipid composition of the seed. Preferred promoters for seed-specific expression include: 1) promoters from genes encoding enzymes involved in lipid biosynthesis and accumulation in seeds (such as desaturases and elongases), 2) promoters from genes encoding seed storage proteins, and 3) promoters from genes encoding enzymes involved in carbohydrate biosynthesis and accumulation in seeds. Suitable seed-specific promoters are the napusin gene promoter of rapeseed ( US 5,608,152 ), the Vicia faba USP promoter ( Baumlein et al., 1991 ), the Arabidopsis oleosin promoter ( WO 98 / 45461 ), the phaseolin promoter ( US 5,504,200 ) of bean ( WO 98 / 45461 ), the Brassica Bce4 promoter ( WO 91 / 13980 ) or the legumin B4 promoter ( Baumlein et al., 1992 ) and promoters which lead to seed-specific expression in monocotyledonous plants such as maize, barley, wheat, rye, rice, etc. Suitable promoters of note are the promoters of the barley lpt2 or lpt1 genes (WO 95 / 15389 and WO 95 / 23230), or the promoters described in WO 99 / 16890 (promoters from hordein genes, rice glutelin genes, rice oryzin genes, rice prolamin genes, wheat prolamin genes, wheat glutelin genes, zein genes, oat glutelin genes, sorghum kasirin genes, rye secalin genes). Other promoters include those described in Broun et al. (1998), Potenza et al. (2004), US20070192902 and US20030159173. In one embodiment, the seed-specific promoter is preferably expressed in a defined part of the seed, such as the cotyledon or endosperm. Examples of cotyledon-specific promoters include, but are not limited to, the FPI promoter (Ellerstrom et al., 1996), the pea legumin promoter (Perrin et al., 2000), and the bean lectin promoter (Perrin et al., 2000). Examples of endosperm-specific promoters include, but are not limited to, the maize zein-1 promoter (Chikwamba et al., 2003), the rice glutelin-1 promoter (Yang et al., 2003), the barley D-hordein promoter (Horvath et al., 2000), and the wheat HMW glutenin promoter (Alvarez et al., 2000). In another embodiment, the seed-specific promoter is not expressed or is expressed only at a low level after embryo and / or seed germination.
[0410] In another embodiment, the plant storage organ-specific promoter is a fruit-specific promoter. Examples include, but are not limited to, the tomato polygalacturonase E8 and Pds promoters, and the apple ACC oxidase promoter (for review, see Potenza et al., 2004). In a preferred embodiment, the promoter preferentially directs expression in the edible portion of the fruit, such as the pith, relative to the peel or seeds within the fruit.
[0411] In one embodiment, the inducible promoter is the Aspergillus nidulans alc system. Examples of inducible expression systems that can be used to replace the Aspergillus nidulans alc system are described in the reviews by Padidam (2003) and Corrado and Karali (2009). In another embodiment, the inducible promoter is a safener-inducible promoter, such as the maize ln2-1 or ln2-2 promoter (Hershey and Stoner, 1991), which is a maize GST-27 promoter (Jepson et al., 1994) or a soybean GH2 / 4 promoter (Ulmasov et al., 1995).
[0412] In another embodiment, the inducible promoter is a senescence-inducible promoter, such as the senescence-inducible promoters SAG (senescence-associated gene) 12 and SAG13 from Arabidopsis (Gan, 1995; Gan and Amasino, 1995) and LSC54 from Brassica napus (Buchanan-Wollaston, 1994). Such promoters show increased expression around the onset of senescence in plant tissues, particularly leaves.
[0413] For expression in vegetative tissues, leaf-specific promoters such as the ribulose bisphosphate carboxylase (RBCS) promoter can be used. For example, the tomato RBCS1, RBCS2, and RBCS3A genes are expressed in leaves and lightly grown seedlings (Meier et al., 1997). The ribulose bisphosphate carboxylase promoter described by Matsuoka et al. (1994) can be used, which is expressed at high levels almost exclusively in the mesophyll cells of leaves and sheaths. Another leaf-specific promoter is the light-harvesting chlorophyll a / b binding protein gene promoter (see Shiina et al., 1997). The Arabidopsis thaliana myb-related gene promoter (Atmby5) described by Li et al. (1996) is leaf-specific. The Atmyb5 promoter is expressed in the developing leaf hairs, stipules, and epidermal cells of young rosettes and cauliflower leaf margins, as well as in immature seeds. The leaf promoter identified in corn by Busk et al. (1997) can also be used.
[0414] In some cases, such as when LEC2 or BBM are recombinantly expressed, it may be desirable that the transgene not be expressed at high levels. An example of a promoter that can be used in this situation is the truncated napin A promoter that retains a seed-specific expression pattern but has reduced expression levels (Tan et al., 2011).
[0415] The 5' non-translated leader sequence can be derived from a promoter selected to express a heterologous gene sequence of the RNA molecule of the present invention, or can be heterologous relative to the coding region of the enzyme to be produced, and can be specifically modified to increase the translation of the mRNA if desired. For a review of optimizing transgenic expression, see Koziel et al., (1996). The 5' non-translated region can also be obtained from plant viral RNA (tobacco mosaic virus, tobacco etch virus, corn dwarf mosaic virus, alfalfa mosaic virus, etc.) of a suitable eukaryotic gene, plant gene (wheat and corn chlorophyll a / b binding protein gene leader sequence) or synthetic gene sequence. The present invention is not limited to constructs in which the non-translated region is derived from a 5' non-translated sequence of a promoter sequence. The leader sequence can also be derived from an unrelated promoter or coding sequence. Useful leader sequences in the context of the present invention include corn Hsp70 leader sequence (US 5,362,865 and US 5,859,347) and TMV ω element.
[0416] Termination of transcription is achieved by being operably connected to the 3' non-translated DNA sequence of the RNA molecule of interest in the expression vector. The 3' non-translated region of the recombinant DNA molecule contains a polyadenylation signal, which works in plants to cause adenylate nucleotides to be added to the 3' end of the RNA. The 3' non-translated region can be obtained from the various genes expressed in plant cells. The 3' non-translated region of nopaline synthase 3' non-translated region, the 3' non-translated region of the pea small subunit Rubisco gene, the 3' non-translated region of the soybean 7S seed storage protein gene are usually used with this ability. 3' transcription, non-translated region containing the polyadenylic acid signal of Agrobacterium (Agrobacterium) tumor induction (Ti) plasmid genes are also suitable.
[0417] transfer nucleic acid
[0418] Transfer nucleic acid can be used for exogenous polynucleotide delivery to cell and comprises one, preferably two edge sequences and one or more RNA molecules of interest. Transfer nucleic acid can encode or not encode selectable marker. Preferably, transfer nucleic acid forms a part for binary vector in bacterium, wherein binary vector further comprises the element that allows vector to replicate in bacterium, selects or maintains the bacterial cell containing binary vector. After being transferred to eukaryotic cell, the transfer nucleic acid component of binary vector can be integrated in the genome of eukaryotic cell, or for transient expression experiment, can only be expressed in cell.
[0419] As used herein, the term "extrachromosomal transfer nucleic acid" refers to a nucleic acid molecule that can be transferred to a eukaryotic cell such as a plant leaf cell from a bacterium (such as Agrobacterium species). Extrachromosomal transfer nucleic acid is a genetic element that is known as an element that can be transferred, and the nucleotide sequence contained in its edge is subsequently integrated into the genome of the recipient cell. In this respect, transfer nucleic acid is flanked by two "edge" sequences, although a single edge at one end can be used in some cases and a second end of the transfer nucleic acid is randomly generated during the transfer process. The RNA molecule of interest is typically located between a left edge-like sequence and a right edge-like sequence of the transfer nucleic acid. The RNA molecule contained in the transfer nucleic acid can be operably connected to a variety of different promoters and terminator regulatory elements that promote its expression, i.e., the transcription of the RNA molecule and / or the translation of the RNA molecule. Transfer of DNA from Agrobacterium species (T-DNAs), such as Agrobacterium tumefaciens or Agrobacterium rhizogenes and their artificial variants / mutants, is probably the best characterized embodiment of the transfer nucleic acid. Another embodiment is P-DNA ("plant-DNA"), which comprises a T-DNA border-like sequence from a plant.
[0420] As used herein, "T-DNA" refers to the T-DNA of Agrobacterium tumefaciens Ti plasmid or Agrobacterium rhizogenes Ri plasmid, or its variant for DNA transfer in plant cells. T-DNA can comprise complete T-DNA, including right and left border sequences, but only needs to comprise the minimum sequence required for cis transfer, i.e., the right T-DNA border sequence. T-DNA of the present invention has been inserted into them, and the RNA molecule of interest is inserted anywhere between the right and left border sequences (if present). The sequence encoding the trans factors (such as vir genes) required for T-DNA transfer in plant cells can be inserted into the T-DNA, or can be present on the replicon identical with the T-DNA, or preferably be trans on the compatible replicon in the Agrobacterium host. Such "binary vector system" is well known in the art. As used herein, "P-DNA" refers to a transfer nucleic acid isolated from a plant genome or a man-made variant / mutant thereof and comprises a T-DNA border-like sequence at each end or at only one end.
[0421] As used herein, the "edge" sequence of a transfer nucleic acid can be isolated from a selected organism, such as a plant or bacterium, or an artificial variant / mutant thereof. The edge sequence promotes and facilitates the transfer of the RNA molecule connected thereto, and can promote its integration in the recipient cell genome. In one embodiment, the length of the border sequence is 10-80bp. Agrobacterium species T-DNA edge sequences are well known in the art and include those described in Lacroix et al. (2008).
[0422] While traditionally only Agrobacterium species have been used to transfer genes into plant cells, a large number of systems have now been identified / developed that function in a manner similar to that of Agrobacterium species. Several non-Agrobacterium species have recently been genetically modified to possess gene transfer capabilities (Chung et al., 2006; Broothaerts et al., 2005). These include Rhizobium species NGR234, Sinorhizobium meliloti, and Mezorhizobium loti.
[0423] Direct transfer of eukaryotic expression plasmids from bacteria to eukaryotic hosts was first achieved decades ago by fusion of protoplasts of mammalian cells and plasmid-carrying Escherichia coli (Schaffner, 1980). Since then, the number of bacteria capable of delivering genes into mammalian cells has steadily increased (Weiss, 2003), with independent discoveries by four groups (Sizemore et al., 1995; Courvalin et al., 1995; Powell et al., 1996; Darji et al., 1997).
[0424] As used herein, the terms "transfection," "transformation," and variations thereof are generally used interchangeably. A "transfected" or "transformed" cell may have been manipulated to introduce an RNA molecule of interest, or may be a daughter cell derived therefrom.
[0425] recombinant cells
[0426] The present invention also provides recombinant cells, such as recombinant bacterial cells, fungal cells, plant cells, insect cells or animal cells, which are host cells transformed with one or more RNA molecules or vectors as defined herein, or a combination thereof. Suitable cells of the present invention include any cells that can be transformed with an RNA molecule or recombinant vector according to the present invention. In one embodiment, the transformed host cell is dead.
[0427] The recombinant cell can be a cell in culture, a cell in vitro, or a cell in an organism such as a plant, or a cell in an organ such as a seed or leaf. Preferably, the cell is in a plant, more preferably in a seed of a plant. In one embodiment, the recombinant cell is a non-human cell. Therefore, in one embodiment, the present invention relates to a non-human organism comprising one or more or all of the RNA molecules disclosed herein.
[0428] In one embodiment, the cell is an insect cell. In one embodiment, the insect cell is derived from Trichoplusia ni.
[0429] Another example of a suitable host cell is electrocompetent HT115 cells.
[0430] The host cell of importing RNA molecule can be an untransformed cell or a cell transformed with at least one nucleic acid.Such nucleic acid can be relevant to lipid synthesis, or irrelevant.Host cell of the present invention can be endogenously (that is, naturally) capable of expressing RNA molecule defined herein, in which case, the recombinant cell derived therefrom has the ability of enhancing production RNA molecule, or only after being transformed with at least one RNA molecule defined herein, can produce the ability of the RNA molecule.In one embodiment, the cell is a cell that can be used to produce lipid.In one embodiment, the recombinant cell of the present invention has the ability of enhancing production of non-polar lipids such as TAG.
[0431] Host cells of the present invention can be any cell capable of expressing at least one RNA molecule as described herein, and include bacteria, fungi (including yeast), parasites, arthropods, animals and plant cells. Examples of host cells include Salmonella, Escherichia, Bacillus, Listeria, Saccharomyces, Spodoptera, Mycobacteria, Trichoplusia, Agrobacterium, BHK (baby hamster kidney) cells, MDCK cells, CRFK cells, CV-1 cells, COS (e.g., COS-7) cells and Vero cells. Further examples of host cells are Escherichia coli, including Escherichia coli K-12 derivatives; Salmonella typhi; Salmonella typhimurium, including attenuated strains; Spodoptera frugiperda; Spodoptera frugiperda; and non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL 1246). Other suitable mammalian cell hosts include other kidney cell lines, other fibroblast cell lines (e.g., human, mouse or chicken embryonic fibroblast cell lines), myeloma cell lines, Chinese hamster ovary cells, mouse NIH / 3T3 cells, LMTK cells and / or HeLa cells.
[0432] In a preferred embodiment, the plant cell is a seed cell, in particular a cell in the cotyledon or endosperm of a seed. In one embodiment, the cell is an animal cell. The animal cell can be any type of animal, such as, for example, a non-human animal cell, a non-human vertebrate cell, a non-human mammalian cell, or a cell of an aquatic animal such as a fish or crustacean, an invertebrate, an insect, etc. Examples of algal cells used as host cells of the present invention include, for example, Chlamydomonas species (e.g., Chlamydomonas reinhardtii), Dunaliella species, Haematococcus species, Chlorella species, Thraustochytrium species, Schizochytrium species, and Volvox species.
[0433] genetically modified plants
[0434] The present invention also provides plants comprising one or more exogenous RNA molecules as defined herein, cells according to the present invention, vectors according to the present invention, or combinations thereof. When used as a noun, the term "plant" refers to a whole plant, while the term "part thereof" refers to a plant organ (e.g., leaves, stems, roots, flowers, fruits, seeds); a single cell (e.g., pollen); a seed; a seed part such as an embryo, endosperm, embryonic disc, or seed coat; a plant tissue such as vascular tissue; a plant cell and its progeny. As used herein, a plant part includes a plant cell.
[0435] As used herein, in the context of modifying a plant, the terms "in a plant" and "in the plant" mean that the modification has occurred in at least one part of the plant, including the case where the modification has occurred in the entire plant, and do not exclude the case where the modification has occurred in only one or more, but not all, parts of the plant. For example, a tissue-specific promoter is said to be expressed "in a plant" even though it may only be expressed in certain parts of the plant. Similarly, a "transcription factor polypeptide that increases the expression of one or more glycolytic and / or fatty acid biosynthetic genes in a plant" means that the increased expression occurs in at least one part of the plant.
[0436] As used herein, the term "plant" is used in its broadest sense to include any organism in the plant kingdom. Also included are red algae, brown algae, and green algae. It includes, but is not limited to, any type of flowering plant, grass, crop or cereal (e.g., oilseed, corn, soybean), feed or fodder, fruit or vegetable plant, herbaceous plant, woody plant, or tree. This is not meant to limit plants to any specific structure. It also refers to unicellular plants (e.g., microalgae). The term "part" with respect to a plant refers to a plant cell and its progeny, a plurality of plant cells, a structure present in any stage of plant development, or a plant tissue. Such structures include, but are not limited to, leaves, stems, flowers, fruits, nuts, roots, seeds, seed coats, and embryos. The term "plant tissue" includes differentiated and undifferentiated tissues of a plant, including those present in leaves, stems, flowers, fruits, nuts, roots, seeds, e.g., embryonic tissue, endosperm, dermal tissue (e.g., epidermis, periderm), vascular tissue (e.g., xylem, phloem), or ground tissue (comprising parenchyma, collenchyma, and / or mesenchymal cells), as well as cells in culture (e.g., single cells, protoplasts, callus, embryos, etc.). The plant tissue can be a plant, organ culture, tissue culture, or cell culture.
[0437] 18:3 and 16:3 fatty acids are found in varying amounts in glycolipids of different plants. This is used to distinguish fatty acids with three double bonds, which are usually C 18 The 18:3 plant atom contains C 16 and C 18In 18:3 plants, the enzyme activity that catalyzes the conversion of phosphatidic acid to diacylglycerol and diacylglycerol to monogalactosyldiacylglycerol (MGD) is significantly lower in 18:3 chloroplasts than in 16:3 chloroplasts. In 18:3 leaves, chloroplasts synthesize stearoyl ACP2 in the stroma, introduce the first double bond in the saturated hydrocarbon chain, and then hydrolyze the thioester. The released oleate is exported across the chloroplast envelope into the membranes of the eukaryotic portion of the cell, probably the endoplasmic reticulum, where it is incorporated into PC. The oleoyl group attached to PC is desaturated in these membranes and then moves back into the chloroplast. The acyl group attached to MGD is the substrate for the introduction of the third double bond to produce MGD with two linolenic acid residues. This galactolipid is characteristic of 18:3 plants such as those in the Asteraceae and Fabaceae families. In photosynthetically active cells of 16:3 plants, such as those represented by members of the Apiaceae and Brassicaceae families, two pathways operate in parallel to provide thylakoids with MGD. The synergistic "eukaryotic" sequence is supplemented to varying degrees by the "prokaryotic" pathway. Its reactions are restricted to the chloroplasts and result in a typical arrangement of acyl groups, and once esterified to MGD, they are completely desaturated. The prokaryotic DAG backbone carries C16:0 and its desaturated products in which the C-2 position is excluded from the C18: fatty acid. The C-1 position is occupied by a C18 fatty acid and, to a lesser extent, by a C16 group. The similarity between the cyanobacterial lipid DAG backbone in 16:3 plants and the DAG backbone synthesized by the chloroplast transport pathway illustrates this phylogenetic relationship and demonstrates the existence of prokaryotes.
[0438] As used herein, the term "vegetative tissue" or "vegetative plant part" is any plant tissue, organ or part other than organs used for sexual reproduction of plants. Organs used for sexual reproduction of plants are specifically seed-bearing organs, flowers, pollen, fruits and seeds. Vegetative tissue and parts include at least plant leaves, stems (including bulbs and tillers, but not including heads), tubers and roots, but not including flowers, pollen, seeds including seed coats, embryos and endosperms, fruits including mesocarp tissue, pods with seeds and heads with seeds. In one embodiment, the vegetative part of a plant is an above-ground plant part. In another or further embodiment, the vegetative plant part is a green part, such as a leaf or stem.
[0439] A "transgenic plant" or variant thereof refers to a plant containing a transgene not found in wild-type plants of the same species, variety, or cultivar. Transgenic plants as defined in the context of the present invention include plants and their progeny that have been genetically modified using recombinant techniques to produce at least one polypeptide as defined herein in the desired plant or part thereof. Transgenic plant parts have a corresponding meaning.
[0440] The terms "seed" and "grain" are used interchangeably herein. "Grain" refers to mature grain, such as harvested grain or grain still on the plant but ready for harvest, but may also refer to grain after imbibition or germination, depending on the context. Mature grain typically has a moisture content of less than about 18%. In a preferred embodiment, the moisture content of the grain is at a level generally considered safe for storage, preferably 5%-15%, 6%-8%, 8%-10%, or 10%-15%. As used herein, "developing seed" refers to a seed before maturity, typically found in the reproductive structures of a plant after fertilization or flowering, but may also refer to such a seed before maturity that has been separated from a plant. Mature seed typically has a moisture content of less than about 12%.
[0441] As used herein, the term "plant storage organ" refers to a part of a plant that is specialized for storing energy, for example, in the form of proteins, carbohydrates, lipids. Examples of plant storage organs are seeds, fruits, tuberous roots, and tubers. Preferred plant storage organs of the present invention are seeds.
[0442] As used herein, the term "phenotypically normal" refers to a genetically modified plant or part thereof, such as a transgenic plant, or a storage organ of the present invention, such as a seed, tuber or fruit, that does not have significantly reduced growth and reproductive capacity compared to an unmodified plant or part thereof. Preferably, when grown under the same conditions, the biomass, growth rate, germination rate, storage organ size, seed size and / or number of viable seeds produced is not less than 90% of the biomass, growth rate, germination rate, storage organ size, seed size and / or number of viable seeds of a plant lacking the recombinant polynucleotide. The term does not include plant characteristics that may differ from wild-type plants but do not affect the usefulness of the plant for commercial purposes, such as the ballerina phenotype of seedling leaves. In one embodiment, the phenotypically normal genetically modified plant or part thereof comprises a recombinant polynucleotide encoding a silencing suppressor operably linked to a plant storage organ-specific promoter and having substantially the same growth or reproductive capacity as a corresponding plant or part thereof that does not comprise the polynucleotide.
[0443] Plant provided by the invention or intended for implementation of the present invention include monocots and dicots. In preferred embodiments, plant of the present invention is crops (for example, cereals and dry beans, corn, wheat, potato, rice, sorghum, millet, cassava, barley) or beans such as soybean, kidney bean or pea. The plant can be grown for the production of edible roots, tubers, leaves, stems, flowers or fruits. Plant can be a vegetable plant whose nutritional parts are used as food. The plant of the present invention can be: Acrocomia aculeata, Arabidopsis thaliana, Aracinishypogaea, Astrocaryum murumuru, Astrocaryum vulgare, Attalea geraensis, Attalea humilis, Attalea oleifera (andaiá), Attalea phalerata (uricuri), Attalea speciosa, Avena sativa, Beta vulgaris, Brassica sp, such as Brassica carinata, Brassica juncea, Brassica napobrassica, Brassica napus, Camelina sativa, Cannabis sativa, Carthamus tinctorius. tinctorius, Brazilian nectarine (Caryocar brasiliense), coconut (Cocos nucifera), Ethiopian two-jointed shepherd's purse (Crambea byssinica), melon (Cucumis melo), African palm (Elaeis guineensis), soybean (Glycine max), cotton (Gossypium hirsutum), Helianthus species such as sunflower (Helianthus annuus), barley (Hordeum vulgare), jatropha (Jatropha curcas), andada tree (Joannesia princeps), Lemna species such as Lemna aequinoctialis, Lemna disperma, Lemna ecuadoriensis, swelling duckweed (Lemna gibba), Japanese duckweed (Lemna japonica),Lemna minor, Lemna minuta, Lemna obscura, Lemna paucicostata, Lemna perpusilla, Lemna Lemnaminuta tenera, Lemna trisulca, Lemna turionifera, Lemna valdiviana, Lemna yungensis, Licania rigida, Linum usitatissimum, Lupinus angustifolius, Mauritia flexuosa, Maximiliana maripa, Miscanthus species such as Miscanthus giganteus and Miscanthus sinensis, Nicotiana species such as Nicotiana tabacum or Nicotiana benthamiana, Oenocarpus bacaba, Oenocarpus bataua, Oenocarpus distichus, Oryza species such as Oryza sativa and Oryza glaberrima, Switchgrass (Panicum virgatum), Mali (Paraqueiba paraensis), Avocado (Persea amencana), Pongamia (Pongamia), Populus trichocarpa, Castor (Ricinus communis), Saccharum species, Sesamum indicum, Solanum tuberosum, Sorghum species such as Sorghum bicolor, Sorghum vulgare), Theobromagrandiforum, Trifolium species, Trithrinax brasiliensis, Triticum species such as wheat (Triticum aestivum), maize (Zea mays), alfalfa (Medicagosativa), rye (Secale cerale), sweet potato (Lopmoea batatus),Cassava (Manihot esculenta), coffee (Cofea) species, pineapple (Anana comosus), citrus (Citrus) species, cocoa (Theobroma cacao), tea (Camellia senensis), banana (Musa) species, avocado (Persea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifer indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macadamia intergrifolia) and almond (Prunus amygdalus). For example, the plant of the present invention can be Nicotiana benthamiana.
[0444] Other preferred plants include C4 grasses, for example, Andropogon gerardi, Bouteloua curtipendula, B. gracilis, Buchloedactyloides, Schizachyrium scoparium, Sorghastrum nutans, Sporobolus creptandrus, in addition to those mentioned above; C3 grasses, such as Elymus canadensis, Lespedeza capitata and Petalostemum villosum, Aster azureus; and woody plants, such as Quercus ellipsoidalis and Q. macrocarpa. Other preferred plants include C3 grasses.
[0445] In a preferred embodiment, the plant is an angiosperm.
[0446] In one embodiment, plant is an oilseed plant, preferably an oilseed crop plant. As used herein, "oilseed plant" is a plant species for commercially producing lipids from the seeds of a plant. Oilseed plants can be, for example, oilseed rape (e.g., rapeseed), corn, sunflower, safflower, soybean, sorghum, flax (linseed) or sugar beet. In addition, oilseed plants can be other rapeseeds, cotton, peanuts, poppy, rapeseed, mustard, castor, sesame, safflower, Jatropha curcas or plants that produce nuts. The plant can produce high levels of lipids in its fruit, for example, olive, oil palm or coconut. Horticultural plants that can be applied to the present invention are lettuce, cabbage or vegetable rapeseed, including cabbage, broccoli or cauliflower. The present invention can be applicable to tobacco, melons, carrots, strawberries, tomatoes or peppers.
[0447] In a preferred embodiment, the transgenic plant is homozygous for each gene (transgene) that has been introduced, so that its progeny do not segregate for the desired phenotype. The transgenic plant can also be heterozygous for the introduced transgene, preferably uniformly heterozygous for the transgene, for example in the F1 progeny grown from hybrid seeds. Such plants can provide advantages well known in the art, such as hybrid vigor.
[0448] conversion
[0449] The RNA molecules disclosed herein can be stably introduced into the above-mentioned host cells and / or non-human organisms, such as plants. For the avoidance of doubt, embodiments of the present invention encompass the above-mentioned plants stably transformed with the RNA molecules disclosed herein. As used herein, the terms "stable transformation," "stably transformed," and variants thereof refer to the integration of RNA molecules or nucleic acids encoding RNA molecules into the genome of a cell so that they are transferred to daughter cells during cell division without the need for positive selection for their presence. Stable transformants or their progeny can be identified by any method known in the art, such as Southern blotting on chromosomal DNA, or in situ hybridization of genomic DNA, so that they can be selected.
[0450] Transgenic plants can be produced using techniques known in the art, such as those generally described in Slater et al., Plant Biotechnology - The Genetic Manipulation of Plants, Oxford University Press (2003), and Christou and Klee, Handbook of Plant Biotechnology, John Wiley and Sons (2004).
[0451] In one embodiment, plants can be transformed by topically applying an RNA molecule according to the present invention to a plant or part thereof. For example, the RNA molecule can be provided as a formulation with a suitable carrier and sprayed, dusted, or otherwise applied to the surface of a plant or part thereof. Thus, in one embodiment, the methods of the present invention encompass introducing an RNA molecule disclosed herein into a plant, the method comprising topically applying a composition comprising the RNA molecule to the plant or part thereof.
[0452] Agrobacterium-mediated transfer is a widely applicable system for gene import into plant cells, because DNA can be imported into cells in whole plant tissues, plant organs or explants in tissue culture for transient expression or for stable integration of DNA in plant cell genomes. For example, the in planta method can be used. It is well known in the art to use plant integration vectors mediated by Agrobacterium to import DNA into plant cells. The DNA region to be transferred is limited by border sequences, and intervening DNA (T-DNA) is usually inserted into the plant genome. Due to the simplicity and clear nature of gene transfer, this method is selected.
[0453] Acceleration methods that can be used include, for example, microparticle bombardment. One embodiment of a method for delivering transforming nucleic acid molecules to plant cells is microparticle bombardment. This method has been reviewed in Yang et al., Particle Bombardment Technology for Gene Transfer, Oxford University Press, Oxford, England (1994). Non-biological particles (microparticles) can be coated with nucleic acids and delivered to cells of, for example, immature embryos by a propulsive force. Exemplary particles include those composed of tungsten, gold, platinum, etc.
[0454] In another method, plasmid can be stably transformed. The disclosed method for plasmid transformation in higher plants includes that the particle gun of the DNA containing selection marker is sent and by homologous recombination, DNA is targeted to plasmid genome (US5,451,513, US 5,545,818, US5,877,402, US 5,932479, and WO 99 / 05265). Other methods of cell transformation can also be used, including but not limited to by DNA being directly transferred into pollen, by DNA being directly injected into the reproductive organs of plant, or by DNA being directly injected into the cell of immature embryo, and then rehydrating the dried embryo, thereby DNA is imported into plant.
[0455] The regeneration, development and cultivation of plants from single plant protoplast transformants or from various transformed explants are well known in the art (Weissbach et al., in: Methods in Plant Molecular Biology (Methods in Plant Molecular Biology), Academic Press, San Diego, CA, (1988)). This regeneration and growth process generally involves the following steps: selecting transformed cells and culturing those individualized cells through the normal stages of embryonic development from the rooted plantlet stage. Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are then planted in a suitable plant growth medium, such as soil.
[0456] The development or regeneration of plants containing exogenous genes is well known in the art. Preferably, the regenerated plants are self-pollinated to provide homozygous transgenic plants. Otherwise, pollen obtained from the regenerated plants is hybridized with seed-grown plants of agronomically important lines. Instead, pollen from plants of these important lines is used to pollinate the regenerated plants. Transgenic plants of the present invention containing the desired polynucleotides are cultivated using methods well known to those skilled in the art.
[0457] In order to confirm the existence of transgenic in transgenic cells and plants, methods well known to those skilled in the art can be used to carry out polymerase chain reaction (PCR) amplification or Southern blot analysis. The expression product of transgenic can be detected in any of a variety of ways, depending on the character of the product, and includes Northern blot hybridization, protein blotting and enzyme assay. Once transgenic plants are obtained, they can be grown to produce plant tissue or parts with desired phenotype. Plant tissue or plant parts can be gathered in the crops, and / or seeds can be collected. Seed can be used as the source of the extra plants of the tissue or part with desired characteristics in growth. Preferably, the vegetative plant parts are gathered in the crops when the output of non-polar lipids is the highest. In one embodiment, the vegetative plant parts are gathered in the crops approximately when flowering or after flowering begins. Preferably, the plant parts are gathered in the crops approximately when aging begins, usually showing as leaf yellowing and drying.
[0458] Transgenic plants formed using Agrobacterium or other transformation methods typically contain a single locus on a chromosome. Such transgenic plants can be considered hemizygous for the added gene. More preferred are transgenic plants that are homozygous for the added gene, i.e., transgenic plants that contain two added genes, one gene at the same locus on each chromosome of a chromosome pair. Homozygous transgenic plants can be obtained by fertilizing the hemizygous transgenic plants themselves, germinating some of the resulting seeds, and analyzing the resulting plants for the gene of interest.
[0459] It should also be understood that two different transgenic plants containing two independently separated foreign genes or loci can also be hybridized (mating) to produce offspring containing two groups of genes or loci. The self-pollination of an appropriate F1 offspring can produce a plant that is isozygous for the foreign gene or locus. Backcrossing with the parent plant and outcrossing with non-transgenic plants, as well as asexual reproduction, are also contemplated. Similarly, transgenic plants can be hybridized with offspring containing both identified transgenics and genetic modifications with a second plant comprising a genetic modification such as a mutant gene. The description of other breeding methods commonly used for different traits and crops can be found in Fehr, In: Breeding Methods for Cultivar Development, Wilcox J. American Society of Agronomy (Breeding Methods for Cultivar Development), Madison, Wisconsin, USA (1987).
[0460] preparation
[0461] The RNA molecules according to the present invention can be provided as various formulations. For example, the RNA molecules can be in the form of solids, ointments, gels, creams, powders, pastes, suspensions, colloids, foams, or aerosols. Solid forms can include powders, pulvis, granules, microspheres, pills, lozenges, tablets, filled films (including seed coatings), etc., which can be water-dispersible. In one embodiment, the composition is in the form of a concentrate.
[0462] In one embodiment, the RNA molecule can be provided as a topical formulation. In one embodiment, the formulation stabilizes the RNA molecule in the formulation and / or in vivo. For example, the RNA molecule can be provided in a lipid formulation. For example, the RNA molecule can be provided in a liposome. In one embodiment, the formulation comprises a transfection facilitator.
[0463] In one embodiment, RNA molecules can be incorporated into a formulation suitable for field application. In one embodiment, the field includes plants. Suitable plants include crops (e.g., cereals and beans, corn, wheat, potato, cassava, rice, sorghum, soybean, cassava, barley or pea), or legumes). The plants can be grown for the production of edible roots, tubers, leaves, stems, flowers or fruits. In one embodiment, crop plants are cereals. Examples of cereals include, but are not limited to, wheat, barley, sorghum, oats and rye. In these embodiments, RNA molecules can be formulated for application to plants or any part of plants in any suitable manner. For example, the composition can be formulated for application to leaves, stems, roots, fruits, vegetables, grains and / or buds of plants. In one embodiment, RNA molecules are formulated for application to the leaves of plants and can be sprayed on the leaves of plants.
[0464] Depending on the desired formulation, the RNA molecules described herein can be formulated with a variety of other agents. Exemplary agents include one or more of suspending agents, coalescing agents, bases, buffers, bittering agents, flavoring agents, preservatives, propellants, thixotropic agents, antifreeze agents, and coloring agents.
[0465] In other embodiments, the RNA molecule formulation may comprise an insecticide, a pesticide, a fungicide, an antibiotic, an anthelmintic, an antiparasitic, an antiviral, or a nematicide.
[0466] In another embodiment, the RNA molecules can be incorporated into pharmaceutical compositions. Such compositions generally include the RNA molecules described herein and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., that are compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
[0467] A pharmaceutical composition is formulated to be compatible with its intended route of administration.Examples of routes of administration include parenteral, eg, intravenous, intradermal, subcutaneous, inhalation, transdermal (topical), transmucosal, oral, and rectal.
[0468] In one embodiment, the active compound is prepared together with a carrier that protects the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. For example, liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in US 4,522,811.
[0469] The RNA molecules according to the present invention can be provided in a kit or package. For example, the RNA molecules disclosed herein can be packaged in a suitable container with written instructions for use in generating the above-mentioned cells or organisms or treating a condition.
[0470] Methods for controlling non-human organisms
[0471] In one embodiment, RNA molecules according to the present invention can be used to control non-human organisms, such as insects. These uses involve applying RNA molecules according to the present invention using various methods. In one embodiment, RNA molecules according to the present invention can be provided as insect bait for ingestion by insects. In another embodiment, RNA molecules can be sprayed on insects as needed. In another embodiment, RNA molecules can be sprayed on plants or crops to protect the plants or crops from insects. Exemplary crops include cotton, corn, tomato, chickpea, pigeon pea, alfalfa, rice, sorghum, and cowpea.
[0472] In one embodiment, RNA molecules can be provided to modify insect behavior. In another embodiment, RNA molecules can be provided to kill insects. In another embodiment, RNA molecules can be provided to reduce insect fertility. Exemplary insect targets include household insects. Other exemplary insect targets include sap-sucking insects such as aphids (e.g., Myzus persicae, Metopolophium dirhodum, Rhopalosiphum padi, Aphis glycines, Aphis glycines). Additional exemplary insect targets include arachnids, mosquitoes, ectoparasites, flies, spider mites, thrips, ticks, red fowl mites, ants, cockroaches, termites, crickets including house crickets, silverfish, booklice, beetles, midges, mosquitoes, and fleas. Other exemplary insect targets include agricultural pests. Examples include sap feeders such as stink bugs and aphids, chewing insects such as caterpillars, beetles, worms, grinding insects such as thrips and slugs, moths, flies such as fruit flies, and grain pests such as grain borers, weevils, and grain moths.
[0473] In one embodiment, the insect is a sap-sucking insect. In this example, the RNA molecule can have antisense activity against MpC002 and / or MpRack-1. In one embodiment, the sap-sucking insect is an aphid. In another embodiment, the aphid is Myzus persicae.
[0474] In one embodiment, the insect target is an ant (e.g., Argentine ant (Linepithema humile)), cotton bollworm or corn earworm (Helicoverpa armigera), or fly (e.g., Lucilia cuprina). In one embodiment, the target insect is cotton bollworm (Helicoverpa armigera), and the RNA molecule has antisense activity against the ABC transporter white gene (ABCwhite). In another embodiment, the target insect is Argentine ant (Linepithema humile), and the RNA molecule has antisense activity against pheromone biosynthesis activating neuropeptide (PBAN). In another embodiment, the target insect is Lucilia cuprina, and the RNA molecule has antisense activity against one or more genes encoding proteins selected from the group consisting of V-type proton ATPase catalytic subunit A, RNase 1 / 2, chitin synthase, ecdysone receptor, and gamma-tubulin 1 / 1-like.
[0475] In the above embodiments, the compositions and RNA molecules disclosed herein can be provided in a dispenser. In one embodiment, the dispenser is a trap or bait. In one embodiment, the trap and / or bait comprises a bait containing one or more RNA molecules disclosed herein.
[0476] In one embodiment, the present invention includes a method for controlling insect behavior comprising spraying, dusting, or otherwise applying the RNA molecules disclosed herein to the insects. In this embodiment, the RNA molecules can be sprayed, dusted, or otherwise applied directly to the insects. In another embodiment, the RNA molecules can be sprayed, dusted, or otherwise applied to plants or crops prior to insect infestation.
[0477] In one embodiment of the present invention, the insects or arachnids may belong to the following orders: Acari, Arachnida, Anoplura, Blattodea, Coleoptera, Collembola, Dermaptera, Dictyoptera, Dipura, Emboptera, Ephemeroptera, Gryllobatodea, Hemiptera, Heteroptera, Homoptera, Hymenoptera, Isoptera, Lepidoptera ), Mallophaga, Mecoptera, Neuroptera, Odonata, Orthoptera, Phasmida, Phithiraptera, Plecoptera, Protura, Pso coptera), Siphunculata, Thysanura, Sternorrhynchoa, Strepsiptera, Thysanoptera, Trichoptera, Zoraptera and Zygentoma.
[0478] In a preferred but non-limiting embodiment of the present invention, the insect or arachnid is selected from the group consisting of: (1) Acari: mites, including the order Ixodida (2) Arachnida: spiders and Opiliones, examples include: black widow (Latrodectus mactans) and brown hair spider (Loxosceles recluse) (3) Anoplura: lice, such as human louse (Pediculus humanus) (4) Blattodea: cockroaches, including German cockroach (Blatella germanica), Periplaneta, including American cockroach (Periplaneta americana) and Australian cockroach (Periplaneta australiasiae), Blatta, including Oriental cockroach (Blatta orientalis) and Brown-banded cockroach (Supella longipalpa). The most preferred target is the German cockroach (Blatella germanica). (5) Coleoptera: Beetles, examples include: Powderpost beetle family (family Bostricholidae); Dendroctonus species (black turpentine beetle, southern rosin beetle, IPS eagle beetle); carpet beetles (Anthrenus, Attagenus); house beetles (family Cerambicyidae: Hylotrupes bajulus; furniture beetle (Anobium punctatum); Tribolium genus Trogoderma granarium; toothed grain beetle (Oryzaephilus)). sarinamensis, etc. (bookworms) (6) Dermaptera: family of the earwig family (7) Diptera: mosquitoes (Culicidae) and flies (Brachycera), examples are: Anophelinae, for example Anopheles and Culicinae, such as Aedes fulvus; Tabanidae, for example Tabanus punctifer, Glossina morsitans morsitans, Psychodidae and Calyptratae, such as Musca domestica,Sarcophagidae, etc. (8) Heteroptera: bugs, such as Cimex lectularius (9) Hymenoptera: Apocrita, including Formicoidea, Apoidea: Solenopsis invicta, Monomorium pharaonis, Camponotus species, Iasius niger, Tetramorium caespitum, Myrmica rubra, Formica species, Crematogaster lineolata species, Iridomyrmex humilis, Pheidole species, Dasymutilla spp. occidentalis) etc. (10) Isoptera: Termites, examples include: Florida black-winged subterranean termite (Amitermes floridensis), Oriental subterranean termite (Reticulitermes flavipes), Western subterranean termite (R. hesperus), Taiwan white-winged termite (Coptotermes formosanus), Western drywood termite (Incisitermes minor), forest termite (Neotermes connexus) and Termitidae (11) Lepidoptera: Moths, examples include: Tineidae and Oecophoridae, such as the common clothes moth (Tineola bisselliella), and Pyrolidae, such as Pyrolis farinalis, etc. (12) Psocids: Book lice (Psocids) (13) Siphonaptera: Fleas, such as Pulex irritans (14) Sternorrhyncha: Aphididae (Aphididae) (15) Zygentoma: Silverfish, examples are: Thermobia domestica and Lepisma saccharina;,
[0479] Other target insects or arachnids include household insects, external parasites and insects and / or arachnids relevant to public health and healthcare, such as, but not limited to, flies, spider mites, thrips, ticks, red poultry mites, ants (e.g., by targeting PBAN), cockroaches, termites, crickets including house crickets, silverfish, book lice, beetles, earwigs, mosquitoes and fleas. More preferred targets are cockroaches (Blattodea), such as, but not limited to, Blatella species (e.g., Blatella germanica), Periplaneta species (e.g., Periplaneta americana, Periplaneta australiasiae); Blatta species (e.g., Blatta orientalis) and Supella species (e.g., Supella longipalpa);Formicoidea, such as, but not limited to, Solenopsis species (e.g., Solenopsis invicta), Monomorium species (e.g., Monomorium pharaonis), Camponotus species (e.g., Camponotus), Lasius (e.g., Iasius niger), Tetramorium spp. (e.g., Tetramorium caespitum), Myrmica (e.g., Myrmica rubra), Formica species, Crematogaster (e.g., Crematogaster lineolata), Crematogaster (e.g., Iridomyrmex spp.), humilis), Pheidole species, and Dasymutilla (e.g., Dasymutilla occidentalis) termites (Isoptera and / or Termitidae), such as, but not limited to, Termitidae (e.g., Amitermes floridensis), Reticulitermes (e.g., Reticulitermes flavipes, Reticulitermes hesperus), Coptotermes (e.g., Coptotermes formosanus), Incisitermes (e.g., Incisitermes minor), Neotermes (e.g., Neotermes connexus).
[0480] In one embodiment, the target RNA encodes an insect lactate synthase.
[0481] When delivered and / or expressed in plants, the RNA molecules of the present invention can possess a wide range of desirable properties that affect, for example, agronomic traits, insect resistance (e.g., by targeting genes such as MpC002, MpRack-1, and ABC transporter genes), disease resistance (e.g., by targeting genes such as LanR), herbicide resistance, sterility, grain characteristics, etc. The target RNA molecules may be involved in the metabolism of oils, starches, carbohydrates, nutrients, etc., or may be involved in the synthesis of proteins, peptides, fatty acids, lipids, recombination frequencies (by targeting genes such as DDM1 and FANCM), waxes, oils (by targeting genes such as TOR), starches, sugars, carbohydrates, flavors, odors, toxins, carotenoids, hormones (by targeting genes such as EIN2, NCED1, and NCED2), polymers, flavonoids (by targeting genes such as chalcone synthase), storage proteins, phenolic acids, alkaloids, lignin, tannins, cellulose, glycoproteins, glycolipids, etc.
[0482] In particular embodiments, the plant produces: increased levels of an enzyme for oil production in plants such as Brassicas plants, e.g., rapeseed or sunflower, safflower, flax, cotton, soybean or corn; an enzyme involved in starch synthesis in plants such as potato, corn and cereals, e.g., wheat, barley or rice; a synthesized enzyme, or the protein itself, a natural drug, e.g., a pharmaceutical or veterinary product.
[0483] In another embodiment, the RNA molecules of the invention are intended to prophylactically or therapeutically treat infection with a fungal pathogen selected from the group consisting of: Altemaria species; Armillaria mellae; Armillaria mellae; Blumeria graminis (by targeting the Mlo gene using an RNA molecule as described in Example 17), Boletus granulatus; Botritis cinerea; Botrytis fabae; Candida albicans; Claviceps purpurea; Cronartium ribicola; Epicoccum purpurescens; Epidermophyton floccosum; Fomes annosus; Fusarium oxysporum oxysporum; Gaeumannomyces graminis var. tritici; Glomerella cingulata; Gymnosporangium juniperi-virginianae; Microsporum canis; Monilinia fructicola; Physoderma alfalfae; Phytoptherainfestans; Pityrosporum orbiculare; Polyporus sulphureus; Puccinia spp.; Saccharomyces cerevisiae; Septoria apiicola; Trichophyton rubrum rubrum); Trichophyton mentagrophytes; Ustilago spp.; Venturia inaequalis; and Venturia inaequalis.
[0484] Exemplary Conditions to be Treated
[0485] The RNA molecules according to the present invention can be used in methods for various conditions. In some embodiments, the present invention relates to a method for treating cancer comprising administering the RNA molecules disclosed herein. The term "cancer" refers to or describes a physiological condition in mammals that is typically characterized by dysregulated cell growth / proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include, but are not limited to, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer), non-small cell lung cancer, lung adenocarcinoma and lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastric cancer or gastric cancer (including gastrointestinal cancer and gastrointestinal stromal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, visceral urinary tract cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, melanoma, superficial spreading melanoma, Lentigo maligna melanoma, acral lentiginous melanoma, nodular melanoma, multiple myeloma and B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL)); mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's macroglobulinemia); chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); hairy cell leukemia; chronic myeloid leukemia; and post-transplant lymphoproliferative disorder (PTLD) as well as abnormal blood vessel proliferation associated with keloids, edema (e.g., edema associated with brain tumors), Meig syndrome, brain cancer and head and neck cancer, and related metastases. Thus, in one embodiment, the present invention relates to methods of treating cancers of the breast, ovary, colon, prostate, lung, brain, skin, liver, stomach, pancreas or blood.
[0486] In other embodiments, the methods described herein are used to treat cancers associated with mutations in BRCA1, BRCA2, PALB2, OR RAD51B, RAD51C, RAD51D, or related genes. In other embodiments, the methods described herein are used to treat cancers associated with mutations in genes related to DNA mismatch repair, such as MSH2, MLH1, PMS2, and related genes. In other embodiments, the methods described herein are used to treat cancers with silenced DNA repair genes, such as BRCA1, MLH1, OR RAD51B, RAD51C, OR RAD51D.
[0487] In other embodiments of the present invention, the methods described herein are used to kill cells with impaired DNA repair processes. For example, cells with impaired DNA repair may abnormally express genes involved in DNA repair, DNA synthesis, or homologous recombination. Exemplary genes include XRCC1, ADPRT (PARP-1), ADPRTL2, (PARP-2), POLYMERASE BETA, CTPS, MLH1, MSH2, FANCD2, PMS2, p53, p21, PTEN, RPA, RPAl, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, PALB2, RAD52, RAD54, RAD50, MREU, NB51, WRN, BLM, KU70, KU80, ATM, ATR CPIK1, HK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, and RAD9. In one embodiment, the methods described herein are used to kill cells with mutated tumor suppressor genes. For example, the cells can have one or more mutations in BRCA1 or BRCA2.
[0488] In other embodiments of the present invention, the methods described herein are used to treat virally transformed cells. In other embodiments of the present invention, the methods described herein are used to kill cells transformed with latent viruses. Exemplary latent viruses include CMV, EBV, herpes simplex virus (type I and type II), and varicella zoster virus. In other embodiments of the present invention, the methods described herein are used to treat active viral infections caused by viruses that cause cancer, immunodeficiency, hepatitis, encephalitis, pneumonia, or respiratory diseases. Exemplary viruses include parvovirus, poxvirus, and herpes virus.
[0489] In other embodiments of the invention, the methods described herein are used to treat Zika virus, Colorado tick fever (caused by the RNA virus Coltivirus), West Nile fever (encephalitis caused by a flavivirus found primarily in the Middle East and Africa), yellow fever, rabies (caused by different strains of the Rhabdoviridae family), viral hepatitis, gastroenteritis (viral) - acute viral gastroenteritis caused by Norwalk and Norwalk-like viruses, rotaviruses, Caliciviruses and Astroviruses, poliomyelitis, influenza (Flu) caused by orthomyxoviruses that undergo frequent antigenic variation, measles (rubella), Paramyxoviridae, mumps, respiratory syndromes including pneumonia and acute respiratory syndrome, including laryngitis caused by various viruses collectively known as acute respiratory viruses, and respiratory diseases caused by respiratory syncytial virus.
[0490] Example
[0491] Example 1: Materials and Methods
[0492] Synthesis of gene constructs
[0493] To design a typical ledRNA construct, a target RNA region of about 100-1000 nucleotides, typically 400-600 nucleotides, is identified. In one embodiment, the 5' half of the sequence and about 130 nt of the flanking regions, and similarly the 3' half and 130 nt of the flanking regions, are oriented in the antisense direction relative to the promoter. These sequences are interrupted by a sense target sequence of 400-600 nucleotides ( Figure 1 A) The 5' end of the resulting construct is preceded by a promoter, such as the T7 or SP6 RNA polymerase promoter, and the 3' end is engineered to include a restriction enzyme cleavage site to allow for termination of in vitro transcription.
[0494] For transcription in cells such as bacterial cells, for example, an inducible promoter is used to introduce promoter and terminator sequences to promote expression as a transgene. The length of the double-stranded region and loop sequence can vary. Constructs are prepared using standard cloning methods or ordered from commercial service providers.
[0495] RNA synthesis
[0496] After digestion with restriction enzymes to linearize the DNA at the 3' end, transcription using RNA polymerase generates 5' and 3' arms of the ledRNAi transcript that anneal to the central target sequence. The molecule contains a central stem or double-stranded region with a single cleavage and terminal loops. The central sequence can be oriented in the sense or antisense direction relative to the promoter (respectively). Figure 1 A, Figure 1 B).
[0497] For in vitro synthesis, the DNA of the construct was digested at the 3' restriction site using the appropriate restriction enzyme, precipitated, purified, and quantified. RNA synthesis was achieved using RNA polymerase according to the manufacturer's instructions. The ledRNA was resuspended in annealing buffer (25 mM Tris-HCl, pH 8.0, 10 mM MgCl2) using DEPC-treated water to inactivate any traces of RNases. The yield and integrity of the RNA produced by this method were determined by nanodroplet analysis and gel electrophoresis (see, respectively). Figure 2 ).
[0498] Synthesis of ledRNA in bacterial cells was achieved by introducing the construct into Escherichia coli strain HT115. Transformed cell cultures were induced with IPTG (0.4 mM) to express T7 RNA polymerase, providing transcription of the ledRNA construct. RNA was extracted and purified from bacterial cells essentially as described by Timmons et al. (2001).
[0499] For Cy3-labeled RNA transcription, the ribonucleotide (rNTP) mixture contains 10mM of ATP, GTP, CTP, 1.62mM UTP and 8.74mM Cy3-UTP. The transcription reaction was incubated at 37°C for 2.5 hours. The transcription reaction (160μl) was transferred to an Eppendorf tube, 17.7μl turbo DNase buffer and 1μl turbo DNA were added, and incubated at 37°C for 10 minutes to digest the DNA. 17.7μl Turbo DNAse inactivation solution was then added, mixed, and incubated at room temperature for 5min. The mixture was centrifuged for 2 minutes, and the supernatant was transferred to a new Eppendorf tube without RNAse. 1.5μl of each transcription reaction sample was electrophoresed on a gel to test the quality of the RNA product. Typically, depending on the construct, an RNA band of 500bp to 1000bp in size was observed. The RNA was precipitated by adding 88.5 μl of 7.5 M ammonium acetate and 665 μl of cold 100% ethanol to each tube. The tubes were cooled to -20°C for several hours or overnight and then centrifuged at 4°C for 30 minutes. The supernatant was carefully removed and the RNA pellet was washed with 1 ml of 70% ethanol (prepared with nuclease-free water) at -20°C and centrifuged. The pellet was dried and the purified RNA was resuspended in 50 μl of 1× RNAi annealing buffer. The RNA concentration was measured using the nanodrop method and stored at -80°C until use.
[0500] Example 2: Design of ledRNA
[0501] like Figure 1As shown schematically in Figure A, a typical ledRNA molecule comprises a sense sequence, which can be considered as two adjacent sense sequences covalently linked and identical to the target RNA; an antisense sequence that is complementary to the sense sequence and divided into two regions; and two loops separating the sense sequence from the antisense sequence. Thus, a DNA construct encoding this form of ledRNA comprises, in 5' to 3' order, a promoter for transcription of the ledRNA coding region; a first antisense region complementary to the region toward the 5' end of the target RNA; a first loop sequence; a sense sequence; a second loop sequence; then a second antisense region complementary to the 3' end of the target RNA; and finally, a means for terminating transcription. In this arrangement, the two antisense sequences flank the sense and loop sequences. During transcription, the two antisense regions anneal to the sense sequence, forming a dsRNA stem with two flanking loops.
[0502] In another but related form of ledRNA, the sense sequence is divided into two regions, while the two antisense regions remain as a single sequence ( Figure 1 B) Thus, a DNA construct encoding this second form of ledRNA comprises, in 5' to 3' order, a promoter for transcription of the ledRNA coding region, a first sense region identical to the region toward the 3' end of the target RNA, a first loop sequence, an antisense sequence, a second loop sequence, then a second sense region identical to the 5' end of the target RNA, and finally a means for terminating transcription. In this arrangement, the two sense sequences flank the antisense and loop sequences.
[0503] Without wishing to be bound by theory, these ledRNA structures will be more resistant to exonucleases than open-ended dsRNAs formed between single-stranded sense and antisense RNAs and without loops, and will also be more resistant to exonucleases than hairpin RNAs with only a single loop, due to the closed loops at each end. Furthermore, the inventors hypothesize that the loops at both ends of the dsRNA stem will allow Dicer to efficiently access both ends, thereby enhancing dsRNA processing into sRNA and silencing efficiency.
[0504] As a first example, a genetic construct was prepared for in vitro transcription using T7 or SP6 RNA polymerase to form LedRNA targeting a gene encoding GFP or GUS. The ledGFP construct contained the following regions, in order: the first half of the antisense sequence corresponding to nucleotides 358-131 of the GFP coding sequence (CDS) (SEQ ID NO: 7), the first antisense loop corresponding to nucleotides 130-1 of the GFP CDS, the sense sequence corresponding to nucleotides 131-591 of the GFP CDS, the second antisense loop corresponding to nucleotides 731-592 of the GFP CDS, and the second half of the antisense sequence corresponding to nucleotides 591-359 of the GFP CDS.
[0505] The ledGUS construct comprises the following regions, in order: the first half of the antisense sequence corresponding to nucleotides 609-357 of the GUS CDS (SEQ ID NO: 8); and the first antisense loop corresponding to nucleotides 356 to 197 of the GUS CDS, the sense sequence corresponding to nucleotides 357-860 of the GUS CDS, the second antisense loop corresponding to nucleotides 1029-861 of the GUS CDS; and the second half of the antisense sequence corresponding to nucleotides 861-610 of the GUS CDS.
[0506] To prepare separate strands of sense / antisense GUS dsRNA (conventional dsRNA), the same target sequence corresponding to nucleotides 357-860 of the GUS CDS was ligated between the T7 and SP6 promoters in the pGEM-TEasy vector. The sense and antisense strands were transcribed using either T7 or SP6 polymerase, respectively, and the transcripts were mixed and heated to denature the RNA strands before annealing in annealing buffer.
[0507] Example 3: Stability of ledRNA
[0508] The ability of ledRNA to form dsRNA structures was compared with open-ended dsRNA (i.e., without loops, formed by annealing separate single-stranded sense and antisense RNAs) and long hpRNA. The mixture of ledRNA, long hpRNA, and sense and antisense RNAs was denatured by boiling and annealed in annealing buffer (250 mM Tris-HCl, pH 8.0 and 100 mM MgCl2 / buffer), followed by electrophoresis in a 1.0% agarose gel under native conditions.
[0509] like Figure 2 As shown, both GUS ledRNA and GFP ledRNA produced dominant RNA bands with the expected mobility for double-stranded molecules, indicating the formation of the predicted ledRNA structure. This contrasts with the mixture of sense and antisense RNA, which only showed a weak dsRNA band, indicating that most of the sense and antisense RNAs did not readily anneal to each other to form dsRNA. The hairpin RNA sample produced two prominent bands, indicating that only a portion of the transcript formed the predicted hairpin RNA structure. Therefore, ledRNA is most effective in forming the predicted dsRNA structure.
[0510] The ability of ledRNA to stay and diffuse on the leaf surface was also compared with dsRNA. When applied to the lower part of the tobacco leaf surface, GUS ledRNA (ledGUS) could be readily detected in the upper part of untreated tobacco leaves after 24 hours ( Figure 3 However, single strand GUS dsRNA (dsGUS) could not be detected in the upper part of untreated leaves ( Figure 3 This result suggests that ledRNA is more resistant to degradation than dsRNA and is therefore able to spread within plant leaf tissue.
[0511] Example 4: Testing ledRNA by local delivery
[0512] The ability of ledRNAs to induce RNAi following topical delivery was tested in Nicotiana benthamiana and Nicotiana tabacum plants expressing either GFP or GUS reporter genes, respectively. The sequences of the GFP and GUS target sequences and the ledRNA encoding constructs are shown in SEQ ID NOs: 7, 8, 4, and 5, respectively. The ribonucleotide sequences of the encoded RNA molecules are shown in SEQ ID NOs: 1 (GFP ledRNA) and 2 (GUS ledRNA).
[0513] To facilitate reproducible and uniform application of ledRNA to the leaf surface, ledRNA at a concentration of 75-100 μg / ml in 25 mM Tris-HCl, pH 8.0, 10 mM MgCl2, and Silwet 77 (0.05%) was applied to the subaxial surface of the leaf using a soft paintbrush. Leaf samples were taken 6 hours and 3 days after ledRNA application for analysis of targeted gene silencing.
[0514] Application of ledRNA for GFP in N. benthamiana leaves and for GUS in Nicotiana tabacum resulted in a significant reduction of 20-40% and 40-50% of the activity of the corresponding target genes at the mRNA (GFP) or protein activity (GUS) levels 6 hours after treatment. However, in this experiment, the reduction was not sustained 3 days after treatment. The inventors believe that the observation at 3 days may be due to some non-specific response of the transgene to the dsRNA treatment or the dissipation of the ledRNA. However, in a separate experiment, GUS silencing was detected in both treated and distal untreated leaf areas 24 hours after ledRNA treatment ( Figure 4 ).
[0515] Example 5. ledRNA-induced silencing of endogenous target genes
[0516] In another embodiment, a ledRNA was designed to target the mRNA encoded by the endogenous gene, the FAD2.1 gene of N. benthamiana. The sequences of the target FAD2.1 mRNA and the ledFAD2.1 encoding construct are shown in SEQ ID NOs: 9 and 6, respectively. The ribonucleotide sequence of the encoded RNA molecule is provided as SEQ ID NO: 3 (N. benthamiana FAD2.1 ledRNA).
[0517] The FAD2.1 ledRNA construct consists of the following: the first half of the antisense sequence corresponding to nucleotides 678-379 of the FAD2.1 CDS (Niben101Scf09417g01008.1); the first antisense loop corresponding to nt378-242 of the FAD2.1 CDS; the sense sequence corresponding to nt379-979; the second antisense loop corresponding to nt1115-980; and the second half of the antisense sequence corresponding to nt979-nt679 of the FAD2.1 CDS.
[0518] In parallel, ledGUS RNA from the previous example was used as a negative control. In the first experiment, the FAD2.1 mRNA level and the accumulated C18:1 fatty acid ( Figure 5 ). The activity level of the related gene FAD2.2 was also determined. For each sample, approximately 3 μg of total RNA was treated with DNase and reverse transcribed using oligo dT primers at 50°C for 50 minutes. The reaction was terminated at 85°C for 5 minutes and diluted to 120 μl with water. Using a rotor gene PCR instrument, 5 μl of each sample was analyzed in triplicate for relative expression of FAD2.1 and FAD2.2 mRNA using gene-specific primers for the housekeeping gene actin. In subsequent experiments, Northern blot hybridization was also used to confirm the silencing of the FAD2.1 gene by topically applied ledFAD2.1 RNA ( Figure 6 ).
[0519] At the 2, 4, and 10 h time points, FAD2.1 mRNA was significantly reduced to almost undetectable levels in leaf tissue treated with ledRNA ( Figure 5 ). In this experiment, it is unclear why the level of FAD2.1 mRNA did not decrease as much at the 6 hour time point. Figure 6 In the replicate experiments shown, strong FAD2.1 downregulation occurred at 6 and 24 hours, particularly at the 24 hour time point. The related FAD2.2 gene, which shares sequence homology with FAD2.1, also showed downregulation by ledRNA at the 2 and 4 hour time points ( Figure 5 ).
[0520] Since FAD2.1 and FAD2.2 encode fatty acid Δ12 desaturases that desaturate oleic acid to linoleic acid, the levels of these fatty acids were determined in leaf tissue treated with ledRNA. At the 2, 4, and 6 hour time points, there was a significant increase in oleic acid (18:1) accumulation in ledRNA-treated leaf tissue, indicating that the amount of FAD2 enzyme was reduced. Figure 5 ). Therefore, qRT-PCR and fatty acid composition analysis showed ledRNA-induced FAD2.1 gene silencing.
[0521] Example 6: Design and testing of hairpin RNAs containing G:U base pairs or mismatched nucleotides
[0522] Modified hairpin RNA targeting GUS RNA
[0523] Reporter genes such as those encoding β-glucuronidase (GUS) provide a simple and convenient assay system that can be used to measure gene silencing efficiency in eukaryotic cells including plant cells (Jefferson et al., 1987). Therefore, the present inventors designed, produced and tested some modified hairpin RNAs to reduce the ability of GUS gene expression as a target gene, provided the hairpin RNA to the cells using a gene delivery method, and compared the modified hairpin RNA with a conventional hairpin RNA. The conventional hairpin RNA used as a control in the experiment had a double-stranded region of 200 adjacent base pairs in length, wherein all base pairs were canonical base pairs, i.e., G:C and A:U base pairs, without any G:U base pairs in the double-stranded region, and without any non-base paired nucleotides (mispairings), targeting the 200nt region identical to the modified hairpin RNA of the GUS mRNA molecule. The sense and antisense sequences forming the double-stranded region were covalently linked by a spacer sequence encompassing the PDK intron (Helliwell et al., 2005; Smith et al., 2000), providing an RNA loop of 39 or 45 nucleotides in length (depending on the cloning strategy used) after splicing of the introns from the primary transcript. The DNA fragments for the antisense sequences were flanked by XhoI-BamHI restriction enzyme sites at the 5' end and HindIII-KpnI restriction enzyme sites at the 3' end to facilitate cloning into the expression cassette, with each sense sequence flanked by XhoI and KpnI restriction sites, respectively. For both the control and modified hairpins, the 200 bp dsRNA region of each hairpin RNA included a 200 nucleotide antisense sequence that was fully complementary to the wild-type GUS sequence from within the protein-coding region. The antisense sequence, corresponding to nucleotides 13-212 of SEQ ID NO: 10, is the complement of nucleotides 804-1003 of the GUS open reading frame (ORF) (the cDNA sequence is provided as SEQ ID NO: 8). The GUS target mRNA is therefore greater than 1900 nt in length. The 200 nucleotide length chosen for the sense and antisense sequences is small enough to reasonably facilitate synthesis of DNA fragments using synthetic oligonucleotides, but long enough to provide multiple sRNA molecules after Dicer processing. As part of the ORF, the sequence is unlikely to contain cryptic splice sites or transcription termination sites.
[0524] Preparation of genetic constructs
[0525] A 200-bp GUS ORF sequence was PCR amplified using oligonucleotide primer pairs GUS-WT-F (SEQ ID NO: 52) and GUS-WT-R (SEQ ID NO: 53) containing either XhoI and BamHI sites or HindIII and KpnI, respectively, to introduce these restriction enzyme sites 5' and 3' to the GUS sequence. The amplified fragment was inserted into the pGEM-T Easy vector, and the correct nucleotide sequence was verified by sequencing. The GUS fragment was excised by digestion with BamHI and HindIII and inserted into the BamHI / HindIII sites of pKannibal (Helliwell and Waterhouse, 2005), with the GUS sequence in the antisense orientation relative to the operably linked CaMV e35S promoter (Grave, 1992) and the ocs gene polyadenylation / transcription terminator (Ocs-T). The resulting vector was named pMBW606 and contained the 35S::PDK intron::antisense GUS::Ocs-T expression cassette in 5' to 3' order.This vector was used as an intermediate vector as a base vector for assembling the four hpRNA constructs.
[0526] Construct hpGUS[wt] with only canonical base pairs
[0527] To prepare a vector with only canonical base pairs encoding a hairpin RNA molecule used as a control, designated hpGUS[wt], a 200 bp GUS PCR fragment with XhoI and KpnI was excised from the pGEM-T Easy plasmid and inserted into the XhoI / KpnI sites between the 35S promoter and the PDK intron in pMBW606. This generated a vector designated pMBW607 containing a 35S::sense GUS[wt]::PDK intron::antisense GUS::OCS-T expression cassette. This cassette was excised by digestion with NotI and inserted into the NotI site of pART27 (Gleave, 1992), resulting in a vector designated hpGUS[wt] encoding a canonical base-paired hairpin RNA targeting GUS mRNA.
[0528] When self-annealed by hybridization of the 200 nt sense and antisense sequences, the hairpin has a double-stranded region of 200 contiguous base pairs corresponding to the GUS sequence. The sense and antisense sequences in the expression cassette are flanked by BamHI and HindIII restriction enzyme sites at the 5' and 3' ends, respectively, relative to the GUS sense sequence. During transcription, nucleotides corresponding to these sites are also able to hybridize, extending the double-stranded region by 6 bp at each end. Following transcription of the expression cassette and splicing of the PDK intron from the primary transcript, the hairpin RNA structure is predicted to have a 39-nucleotide loop structure before any processing by Dicer or other RNases. The nucleotide sequence of the hairpin RNA structure, including its loop, is provided as SEQ ID NO: 15, and its folding free energy is predicted to be -471.73 kcal / mol. Therefore, this is an energetically stable hairpin structure. The free energy was calculated using “RNAfold” (http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi) based on the nucleotide sequence after splicing of the PDK intron sequence.
[0529] When transcribed from an expression cassette with a 35S promoter and an OCS-T terminator, the resulting hairpin RNA is embedded within a larger RNA molecule, adding 8 nucleotides to the 5' end and approximately 178 nucleotides to the 3' end, regardless of any poly(A) tail added to the 3' end. Because the modified hairpin RNAs use the same promoter-terminator design, these molecules also have these extensions at the 5' and 3' ends. Thus, the length of the hairpin RNA molecule after splicing of the PDH intron is approximately 630 nucleotides.
[0530] Construct hpGUS[G:U] containing a G:U base pair
[0531] A DNA fragment containing the same 200-nucleotide sense sequence, but with all 52 cytosine nucleotides (C) replaced with thymidine nucleotides (T), was assembled by annealing overlapping oligonucleotides GUS-GU-F (SEQ ID NO: 54) and GUS-GU-R (SEQ ID NO: 55) and 3'-end PCR extension using high-fidelity LongAmp Taq polymerase (New England Biolabs, catalog number M0323). The amplified DNA fragment was inserted into the pGEM-T Easy vector and the correct nucleotide sequence was verified by sequencing (SEQ ID NO: 11). The DNA fragment containing the modified sequence was then excised by digestion with XhoI and KpnI and inserted into the XhoI / KpnI sites of the basic vector pMBW606. This resulted in a construct designated pMBW608, which contained the expression cassette 35S::sense GUS[G:U]::PDK intron::antisense GUS::OCS-T. This expression cassette was excised by digestion with NotI and inserted into the NotI site of pART27, resulting in a vector designated hpGUS[G:U], which encodes a G:U base-paired hairpin RNA molecule.
[0532] This cassette encodes a hairpin RNA targeting GUS mRNA. When self-annealed by hybridization of the 200-nt sense and antisense sequences, it has 52 G:U base pairs (instead of the G:C base pairs in hpGUS[wt]) and 148 canonical base pairs, meaning that 26% of the nucleotides in the double-stranded region consist of G:U base pairs. The 148 canonical base pairs in hpGUS[G:U] are identical to those in the control hairpin RNA, including 49 U:A base pairs, 45 A:U base pairs, and 54 G:C base pairs at the corresponding positions. The longest stretch of the double-stranded region adjacent to canonical base pairing is 9 base pairs. Therefore, the antisense nucleotide sequence of hpGUS[G:U] is identical in length (200 nt) and sequence to the antisense sequence of the control hairpin RNA hpGUS[wt]. After transcription of the expression cassette and splicing of the PDK intron from the primary transcript, the hairpin RNA structure is predicted to have a 45-nucleotide loop structure before any processing by Dicer or other RNases. The nucleotide sequence of the hairpin structure, including its loop, is provided as SEQ ID NO: 16, and its folding free energy is predicted to be -331.73 kcal / mol. For hpGUS [wt], although the 52 G:U base pairs are much weaker than the G:C base pairs in hpGUS [wt], this is therefore an energetically stable hairpin structure.
[0533] Figure 7Shown is an alignment of the modified GUS sense sequence (nucleotides 9-208 of SEQ ID NO: 11) with the corresponding region of the GUS target gene (SEQ ID NO: 14).
[0534] Construct hpGUS[1:4] containing a mismatched nucleotide at every fourth nucleotide
[0535] DNA fragments containing the same 200 bp sense sequence but with every fourth nucleotide of the corresponding wild-type GUS sequence replaced were designed and assembled. Every fourth nucleotide of each group of four nucleotides (nucleotides at positions 4, 8, 12, 16, 20, etc.) was replaced by changing C' to G', G' to C', A' to T', and T' to A', leaving the other nucleotides unchanged. These substitutions are all translocation substitutions and are expected to have a greater destabilizing effect on the resulting hairpin RNA structure than transition substitutions. The DNA fragments were assembled by annealing overlapping oligonucleotides GUS-4M-F (SEQ ID NO: 56) and GUS-4M-R (SEQ ID NO: 57) and performing 3' end PCR extension using LongAmpTaq polymerase. The amplified DNA fragments were inserted into the pGEM-T Easy vector and the correct nucleotide sequence was verified by sequencing (SEQ ID NO: 12). The DNA fragment containing the modified sequence was then excised by digestion with XhoI and KpnI and inserted into the XhoI / KpnI sites of the base vector pMBW606. This generated a construct designated pMBW609, which contains the expression cassette 35S::sense GUS[1:4]::PDK intron::antisense GUS::OCS-T. This expression cassette was excised by digestion with NotI and inserted into the NotI site of pART27, resulting in a vector designated hpGUS[1:4], which encodes a 1:4 mismatched hairpin RNA molecule.
[0536] This cassette encodes a hairpin RNA that targets GUS mRNA and, upon self-annealing through hybridization of the sense and antisense sequences, has 50 mismatches with the 200 nucleotide antisense sequence, including a mismatch with the nucleotide at position 200. Beyond position 200, the double-stranded region of the hairpin RNA has 150 canonical base pairs and 49 mismatched nucleotide pairs across the 199 nt sense and antisense sequences, meaning that 24.6% of the nucleotides in the double-stranded region are predicted to be mismatched (not involving base pairs). Following transcription of the expression cassette and splicing of the PDK intron from the primary transcript, the hairpin RNA structure is predicted to have a 45-nucleotide loop structure before any processing by Dicer or other RNases. The nucleotide sequence of the hairpin structure, including its loop, is provided as SEQ ID NO: 17, and its folding free energy is predicted to be -214.05 kcal / mol. This is therefore an energetically stable hairpin structure for hpGUS [wt], excluding the mismatched nucleotides.
[0537] Figure 8 Shown is an alignment of the modified GUS sense sequence (nucleotides 9-208 of SEQ ID NO: 12) with the corresponding region of the GUS target gene (SEQ ID NO: 14).
[0538] Construct hpGUS[2:10], in which 9 and 10 nucleotides of 10 are mismatched
[0539] DNA fragments containing the same 200 bp sense sequence but with every ninth and tenth nucleotide of the corresponding wild-type GUS sequence replaced were designed and assembled. Every ninth and tenth nucleotide of each 10-nucleotide group (nucleotides at positions 9, 10, 19, 20, 29, 30, etc.) was replaced by changing C' to G', G' to C', A' to T', and T' to A', leaving the other nucleotides unchanged. The DNA fragments were assembled by annealing overlapping oligonucleotides GUS-10M-F (SEQ ID NO: 58) and GUS-10M-R (SEQ ID NO: 59) and performing 3' end PCR extension using LongAmp Taq polymerase. The amplified DNA fragments were inserted into pGEM-T Easy and the correct nucleotide sequence was verified by sequencing (SEQ ID NO: 13). The DNA fragments containing the modified sequences were then excised by digestion with XhoI and KpnI and inserted into the XhoI / KpnI sites of the base vector pMBW606. This generated a construct named pMBW610, which contains the expression cassette 35S::sense GUS[2:10]::PDK intron::antisense GUS::OCS-T. This expression cassette was excised by digestion with NotI and inserted into the NotI site of pART27, resulting in a vector named hpGUS[2:10], which encodes a 2:10 mismatched hairpin RNA molecule.
[0540] This cassette encodes a hairpin RNA targeting GUS mRNA. When self-annealed by hybridization of the sense and antisense sequences, it has 50 mismatches with the 200-nt antisense sequence, including mismatches with nucleotides at positions 199 and 200. Excluding positions 199 and 200, the double-stranded region of the hairpin RNA has 160 canonical base pairs and 19 dinucleotide mismatches across the 198-nt sense and antisense sequences, meaning that 19.2% of the nucleotides in the double-stranded region are predicted to be mismatched (not involving base pairs). The 160 base pairs in hpGUS[2:10] are identical to those in the control hairpin RNA, including 41 U:A base pairs, 34 A:U base pairs, and 42 G:C and 43 G:C base pairs at the corresponding positions. Following transcription of the expression cassette and splicing of the PDK intron from the primary transcript, the hairpin RNA structure, prior to any processing by Dicer or other RNases, is predicted to have a 45-nucleotide loop structure. The nucleotide sequence of the hairpin structure, including its loop, is provided as SEQ ID NO: 18, and its folding free energy is predicted to be -302.78 kcal / mol. For hpGUS [wt], this is therefore an energetically stable hairpin structure, despite the mismatched nucleotides expected to protrude from the stem of the hairpin structure.
[0541] Figure 9Shown is an alignment of the modified GUS sense sequence (nucleotides 9-208 of SEQ ID NO: 13) with the corresponding region of the GUS target gene (SEQ ID NO: 14).
[0542] Figure 10 Four genetic constructs used to express control and modified hairpin RNAs are shown schematically.
[0543] Example 7: Detection of modified hairpin RNA in transgenic plants
[0544] Plants of the common tobacco (Nicotiana tabacum) species transformed with the GUS target gene were used to test the efficacy of the four hairpin RNA constructs described above. Specifically, the target plants were from two homozygous independent transgenic lines PPGH11 and PPGH24, each containing a single copy insertion of the GUS transgene from the vector pWBPPGH, as shown in FIG. Figure 11As shown schematically, the GUS gene in the T-DNA of pWBPPGH contains the GUS coding region (nucleotides 7-1812 of SEQ ID NO: 8) operably linked to a 1.3 kb promoter from the phloem protein 2 (PP2) gene of Cucurbita pepo L. cv. Autumn Gold (Wang et al., 1994; Wang, 1994). Construct pWBPPGH was constructed by excising the PP2 promoter plus 54 nucleotides of the 5' UTR and PP2 protein coding region (encoding the first 18 amino acids of PP2) from the lambda genomic clone CPP1.3 (Wang, 1994). This fragment containing the GUS coding sequence was fused starting from the nucleotide encoding the third amino acid of GUS to produce an N-terminal fusion polypeptide with GUS activity. pPP2:: The GUS: Nos-T cassette was inserted into pWBVec2a (Wang et al., 1998) to generate pWBPPGH, which was used to transform plants of Nicotiana tabacum cv. Wisconsin 38 using Agrobacterium tumefaciens-mediated leaf disc transformation (Ellis et al., 1987) and selection for hygromycin resistance. GUS activity was similar in homozygous progeny plants of the two transgenic lines, PPGH11 and PPGH24. GUS expression in both transgenic plants was not limited to the phloem, but was present in most tissues of the plant. Therefore, in these plants, GUS expression from the PP2 promoter appears to be constitutive. PP2-GUS plants were chosen as test plants for two reasons: i) they gave approximately the same constitutively high level of GUS expression as 35S-GUS plants; ii) the PP2 promoter is derived from the endogenous PP2 gene promoter of zucchini (Cucurbita pepo), which has a different sequence from the 35S promoter used to drive hpRNA transgene expression and is therefore not transcriptionally co-repressed by the imported 35S promoter.
[0545] All 4 kinds of hairpin RNA constructs (Example 6) were used to transform PPGH11 and PPGH24 plants using the leaf disc method (Ellis et al., 1987) mediated by Agrobacterium, using 50 mg / L kanamycin as a selection agent. This selection system, which uses kanamycin as a different agent from the hygromycin used previously to import the T-DNA of pWBPPGH, was observed to produce only transformed plants, with no untransformed plants being regenerated. The regenerated transgenic plants containing the T-DNA from the hpGUS construct were transferred to soil for growth in a greenhouse and kept for about 4 weeks before measuring GUS activity. When measured, the transgenic plants were healthy and actively growing, and were identical in appearance to the untransformed control plants and the parent PPGHII and PPGH24 plants. In total, 59 transgenic plants transformed with T-DNA encoding hpGUS[wt] were obtained, 74 plants transformed with T-DNA encoding hpGUS[G:U] were obtained, 33 plants transformed with T-DNA encoding hpGUS[1:4] were obtained, and 41 plants transformed with T-DNA encoding hpGUS[2:10] were obtained.
[0546] GUS expression levels were determined using the fluorescent 4-methylumbelliferyl β-D-glucuronide (MUG) assay (Jefferson et al., 1987) following a modified kinetic method described by Chen et al. (2005). Plants were assayed by collecting leaf samples approximately 1 cm in diameter from three different leaves per plant, selecting well-swollen, healthy, and green leaves. It was noted that the test plants were at the same growth and developmental stage as the control plants. Each assay used 5 μg of protein extracted from each leaf sample, and the cleavage rate of MUG was measured as described by Chen et al. (2005).
[0547] Representative data are shown in Figure 12 In the Figures 2 and 3, the GUS activity (MUG units in the assay) of each independent transgenic plant is shown. Because the data for the hpGUS[wt] construct showed that some plants exhibited strong silencing, with activity reduced by at least 90%, while others were more weakly silenced, 10% GUS activity relative to control plants was chosen herein as the activity level used to classify plants into two categories and to compare the different constructs.
[0548] Using a 10% activity level as a benchmark for strong silencing, the genetic construct encoding canonically base-paired hpGUS [wt] induced strong GUS silencing in 32 of the 59 transgenic plants tested (54.2%). The other 27 plants all showed reduced GUS activity, but retained more than 10% of the enzyme activity relative to the control plants and are therefore considered to show weak silencing herein. Transgenic plants with this construct showed a wide range of degrees of GUS gene silencing ( Figure 12 ), ranging from less than 1% to approximately 80% activity retention, which is typical for conventional hairpin structures (Smith et al., 2000).
[0549] In stark contrast, the hpGUS[G:U] construct induced consistent and uniform silencing across independent transgenic lines, with 71 of 74 plants tested (95.9%) showing strong GUS silencing. Again, unlike all 33 hpGUS[1:4] plants tested, which showed reduced levels of GUS activity, only 8 (24%) produced <10% GUS activity relative to the control plants, and the other 25 were classified as having weaker silencing. These results indicate that this construct induces weaker but more uniform levels of GUS downregulation across transgenic lines. The hpGUS[2:10] construct behaved more like the hpGUS[wt] construct, inducing good levels of silencing in some lines (28 of 41, or 68.3%) and little or no GUS silencing in the remaining 13 plants.
[0550] When only silenced lines (residual activity <10%) were used for comparison and the average GUS activity was calculated, hpGUS[wt] plants showed the highest average degree of silencing, followed by hpGUS[G:U] plants and hpGUS[2:10] plants ( Figure 13 The HPGUS[1:4] plants showed the smallest average reduction in GUS activity. The extent of GUS silencing showed a good correlation with the thermodynamic stability of the predicted hpRNA structures derived from the four different hpRNA constructs (Example 6).
[0551] To test whether these differences persisted in progeny plants, representative transgenic plants containing the target GUS gene (which was homozygous) and the hpGUS transgene (which was hemizygous) were self-pollinated. Kanamycin-resistant progeny plants from the hpGUS line were selected, and any null segregants lacking the hpGUS transgene were discarded. This ensured that the hpGUS transgene was present in all progeny in either a homozygous or heterozygous state. GUS activity was determined in progeny plants, and representative data are shown in Table 1. Figure 14Progeny containing the hpGUS[wt] transgene clearly fell into two categories: those with strong GUS silencing and those showing weak or no silencing. These categories correlated well with the phenotypes of the previous generation, indicating that the degree of target gene silencing is heritable. All plants in the hpGUS[G:U] lines tested consistently showed strong silencing, while plants in the hpGUS[1:4] line consistently showed weaker silencing. The inventors concluded that the phenotypes observed in the parental generation are generally maintained in the progeny plants.
[0552] Southern blot hybridization experiments of transformed plants
[0553] The uniformity of strong gene silencing observed in a large number of independent transgenic plants generated with the hpGUS[G:U] construct was surprising and unexpected. The inventors sought to determine whether any explanation other than the effect caused by the hpGUS[G:U] RNA was responsible for the uniformity of silencing. To test whether the multiple transgenic plants were generated from the expected independent transformation events, Southern blot hybridization experiments were performed on DNA isolated from 18 representative transgenic plants containing the hpGUS[G:U] construct. DNA was isolated from leaf tissue using the hot phenol method described by Wang et al. (2008). For Southern blot hybridization, approximately 10 μg of DNA from each plant sample was digested with HindIII enzyme, separated by gel electrophoresis in 1% agarose gel in TBE buffer, and blotted onto Hybond-N+ membrane (Sambrook et al., 1989) using a capillary method. The membrane was incubated at 42°C with a 1% agarose gel from the OCS-T terminator region. 32 A P-labeled DNA fragment was hybridized overnight. This probe was chosen because it hybridizes to the hpGUS[G:U] transgene but not to the GUS target gene, which lacks the OCS-T terminator sequence. The membrane was washed at high stringency, and the retained probe was visualized using a phosphoimager.
[0554] The autoradiogram of the hybridization blot is shown in Figure 15 Each lane showed 1-5 or 1-6 hybridizing bands. No two lanes displayed the same pattern; that is, the autoradiographs revealed that each of the 16 representative hpGUS[G:U] plants had a different pattern of post-hybridization HindIII fragments, thus originating from different transgene insertions. The inventors concluded that the uniform GUS silencing observed for the hpGUS[G:U] lines was not due to a similar transgene insertion pattern across the plants, and that the uniformity of silencing was due to the structure of the hpGUS[G:U] RNA. The inventors also concluded that multiple copies of the hpGUS[G:U] transgene are not required to achieve strong gene silencing; a single copy of the transgene is sufficient.
[0555] Northern blot hybridization experiments of transformed plants
[0556] To determine whether hpGUS[G:U] RNA is processed in the same manner as control hairpin RNA in transgenic plants, Northern blot hybridization experiments were performed on RNA isolated from leaves of transgenic plants. Northern blot experiments were performed to detect shorter RNAs (sRNAs, approximately 21-24 nucleotides in length) produced after Dicer-processing of the hairpin RNA. Experiments were performed on small RNAs isolated from transgenic HPGUS[wt] and HPGUS[G:U] plants, which also contained the GUS target gene expressed as (sense) mRNA. Nine plants were selected for sRNA analysis for each construct. For the hpGUS[wt] transgenic population, plants showing weak GUS silencing and some plants showing strong GUS silencing were included. Small RNA samples were isolated using the hot phenol method (Wang et al., 2008) and Northern blot hybridization was performed as described by Wang et al. (2008), and gel electrophoresis of RNA samples was performed under denaturing conditions. The probe used was 32P-labeled RNA corresponding to the sense sequence or antisense sequence corresponding to nucleotides 804-1003 of SEQ ID NO:8.
[0557] Figure 16 Shown are autoradiograms of Northern blots hybridized with an antisense probe (upper panel) to detect sense sRNA molecules derived from hairpin RNA, or with a sense probe (lower panel) to detect antisense sRNA. At the bottom, the figure shows qualitative scoring of GUS expression levels relative to control plants lacking the hpGUS construct. In other experiments, hybridization to small RNAs of approximately 20-25 nucleotides was observed based on the mobility of sRNAs compared to RNAs of known length. hpGUS[wt] lines showed a range of sRNA accumulation. This was observed for both sense and antisense sRNAs, although the antisense sRNA bands were less distinct than the sense bands. Because hpGUS[wt] plants contain both a hpGUS transgene expressing sense and antisense sequences corresponding to the 200 nt target region and a GUS target gene expressing the full-length sense gene, sense sRNA can be generated from either hairpin RNA or target mRNA. sRNA levels in hpGUS[wt] were negatively correlated with the degree of GUS silencing. For example, the two plants represented in lanes 4 and 5 accumulated relatively more sRNA but showed only moderate GUS downregulation. In contrast, the two plants presented in lanes 7 and 8 had strong GUS silencing but accumulated relatively low levels of sRNA.
[0558] In contrast to the hpGUS[wt] plants and consistent with the relatively consistent degree of silencing across the hpGUS[G:U] construct, the hpGUS[G:U] plants accumulated consistent amounts of antisense sRNA across lines. Furthermore, the extent of GUS silencing appeared to correlate well with the amount of antisense sRNA. Almost no sense sRNA was detected in these plants. This was expected, as the RNA probe used in the Northern blot hybridization was transcribed from the wild-type GUS sequence and therefore had a lower level of complementarity to sense sRNA from hpGUS[G:U], in which all C nucleotides were replaced with U nucleotides, allowing only lower stringency hybridization. However, this experiment does not rule out the possibility that the hpGUS[G:U] RNA is processed to produce less sense sRNA or to cause it to degrade more rapidly.
[0559] The Northern blot hybridization experiment was repeated, this time using only the sense probe to detect the antisense sRNA; the autoradiogram showed Figure 17 Again, the production of antisense sRNA from the hpGUS[wt] construct was negatively correlated with GUS activity ( Figure 17 The strong silenced plants produced high levels of antisense sRNA (lanes 1, 3, 5, 8, and 10), while plants that showed only weak silencing or no silencing did not produce hybridization signals in this experiment (lanes 2, 4, 6, 7, and 9). In contrast, plants expressing hpGUS[G:U] produced much lower but consistent amounts of antisense sRNA. It is interesting to observe that plants expressing strong silencing of hpGUS[G:U] accumulate much lower levels of sRNA than plants expressing strong silencing of hpGUS[wt] and suggest to the inventors that hpGUS[wt] is processed by a different mechanism in plants, but is still as effective as the hpGUS[wt] construct. Further observations in this experiment provide clues, as the two relatively faint antisense bands for hpGUS[G:U] plants appear to have the same mobility as the second and fourth bands observed for the antisense sRNA bands from hpGUS[wt]. This is confirmed in further experiments described below. The present inventors hypothesized that the four bands of sRNA from hpGUS[wt] represent 24-, 22-, 21-, and 20-mers, and that hpGUS[G:U] RNA is primarily processed to generate 22- and 20-mer antisense sRNAs.
[0560] An important, unequivocal conclusion from the above data is that hpGUS[G:U] RNA molecules are processed by one or more Dicer enzymes to produce sRNAs, particularly antisense sRNAs, which are thought to mediate RNA interference in the presence of various proteins, such as Argonaute. The observed production of antisense sRNAs suggests that sense sRNAs are also produced, but this experiment does not distinguish between degradation / instability of the sense sRNAs or lack of detection of the sense sRNAs due to insufficient hybridization with the probes used. From these experiments, the inventors also concluded that there are significant differences between hpGUS[wt] and hpGUS[G:U] RNA molecules in their processing. This suggests that the molecules are differentially recognized by one or more Dicers.
[0561] Example 8: sRNA Analysis of Transgenic Plants Expressing Modified Hairpin RNA
[0562] Another Northern blot hybridization experiment was performed to detect antisense sRNAs from hpGUS[G:U] plants and compare their sizes with those produced by hpGUS[wt]. Figure 18 At this time, the size difference of the two antisense sRNA bands from hpGUS[G:U] was more obvious than the two main bands from hpGUS[wt]. Figure 18 This can be best seen by the mobility of the bands in adjacent lanes 9 and 10. This result confirms that the two hairpin RNAs are differentially processed by one or more Dicers in plants.
[0563] To further investigate this, we analyzed the small RNA populations from hpGUS[wt] and hpGUS[G:U] plants by deep sequencing total, adaptor-amplifiable small RNAs isolated from the plants. We determined the frequency of small RNAs mapping to the duplex region of the hairpin RNA and their length distribution. The results showed an increased frequency of 22-mer antisense RNAs in the hpGUS[G:U] construct compared to the hpGUS[wt] construct. The increased proportion of 22-nt sRNAs suggests altered Dicer-2 processing of the hpGUS[G:U] hairpin relative to hpGUS[wt].
[0564] Example 9: DNA methylation analysis of plant transgenics
[0565] The observation of variability in the degree of GUS silencing conferred by hpGUS[wt] and the detection of antisense 24-mer sRNA in hpGUS[wt] plants, but not in hpGUS[G:U] plants, led the inventors to question whether the two plant populations differed in the level of DNA methylation of the target GUS gene. Sequence-specific 24-mer sRNAs are thought to be involved in promoting DNA methylation of inverted repeat structures in plants (Dong et al., 2011). Therefore, the inventors tested the DNA methylation level of the GUS transgene in hpGUS plants, specifically the DNA methylation level of the 35S promoter region of the hairpin-encoding gene (silencer gene).
[0566] For this purpose, the DNA methylation-dependent endonuclease McrBC was used. McrBC is a commercially available endonuclease that cleaves DNA containing methylcytosine ( m C) bases in DNA (Stewart et al., 2000). McrBC recognizes two sites on DNA, which are separated by 5' (G or A) m C 3' consists of two half sites, preferably G m C. These half sites can be separated by hundreds of base pairs, but the optimal spacing is 55 to about 100 bp. Double-stranded DNA with such linked GmC dinucleotides on both strands is the best substrate. McrBC activity depends on one or both GC dinucleotides being methylated. Since plant DNA can be methylated at C in CG, CHG, or CHH sequences, where H represents A, C, or T (Zhang et al., 2018), digestion of DNA with McrBC and subsequent PCR amplification of gene-specific sequences can be used to detect specific DNA sequences in plant genomes. m The presence or absence of C. In this assay, PCR amplification of methylated McrBC-digested genomic DNA produces reduced amounts of amplification product compared to unmethylated DNA, but if the DNA is unmethylated, the same amount of PCR product as untreated DNA will be produced.
[0567] Genomic DNA was isolated from plants containing hpGUS[wt], hpGUS[G:U], or hpGUS[1:4] constructs in addition to the target GUS gene by standard methods (Draper and Scott, 1988). MgCl2, a 5-mercaptoethanol (MgCl2)-binding fragment, was included according to the manufacturer's instructions. 2+ions and GTP, the purified DNA samples were treated with McrBC (Cat. No. M0272; New England Biolabs, MA). In summary, approximately 1 μg of genomic DNA was digested overnight with McrBC in a 30 μl reaction volume. The digested DNA samples were diluted to 100 μl and PCR amplified for the region of interest as follows.
[0568] The treated DNA samples were used for PCR reactions using the following primers. For the 35S-GUS junction sequence of hpGUS[wt]: forward primer (35S-F3), 5'-TGGCTCCTACAAATGCCATC-3' (SEQ ID NO: 60); reverse primer (GUSwt-R2, 5'-CARRAACTRTTCRCCCTTCAC-3' (SEQ ID NO: 61). For the 35S-GUS junction sequence of hpGUS[G:U]: forward primer (GUSgu-R2), 5'-CAAAAACTATTCACCCTTCAC-3' (SEQ ID NO: 62); reverse primer (GUS4m-R2), CACRAARTRTACRCRCTTRAC (SEQ ID NO: 63). For the 35S promoter sequence of both constructs: forward primer (35S-F2, reverse, 5'-GAGGATCTAACAGAACTCGC-3' (SEQ ID NO: NO: 64); reverse primer (35S-R1), 5'-CTCTCCAAATGAAATGAACTTCC-3' (SEQ ID NO: 65). In each case, R = A or G, and Y = C or T. PCR reactions were performed using the following cycling conditions: 94°C for 1 minute, followed by 35 cycles of 94°C for 30 seconds, annealing at 55°C for 45 seconds, extension at 68°C for 1 minute, and a final extension at 68°C for 5 minutes. PCR amplification products were subjected to electrophoresis, and band intensities were quantified.
[0569] Representative results are shown in Figure 19 and 20For the 200bp 35S-GUS junction region, which includes the 35S promoter sequence containing the transcription start site, most hpGUS[wt] plants showed significant levels of DNA methylation. Within the hpGUS[wt] plant population, individual plants that maintained higher levels of GUS activity, i.e., less silence, appeared to have more methylation of the promoter-GUS sense junction region. The results for the 35S promoter region were similar. In contrast, most hpGUS[G:U] and hpGUS[1:4] plants showed weaker DNA methylation at the 35S-GUS junction. The inventors believe that this proximal promoter sequence is important for transgenic expression, and that methylation in this region will likely reduce the expression of the silencing construct through transcriptional gene silencing (TGS) of the transgene. This is called "self-silencing."
[0570] General Discussion of Examples 6-9
[0571] Disruption of inverted repeat DNA structure in transgenes enhances their stability
[0572] Both hpGUS[wt] and hpGUS[2:10] transgenic plant populations exhibited widespread target gene silencing. In contrast, two populations containing hpGUS[G:U] and hpGUS[1:4] plants showed relatively uniform GUS silencing across numerous independent lines, with strong silencing observed with the former construct and relatively weaker, but still significant, reductions in gene activity observed with the latter construct. In the hairpin RNAs from the [G:U] and [1:4] constructs, approximately 25% of the nucleotides in the sense and antisense sequences participated in G:U base pairs or sequence mismatches evenly distributed across the 200-nucleotide sense / antisense sequence. Due to the sequence differences between the sense and antisense sequences, it is believed that mismatches in the DNA construct between the sense and antisense "arms," or reverse request structures, significantly disrupt the inverted repeat DNA structure. Repeated DNA structures can attract DNA methylation and silencing in various organisms (Hsieh and Fire, 2000). The hpGUS[2:10] construct also contains mismatches in the sense and antisense regions, but each 2-bp mismatch between the sense and antisense sequences is flanked by 8-bp adjacent mismatches, so the mismatches likely do not disrupt the inverted repeat DNA structure as they do in the [G:U] and [1:4] transgenes. Therefore, the uniformity of GUS silencing induced by hpGUS[G:U] and hpRNA[1:4] may be due, at least in part, to the disruption of the inverted repeat DNA structure, which results in lower methylation and, therefore, reduced autosilencing of both transgenes. An additional benefit of the mismatches between the sense and antisense DNA regions is that they facilitate cloning of inverted repeats in E. coli, as bacteria tend to delete or rearrange perfectly normal inverted repeats.
[0573] Thermodynamic stability of hpRNA is an important factor affecting the degree of target gene silencing
[0574] When comparing only the strongly silenced transgenic lines, hpGUS[wt] plants showed the greatest degree of target gene downregulation, followed by hpGUS[G:U], hpGUS[2:10], and hpGUS[1:4]. RNAFold analysis predicted that the hpGUS[wt] hairpin RNA structure had the lowest free energy, i.e., the greatest stability, followed by the hpGUS[G:U], hpGUS[2:10], and hpGUS[1:4] hairpins. The inventors believe that the more stable the hairpin RNA structure, the greater the degree of target gene silencing it can induce. This also favors longer double-stranded RNA structures over shorter ones. Efficient Dicer processing is believed to require stable double-stranded RNA formation. The experimental results described herein demonstrate another important advantage of G:U base-paired constructs over constructs containing a majority of simple mismatched nucleotides, such as hpGUS[1:4]. Although...
Claims
1. An RNA molecule comprising a first RNA component, a second RNA component covalently linked to the first RNA component, and optionally one or more or all of the following: (i) a linking ribonucleotide sequence covalently linked to the first and second RNA components, (ii) a 5' leader sequence and (iii) a 3' trailer sequence, wherein the first RNA component consists of a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide in a 5' to 3' order, wherein the first 5' and 3' ribonucleotides in the first RNA component are base paired with each other, wherein the first RNA sequence comprises a first sense ribonucleotide sequence of at least 40 contiguous ribonucleotides, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence of at least 40 contiguous ribonucleotides, wherein the first antisense ribonucleotide sequence of at least 40 contiguous ribonucleotides is base paired with the first sense ribonucleotide sequence of at least 40 contiguous ribonucleotides in the RNA molecule, wherein the at least 40 contiguous ribonucleotides of the first antisense ribonucleotide sequence are fully complementary to and capable of hybridizing with a first region of a target RNA molecule, in, the second RNA component is covalently linked to the first 5' ribonucleotide or the first 3' ribonucleotide via the linking ribonucleotide sequence if present, or directly to the first 5' ribonucleotide or the first 3' ribonucleotide if the linking ribonucleotide sequence is not present, wherein the second RNA component consists of, in 5′ to 3′ order, a second 5′ ribonucleotide, a second RNA sequence, and a second 3′ ribonucleotide, wherein the second 5′ and 3′ ribonucleotides are base paired with each other in the RNA molecule, wherein the second RNA sequence comprises a second antisense ribonucleotide sequence of at least 21 contiguous ribonucleotides, a second loop sequence of at least 4 ribonucleotides, and a second sense ribonucleotide sequence of at least 21 contiguous ribonucleotides, wherein in the RNA molecule the second sense ribonucleotide sequence hybridizes with the second antisense ribonucleotide sequence; wherein the 5' leader sequence, if present, consists of a ribonucleotide sequence covalently linked to the first 5' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or covalently linked to the second 5' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide, and wherein the 3' trailer sequence, if present, consists of a ribonucleotide sequence covalently linked to the second 3' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or covalently linked to the first 3' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide, and wherein the RNA molecule comprises a single ribonucleotide chain, the single ribonucleotide chain comprises a 5' end and a 3' end, and The target RNA molecule is an arthropod gene transcript and / or the target RNA molecule is located in a plant or arthropod cell.
2. An RNA molecule comprising a first RNA component, a second RNA component covalently linked to the first RNA component, and optionally one or more or all of the following: (i) a linking ribonucleotide sequence covalently linked to the first and second RNA components, (ii) a 5' leader sequence and (iii) a 3' trailer sequence, wherein the first RNA component consists of, in 5' to 3' order, a first 5' ribonucleotide, a first RNA sequence, and a first 3' ribonucleotide, wherein the first 5' and 3' ribonucleotides are base paired, wherein the first RNA sequence comprises a first sense ribonucleotide sequence, a first loop sequence of at least 4 ribonucleotides, and a first antisense ribonucleotide sequence, wherein the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence are each at least 40 contiguous ribonucleotides, and wherein the at least 40 contiguous ribonucleotides of the first sense ribonucleotide sequence are completely base paired with at least 40 contiguous ribonucleotides of the first antisense ribonucleotide sequence, wherein the at least 40 contiguous ribonucleotides of the first sense ribonucleotide sequence are identical in sequence to a first region of a target RNA molecule, in, If said linking ribonucleotide sequence is present, said second RNA component is covalently linked to said first 5' ribonucleotide or said first 3' ribonucleotide via said linking ribonucleotide sequence, wherein the second RNA component consists of, in 5' to 3' order, a second 5' ribonucleotide, a second RNA sequence, and a second 3' ribonucleotide, wherein the second 5' and 3' ribonucleotides are base paired, wherein the second RNA sequence comprises a second antisense ribonucleotide sequence of at least 21 contiguous ribonucleotides, a second loop sequence of at least 4 ribonucleotides, and a second sense ribonucleotide sequence of at least 21 contiguous ribonucleotides, wherein the second sense ribonucleotide sequence is base paired with the second antisense ribonucleotide sequence, wherein the 5' leader sequence, if present, consists of a ribonucleotide sequence covalently linked to the first 5' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide component, or covalently linked to the second 5' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide, and wherein the 3' trailer sequence, if present, consists of a ribonucleotide sequence covalently linked to the second 3' ribonucleotide if the second RNA component is linked to the first 3' ribonucleotide, or covalently linked to the first 3' ribonucleotide if the second RNA component is linked to the first 5' ribonucleotide, and wherein the RNA molecule comprises a single ribonucleotide chain, the single ribonucleotide chain comprises a 5' end and a 3' end, and The target RNA molecule is an arthropod gene transcript and / or the target RNA molecule is located in a plant or arthropod cell.
3. The RNA molecule of claim 1, wherein (i) the first and second antisense ribonucleotide sequences flank the first and second sense ribonucleotide sequences, or (ii) the first and second sense ribonucleotide sequences flank the first and second antisense ribonucleotide sequences.
4. The RNA molecule of claim 1, wherein the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence, and / or the second sense ribonucleotide sequence and the second antisense ribonucleotide sequence are each at least 40 nucleotides, at least 50 nucleotides, at least 100 nucleotides, or 100 to 1000 nucleotides in length.
5. The RNA molecule of claim 1, wherein the first sense ribonucleotide sequence and the first antisense ribonucleotide sequence are each 100 to 1000 nucleotides in length.
6. The RNA molecule of claim 1, wherein the first sense ribonucleotide sequence is covalently linked to the first 5' ribonucleotide without any intervening nucleotide, or the first antisense ribonucleotide sequence is covalently linked to the first 3' ribonucleotide without any intervening nucleotide, or both.
7. The RNA molecule of claim 1, comprising the linking ribonucleotide sequence, wherein the linking ribonucleotide sequence is less than 20 ribonucleotides.
8. The RNA molecule of claim 7, wherein the linking ribonucleotide sequence hybridizes to the target RNA molecule.
9. The RNA molecule of claim 7, wherein the linking ribonucleotide sequence is identical to a portion of the complement of the target RNA molecule.
10. The RNA molecule according to claim 7, wherein the length of the linking ribonucleotide sequence is 1 to 10 ribonucleotides.
11. The RNA molecule according to claim 1, comprising two or more sense ribonucleotide sequences and an antisense ribonucleotide sequence that is completely base-paired therewith, which are identical in sequence to a region of a target RNA molecule.
12. The RNA molecule of claim 11, wherein the two or more sense ribonucleotide sequences are identical in sequence to different regions of the same target RNA molecule.
13. The RNA molecule of claim 11, wherein the two or more sense ribonucleotide sequences are identical in sequence to regions of different target RNA molecules.
14. The RNA molecule of claim 11, wherein the two or more sense ribonucleotide sequences have no intervening loop sequence.
15. The RNA molecule of claim 1, comprising two or more antisense ribonucleotide sequences and a sense ribonucleotide sequence that is perfectly base-paired therewith, each being complementary to a region of a target RNA molecule.
16. The RNA molecule according to claim 1, comprising two or more antisense ribonucleotide sequences and a sense ribonucleotide sequence that is completely base paired therewith, wherein the two or more antisense ribonucleotide sequences are complementary to different regions of the same target RNA molecule.
17. The RNA molecule of claim 1, comprising two or more antisense ribonucleotide sequences and a sense ribonucleotide sequence that is completely base paired therewith, wherein the second of the two or more antisense ribonucleotide sequences is complementary to a region of the target RNA molecule that is different from the first of the two or more antisense ribonucleotide sequences.
18. The RNA molecule of claim 15, wherein the two or more sense ribonucleotide sequences have no intervening loop sequence.
19. The RNA molecule of claim 1, which is a single-stranded ribonucleotide having a 5' end, at least one sense ribonucleotide sequence of at least 40 contiguous ribonucleotides in length, an antisense ribonucleotide sequence that is completely base paired with each sense ribonucleotide sequence on the at least 40 contiguous ribonucleotides, at least two loop sequences and a 3' end.
20. The RNA molecule of claim 2, which is a single-stranded ribonucleotide having: a 5' end, at least one sense ribonucleotide sequence of at least 40 contiguous ribonucleotides in length, an antisense ribonucleotide sequence that is completely base paired with each sense ribonucleotide sequence over at least 40 contiguous ribonucleotides, at least two loop sequences, and a 3' end.
21. The RNA molecule of claim 1, wherein the RNA molecule is a single-stranded ribonucleotide comprising a 5' end; the first RNA component comprising a first sense ribonucleotide sequence of at least 40 contiguous ribonucleotides in length, at least one loop sequence, a first antisense ribonucleotide sequence that hybridizes to the first sense ribonucleotide sequence over a length of at least 40 contiguous ribonucleotides; and the second RNA component comprising a second sense ribonucleotide sequence of at least 21 nucleotides in length, a loop sequence, a second antisense ribonucleotide sequence that hybridizes to the second sense ribonucleotide sequence over a length of at least 40 contiguous ribonucleotides; and a 3' end, wherein the RNA molecule has only one 5' end and only one 3' end.
22. The RNA molecule according to claim 21, wherein the ribonucleotide at the 5' end and the ribonucleotide at the 3' end are adjacent, each base is paired, and are not directly covalently bonded.
23. An RNA molecule according to claim 1, wherein the RNA molecule comprises a first antisense ribonucleotide sequence that hybridizes to a first region of a target RNA, a second antisense ribonucleotide sequence that hybridizes to a second region of the target RNA, the second region of the target RNA being different from the first region of the target RNA, and the RNA molecule comprises only one sense ribonucleotide sequence that is at least 60% identical to the first and second regions of the target RNA, wherein the two antisense sequences are not adjacent in the RNA molecule.
24. The RNA molecule of claim 1, comprising a first sense ribonucleotide sequence that is at least 60% identical to a first region of a target RNA, a second sense ribonucleotide sequence that is at least 60% identical to a second region of the target RNA, the second region of the target RNA being different from the first region of the target RNA, and the RNA molecule comprising only one antisense ribonucleotide sequence that hybridizes to the first region and the second region of the target RNA, wherein the two sense sequences are not adjacent in the RNA molecule.
25. The RNA molecule of claim 1, having a 5' leader sequence.
26. The RNA molecule of claim 1, having a 3' trailer sequence.
27. The RNA molecule of claim 1, wherein each ribonucleotide is covalently linked to two other ribonucleotides.
28. The RNA molecule of claim 27, wherein at least one or all loop sequences are longer than 20 nucleotides.
29. The RNA molecule of claim 1, wherein the RNA molecule has no, one, or two or more bulges, or the double-stranded region of the RNA molecule comprises one, two, or more nucleotides that are not base paired in the double-stranded region.
30. The RNA molecule of claim 1, having three, four or more loops.
31. The RNA molecule of claim 1, having only two loops.
32. The RNA molecule of claim 1, wherein the target RNA is an arthropod gene transcript.
33. The RNA molecule of claim 32, which is produced in a bacterial cell or a fungal cell.
34. The RNA molecule of claim 1, wherein at least one of the loops is 4 to 1,000 ribonucleotides, or 4 to 200 ribonucleotides in length.
35. The RNA molecule of claim 34, wherein all loops are 4 to 1,000 ribonucleotides in length, or 4 to 200 ribonucleotides in length.
36. The RNA molecule of claim 35, wherein all loops are 4 to 50 ribonucleotides in length.
37. The RNA molecule of claim 34, wherein each loop is 20 to 30 ribonucleotides in length.
38. The RNA molecule of claim 1, wherein the target RNA encodes a protein.
39. The RNA molecule of claim 1, comprising a double-stranded RNA (dsRNA) region comprising a first sense ribonucleotide sequence and a second antisense ribonucleotide sequence that are capable of hybridizing to each other to form the dsRNA region, wherein Between 5% and 40% of the ribonucleotides in the dsRNA region are base paired in non-canonical base pairs.
40. The RNA molecule of claim 39, wherein a total of 15% to 30%, or 16% to 25%, of the ribonucleotides of the sense ribonucleotide sequence and the antisense ribonucleotide sequence are base paired with non-canonical base pairs or are not base paired.
41. The RNA molecule of claim 39, wherein at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or 100% of the non-canonical base pairs are G:U base pairs.
42. The RNA molecule of claim 39, wherein all ribonucleotides in the dsRNA region are base paired.
43. The RNA molecule of claim 39, wherein each of 4 ribonucleotides to each of 6 ribonucleotides in the dsRNA region forms a non-canonical base pair.
44. The RNA molecule of claim 39, wherein the dsRNA region does not comprise 8 contiguous canonical base pairs.
45. The RNA molecule of claim 39, wherein the dsRNA region comprises at least 8 contiguous canonical base pairs.
46. The RNA molecule of claim 39, wherein all ribonucleotides in the dsRNA region are base paired in canonical base pairs or G:U base pairs.
47. The RNA molecule of claim 39, wherein one or more ribonucleotides of the first sense ribonucleotide sequence or one or more ribonucleotides of the first antisense ribonucleotide sequence, or both, are not base paired.
48. An RNA molecule according to claim 39, wherein the first antisense RNA sequence is less than 100% identical in sequence, or 80% to 99.9% identical, or 90% to 98% identical, or 95% to 98% identical to the complement of a region of the target RNA molecule.
49. The RNA molecule of claim 39, wherein the first antisense RNA sequence is 100% identical in sequence to the complement of a region of the target RNA molecule.
50. The RNA molecule of claim 39, wherein the first sense and / or first antisense ribonucleotide sequence is at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1,000, or between 100 and 1,000 in length.
51. The RNA molecule of claim 39, wherein the number of ribonucleotides in the first sense ribonucleotide sequence is 90% to 110% of the number of ribonucleotides in the first antisense ribonucleotide sequence.
52. The RNA molecule of claim 39, wherein the number of ribonucleotides in the first sense ribonucleotide sequence is the same as the number of ribonucleotides in the first antisense ribonucleotide sequence.
53. The RNA molecule of claim 39, wherein the first 3' ribonucleotide and the second 5' ribonucleotide are covalently linked via a loop sequence consisting of at least 4 ribonucleotides, or 4 to 1,000 ribonucleotides, or 4 to 200 ribonucleotides, 4 to 50 ribonucleotides.
54. The RNA molecule of claim 39, wherein the RNA molecule further comprises a 5' extension sequence covalently linked to the first 5' ribonucleotide or a 3' extension sequence covalently linked to the second 3' ribonucleotide, or both.
55. The RNA molecule of claim 39, wherein the RNA molecule further comprises a 5' extension sequence covalently linked to the second 5' ribonucleotide or a 3' extension sequence covalently linked to the first 3' ribonucleotide, or both.
56. The RNA molecule of claim 39, comprising two or more different dsRNA regions.
57. The RNA molecule of claim 39, wherein when expressed in a eukaryotic cell, more short antisense RNA molecules are formed from RNA molecules of 22 and / or 20 ribonucleotides in length compared to processing of a similar RNA molecule having a corresponding dsRNA region that is fully base paired to canonical base pairs.
58. The RNA molecule according to claim 39, comprising the features as defined in claim 3.
59. An isolated and / or exogenous polynucleotide encoding an RNA molecule according to any one of claims 1 to 58.
60. The polynucleotide of claim 59 which is a DNA construct.
61. The polynucleotide of claim 59, operably linked to a promoter capable of directing expression of the RNA molecule in a host cell.
62. A polynucleotide according to claim 61, wherein the promoter is an RNA polymerase promoter, or a promoter that functions in vitro.
63. The polynucleotide of claim 59, encoding an RNA precursor molecule comprising an intron in at least one loop sequence, said intron being capable of being spliced out during transcription of said polynucleotide in a host cell.
64. A vector comprising the polynucleotide of claim 59.
65. The vector according to claim 64, which is a viral vector.
66. A host cell comprising one or more or all of the RNA molecule according to any one of claims 1 to 58, the polynucleotide according to claim 59, or the vector according to claim 64, wherein the host cell is a bacterial cell or a fungal cell.
67. The host cell of claim 66, which is dead.
68. The polynucleotide according to claim 61, wherein The promoter region of the polynucleotide has a lower level of methylation when compared to the promoter of the corresponding polynucleotide encoding an RNA molecule having a corresponding dsRNA region that is completely base paired to canonical base pairs.
69. The host cell of claim 66, comprising at least two copies of the polynucleotide, and wherein i) the level of reduction in expression or activity of the target RNA molecule in the eukaryotic cell is at least the same as when the cell has a single copy of the polynucleotide, and / or ii) expression or activity of the target RNA molecule in the eukaryotic cell is reduced to a lower level when compared to a corresponding cell comprising an RNA molecule having a corresponding dsRNA region that is fully base paired with canonical base pairs.
70. The host cell of claim 66, wherein the cell encodes and / or comprises the RNA molecule, and the level of the sense ribonucleotide sequence in the cell is less than 50% to 99% of the level of the antisense ribonucleotide sequence.
71. A method for producing an RNA molecule according to any one of claims 1 to 58, the method comprising expressing a polynucleotide encoding the RNA molecule in a host cell or a cell-free expression system.
72. The method of claim 71, further comprising at least partially purifying the RNA molecule.
73. A method for producing a plant, the method comprising introducing the polynucleotide according to claim 59 into a plant cell so that it is stably integrated into the genome of the cell, and producing a plant from the cell.
74. The method of claim 73, wherein the plant produces the RNA molecule of any one of claims 1 to 58.
75. An extract of a host cell according to claim 66, wherein the extract comprises the RNA molecule and / or the polynucleotide.
76. A composition comprising an RNA molecule according to any one of claims 1 to 58 or a polynucleotide according to claim 59, and one or more suitable carriers.
77. The composition of claim 76, which is a pharmaceutical composition.
78. The composition of claim 76, further comprising at least one compound that enhances the stability of the RNA molecule or polynucleotide and / or aids in the uptake of the RNA molecule or polynucleotide by cells of an organism.
79. The composition of claim 78, wherein the compound is a transfection facilitating agent.
80. A method for downregulating the level and / or activity of a target RNA molecule in a plant, pest or plant pathogen, the method comprising delivering to the plant, pest or plant pathogen one or more of: an RNA molecule according to any one of claims 1-58 or a polynucleotide according to claim 59.
81. The method of claim 80, wherein the target RNA molecule encodes a protein.
82. A method for controlling plants, pests or plant pathogens, the method comprising delivering to the plants, pests or plant pathogens one or more of the following: an RNA molecule according to any one of claims 1-58 and / or a polynucleotide according to claim 59, wherein the RNA molecule has a deleterious effect on the plants, pests or plant pathogens.
83. A method for introducing an RNA molecule into a plant, the method comprising topically applying to said plant or part thereof a composition comprising an RNA molecule according to any one of claims 1 to 58 and / or a polynucleotide according to claim 59.
Citation Information
Patent Citations
RNA molecules
AU2018902840
RNA molecules
AU2018902896
Herbicide resistance in plants
EP0154204A2
Herbicide tolerant plants containing a glutathione-S-transferase gene
EP0256223A1
Plant-functional phosphinothricin resistance gene and its use
EP0275957A2
